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Abstract
Alternative splicing is a mechanism of gene regulation that expands the genome's coding capacity. The
ability to regulate alternative splicing in response to external signals is critical for immune responses. I
profiled alternative splicing during T cell activation using next-generation sequencing and identify
hundreds of genes that are regulated by alternative splicing during activation of a T cell line and primary
human T cells. Alternative splicing in response to T cell receptor signaling is enriched for genes encoding
signaling proteins; suggesting interplay between signaling and splicing regulation. In this thesis I describe
the selection of the JNK kinase MKK7, as a model system to understand the connections between
signaling and splicing in T cells. Specifically, I find that that in response to T cell activation, MKK7 is
alternatively spliced to favor an isoform that lacks exon 2. This isoform restores a MAPK docking site
within MKK7 that is disrupted in the larger isoform. Consistently, skipping of exon 2 enhances JNK
pathway activity, as indicated by c-Jun phosphorylation and upregulation of the c-Jun target gene TNFalpha. Notably, signaling through JNK itself is necessary and sufficient to promote activation-induced
repression of exon 2 of the MKK7 gene. Thus, JNK-induced MKK7 alternative splicing represents a
positive feedback loop through which JNK promotes its own signaling.
Through minigene based analysis I identify sequences within the introns flanking MKK7 exon 2 that are
necessary and sufficient to promote activation-induced skipping. Analysis of RNA-protein interactions and
knockdown experiments identified CELF2 as a protein that binds to MKK7 introns in an activationdependent manner and represses exon 2 inclusion. The repressive activity of CELF2 on MKK7 exon 2 is
mediated through a JNK-dependent increase in CELF2 protein, that results from stabilization of the CELF2
mRNA. Finally, I show that ~25% of T cell receptor-mediated alternative splicing events are dependent on
JNK signaling. These JNK-dependent events are also significantly enriched for CELF2-dependence.
Together, the data presented in this thesis demonstrates a broad role for the JNK-CELF2 axis in
controlling splicing during T cell activation, including a specific role in potentiating JNK signaling.
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ABSTRACT

INTERPLAY BETWEEN SIGNALING AND SPLICING DURING T CELL ACTIVATION: A
STUDY ON MKK7
Nicole M Martinez
Kristen W Lynch

Alternative splicing is a mechanism of gene regulation that expands the
genome's coding capacity. The ability to regulate alternative splicing in response to
external signals is critical for immune responses. I profiled alternative splicing during T
cell activation using next-generation sequencing and identify hundreds of genes that are
regulated by alternative splicing during activation of a T cell line and primary human T
cells. Alternative splicing in response to T cell receptor signaling is enriched for genes
encoding signaling proteins; suggesting interplay between signaling and splicing
regulation. In this thesis I describe the selection of the JNK kinase MKK7, as a model
system to understand the connections between signaling and splicing in T cells.
Specifically, I find that that in response to T cell activation, MKK7 is alternatively spliced
to favor an isoform that lacks exon 2. This isoform restores a MAPK docking site within
MKK7 that is disrupted in the larger isoform. Consistently, skipping of exon 2 enhances
JNK pathway activity, as indicated by c-Jun phosphorylation and upregulation of the cJun target gene TNF-alpha. Notably, signaling through JNK itself is necessary and
sufficient to promote activation-induced repression of exon 2 of the MKK7 gene. Thus,
JNK-induced MKK7 alternative splicing represents a positive feedback loop through
which JNK promotes its own signaling.

iv

Through minigene based analysis I identify sequences within the introns flanking
MKK7 exon 2 that are necessary and sufficient to promote activation-induced skipping.
Analysis of RNA-protein interactions and knockdown experiments identified CELF2 as a
protein that binds to MKK7 introns in an activation-dependent manner and represses
exon 2 inclusion. The repressive activity of CELF2 on MKK7 exon 2 is mediated through
a JNK-dependent increase in CELF2 protein, that results from stabilization of the CELF2
mRNA. Finally, I show that ~25% of T cell receptor-mediated alternative splicing events
are dependent on JNK signaling. These JNK-dependent events are also significantly
enriched for CELF2-dependence. Together, the data presented in this thesis
demonstrates a broad role for the JNK-CELF2 axis in controlling splicing during T cell
activation, including a specific role in potentiating JNK signaling.
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CHAPTER 1: INTRODUCTION
The adaptive immune system is marked by its ability to detect an invading pathogen or
foreign antigen and direct an appropriate effector response. T cells, for example,
recognize antigen through the T cell receptor (TCR), which triggers extensive proximal
signaling and downstream signaling cascades. These signaling events ultimately lead to
changes in cell morphology, proliferation, secretion of cytokines and cytotoxins,
migration and homing, and a plethora of effector function (Smith-Garvin et al. 2009).
Studies over the past decades have focused on how transcriptional control regulates
gene expression in an immune response. However, post-transcriptional mechanisms of
gene regulation are increasingly emerging as important regulators of immune cell
function. In particular, one mechanism of post-transcriptional gene regulation that has
garnered much interest in the past few years is alternative pre-mRNA splicing.
Alternative splicing (AS) is an essential and ubiquitous mechanism for regulated
gene expression that goes beyond turning genes “on” and “off”. In broad terms, AS
refers to any case of variable inclusion of an exon, intron or portion-thereof in some
fraction of transcripts derived from a given gene. As such, AS results in the generation of
multiple distinct mRNAs from a given gene. The most common form of AS is variable
inclusion of an internal “cassette” exon, although essentially all other potential patterns
have been described in at least some genes (Figure 1.1) (Wang et al. 2008). Variable
inclusion of sequences internal to a gene (cassette exon, alternative splice site usage or
intron retention) typically leads to alterations in coding sequence, either by adding or
deleting a peptide domain or by introducing premature stop codons (PTCs). By contrast,
differential splicing of the 5’ or 3’ UTRs can alter the presence of regulatory motifs and
miRNA binding sites, thereby influencing mRNA stability, expression and/or translation
1

Figure 1.1 Common patterns of AS. Rectangles represent exons and lines represent introns.
Dotted98 lines connect exons that are joined together to form the final mRNA. Red and blue regions
are those that can be differentially included in the mature mRNA. Dotted lines above and below
represent the two alternate possible splicing patterns.

(Sandberg et al. 2008; Moore and Proudfoot 2009; Pan et al. 2008). Thus, regardless of
pattern, AS has a profound effect on the identity, level or expression pattern of the
resulting protein.
It is now well established that the majority of multi-exon mammalian genes
(>95%) undergo AS (Wang et al. 2008; Martinez et al. 2012). Given the diversity and
plasticity required for immune effector functions it seems inevitable that cells of the
adaptive immune system rely on regulated pre-mRNA splicing to at least some extent to
control protein expression and function.
In this dissertation I explain my contribution to our understanding of how T cells
utilize alternative splicing to achieve immune effector functions. My dissertation starts
out broad, describing how we used profiling studies to determine the scope of signal2

induced alternative splicing during T cell immune responses, using a model T cell line
and primary T cells from human donors. Since I found that genes encoding signaling
proteins are enriched amongst genes that are alternatively spliced in response to T cell
receptor signaling, this suggested an interdependent regulation between signaling and
splicing. I then narrow the focus of the thesis to the study of one example of this type of
alternative splicing in the kinase MKK7. Below I provide an introduction of the breadth,
impact and mechanisms of alternative splicing in immune responses to place my results
in the context of what is known from the literature.

Breadth and impact of alternative splicing in immune responses
The accessibility of high-throughput genomics has shifted the way we think about AS
from a gene centric to a networks point of view. In light of this, a flurry of high throughput
genomic studies has emerged in an attempt to identify AS programs that are coordinated
in response to stimuli, perturbations to cell states, and differentiation among others. In
particular, the studies listed in Table 1.1 have provided a quantitative and defined
analysis of AS in various functional states of primary immune cells and model cell lines,
and support a role for widespread regulated splicing in immune responses. Specifically,
these studies have identified hundreds of potential changes in AS during T cell
activation, B cell stimulation and HIV (human immunodeficiency virus) infection. The
described splicing changes include those predicted to impact the coding potential of the
genes, as well as differential use of terminal exons which alters the presence of miRNA
binding sites in the 3’ UTR (Table 1.1).
One general conclusion from the profiling studies in Table 1.1 is that AS
regulates a unique and substantial set of genes that are not altered at the level of
3

transcription (Grigoryev et al. 2009; Ip et al. 2007; Lynch 2004). This suggests that
transcription and AS contribute independently to T cell antigen responses, underscoring
the unique role of AS in molding immune responses. Furthermore, some of the studies in
Table 1.1 found that signal-responsive AS events are enriched in genes involved in
many aspects of T cell biology and effector functions ((Martinez et al. 2012; Grigoryev et
al. 2009; Ip et al. 2007) and see chapter 2). Enriched activities include canonical T cell
signaling pathways such as NF-kB and JNK and MAP kinase signaling, Rho-mediated
changes in lymphocyte migration, and genes involved in cell proliferation (Grigoryev et
al. 2009; Martinez et al. 2012), again highlighting the potential impact of AS on immune
responses.
We note that an important aspect of the papers in Table 1.1 was providing
sufficient data to warrant the conclusions drawn. As high-throughput analyses are
becoming more accessible, the need for caution in data analysis and interpretation is
essential. It is widely accepted among splicing experts that a minimum threshold for
confidence in AS is a 10% change (i.e. 20% inclusion to 30% inclusion of a variable
exon) (Sandberg et al. 2008; Pan et al. 2008). Below this differential, the ability to detect
and quantify changes is not sufficient for rigorous conclusions. Furthermore, the biologic
significance of very minor changes in exon inclusion, even if statistically significant, is
highly suspect. Thus, it is imperative that any profiling studies state the predicted
differences for any AS events reported. Finally, defining the AS event beyond providing
a gene name is necessary for any conclusions to be drawn, as there are often more than
one potential AS event within a given gene.

4

Table 1.1: Studies identifying splicing regulation in immune cells.
Cell Type

Conditions

Experimental
Platform

Reference

Observations

JSL1 Jurkat,
primary
human CD4+
T cells

PMA (Jurkat),
PHA (primary T
cells)

RNA-seq

(Martinez et
al. 2012)

178 AS events in response to
activation of Jurkat cells, 80%
validation rate (43/52) by RT-PCR.
Validated in primary CD4+ T cells.
AS genes enriched for functions
relevant to immune response

primary
human CD4+
T cells

HIV-1 infection

exon array

(Imbeault et
al. 2012)

323 , 129 and 107 AS events are
regulated in response to HIV-1
+
infection of CD4 T cells at 24, 48
and 72 h post-infection.

PBMCs

PHA, IL-2 &
ionomycin

exon array

(Whistler et
al. 2010)

472 alternatively spliced
transcripts, >70% validation rate
(5/7) by RT-PCR, AS genes
enriched for splicing factors

primary
human
CD2+ T,
CD19+ B
cells

a -CD3/28
(T cells),

exon array

(Grigoryev et
al. 2009)

Array predicts 50-70% of
constitutively expressed genes in
T cells and 40% in B cells are
alternatively spliced. Only 4/22
predictions (18%) validate by RTPCR

Primary
murine T
cells

a-CD3/28

exon array

(Sandberg et
al. 2008)

Quantify and validate AS of
alternate terminal exons. Do not
differentiate between mechanism
of AS and APA

Primary
murine T
cells

naive and memory
T cells purified
from mice

exon array

(Wu et al.
2008)

Provide quantitative measure of
individual exons in numerous
genes that differ in array
expression between naïve and
memory murine T cells. No RTPCR validation given.

JSL1 Jurkat,
primary
human CD4+
and CD8+ T
cells

PMA (Jurkat),
PHA (primary cells)

exon junction
array

(Ip et al.
2007)

First large scale analysis of AS in
T cells. Initial analysis done in
Jurkat cells, validated predictions
in primary CD4+ and CD8+ T cells

a -CD40, IL2 +IL10
(B-cells)

Regardless of the platform and analysis pipeline used to profile mRNA
expression, rigorous validation of AS predictions by independent assays such as RTPCR are of utmost importance to define threshold criteria for meaningful data and
ultimately confirm AS events. Importantly, validation rates differ considerably among
5

published studies (Table 1.1) thus predictions from exon array or RNA-Seq cannot be
assumed a priori to be accurate. However, even if the conclusions from some of the
profiling experiments are overstated, the general conclusion that AS plays a functionally
relevant role in immune responses has been well documented. Indeed, a literature
search reveals close to one hundred genes that have now been validated to exhibit
significant changes in isoform expression during an immune response, including several
instances in which the AS changes are known to impact lymphocyte function (Table 1.2).
Many of the validated AS events in immune cells have been identified in work
done by our group in collaboration with the lab of Dr. Benjamin Blencowe. Our
microarray profiling of naive and activated T cells was the first large scale analysis of AS
in T cells (Ip et al. 2007). More recently we have expanded this analysis by employing
RNA-seq to identify further novel instances of AS (See Chapter 2) (Martinez et al. 2012).
As mentioned above, many of the genes that we and others have validated to
undergo changes in AS during immune responses include genes with known functions in
immunobiology. These include cell surface receptors, kinases, phosphatases and
adaptor proteins, transcription factors and chromatin modifying enzymes and RNA
binding proteins and others involved in regulating mRNA processing of many messages
(see Table 1.2). These studies have provided substantive evidence for the critical role
that AS plays in assuring proper function of the adaptive immune response. To
underscore the functional connection between AS and lymphocyte function, I highlight
below a few examples where regulated pre-mRNA AS of particular classes of genes has
been directly linked to immune responses and/ or susceptibility to autoimmune diseases.

6

Table 1.2: Validated instances of alternative splicing during immune responses.
Gene

Exon

a

Cell Type

b

Condition

c

Change

Reference

Cell Surface Receptors
CD3-zeta

intron 8

T

α-CD3/28

retention

(Moulton and Tsokos 2010)

CD3-zeta

intron 4

PBMC

PHA

retention

(Atkinson et al. 2003)

CD28

exon 3

T

α-CD3/28

inclusion

(Magistrelli et al. 1999)

CD45

exon 4

Jk, CD4

various

skipping

(Lynch and Weiss 2000)

CD45

exon 5

Jk, CD4

various

skipping

(Lynch and Weiss 2000)

CD45

exon 6

Jk, CD4

various

skipping

(Lynch and Weiss 2000)

CD46

mutually
exclusive

T

α-CD3/46

inclusion
exon 14

(Astier et al. 2006)

CD6

exon 5

T

various

skipping

(Castro et al. 2007)

CD8

exon 7

CD8

α-CD3/28

retention

(Thakral et al. 2008)

CD83

exon 3-4

PBMC

various

inclusion

(Dudziak et al. 2005)

CD96

exon 4

CD4, CD8

resting

skipping

(Meyer et al. 2009)

CTLA-4

exon 3

T

α-CD3/28

inclusion

(Magistrelli et al. 1999)

Fas

exon 6

PBMC

PHA

inclusion

(Liu et al. 1995)

HMMR

exon 3

CD4, CD8

PHA

inclusion

(Ip et al. 2007)

ICAM-1

exon 2-5

T, Thy

LPS

variable

(King et al. 1995)

PECAM1

exon 14-15

Jk

PMA

skipping

(Wang et al. 2003)
d

SEC16A

exon 29

Jk, CD4

PMA, PHA

variable

SEC16A

exon 30

Jk, CD4

PMA, PHA

inclusion

(Martinez et al. 2012)
(Martinez et al. 2012)

Cytokine-related
IL-4

exon 2

T

α-CD3

inclusion

(Alms et al. 1996)

IL-7Rα

exon 6

PBMC

HIV

variable

(Gregory et al. 2007)

TIR8

exon 8

Jk, CD4

PMA, PHA

inclusion

(Martinez et al. 2012)

Transcriptional regulators
ATF2

exon 14

Jk

PMA

inclusion

(Martinez et al. 2012)

BRD8

exon 20

Jk, CD4

PMA, PHA

skipping

(Martinez et al. 2012)

EHMT2

exon 10

Jk, CD4

PMA, PHA

inclusion

(Martinez et al. 2012)

FOXP3

exon 7

CD4, Tregs

α-CD3/28

skipping

(Kaur et al. 2010)

GATA3

exon 4

CD4

PHA

skipping

(Ip et al. 2007)

HIF1α

exon 14

CD4

PHA

inclusion

(Ip et al. 2007)

ILF3

exon 9

CD4, CD8

PHA

inclusion

(Ip et al. 2007)

e

IRF1

exon 7

CD4, CD8

PHA

variable

LEF1

exon 6

Jk, Thy, CD4

various

variable

(Ip et al. 2007; Mallory et al.
2011)

RUNX1

exon 1-2

CD4

HIV-1

skipping

ZNF384

exon 5

Jk

PMA

inclusion

(Imbeault
et al. 2012) 2012
, Mallory 2011,Imbeault
(Martinez et al. 2012)
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(Ip et al. 2007)

Table 1.2: (con’t)
Gene

Exon

a

Cell Type

b

Condition

c

Change

Reference

RNA-processing
AUF-1

exon 2

CD4, CD8

PHA

inclusion
d

(Ip et al. 2007)

CELF2

exon 6

Jk, CD4, CD8

PMA, PHA

variable

EIF4G2

exon 3

CD4, CD8

PHA

skipping

(Ip et al. 2007)
(Ip et al. 2007)

FIP1L1

exon 8

Jk

PMA

skipping

(Martinez et al. 2012)

HRB

exon 3

CD4, CD8

PHA

skipping

(Ip et al. 2007)
e

LUC7L

exon 2a

Jk, CD4

PMA, PHA

variable

(Martinez et al. 2012)

RBM25

exon 6

PBMC

P2I

skipping

(Whistler et al. 2010)

SAM68

exon 3

CD4, CD8

PHA

skipping

(Ip et al. 2007)

SFRS2

exon 2b

PBMC

P2I

skipping

(Whistler et al. 2010)

SFRS10

intron 1

PBMC

P2I

removal

(Whistler et al. 2010)

SNRPB

ND

PBMC

P2I

inclusion

(Whistler et al. 2010)

TIA-1

exon 5

Jk

resting

skipping

(Izquierdo and Valcárcel 2007)

U2AF

exon 11

PBMC

P2I

inclusion

(Whistler et al. 2010)

ZC3H14

exon 10

Jk, CD4

PMA, PHA

inclusion

(Martinez et al. 2012)

d

(Martinez et al. 2012)

Intracellular signaling/transport
AKAP9

exon 4

Jk, CD4

PMA, PHA

variable

CARD8

exon 5

Jk

PMA

skipping

(Martinez et al. 2012)

CLK2

exon 7

CD4, CD8

PHA

skipping

(Ip et al. 2007)

DOCK10

mutually
exclusive

T

resting

inclusion
of exon 1a

(Alcaraz-García et al. 2011)

Erk

exon 6

CD8

PHA

skipping

(Ip et al. 2007)

ERP29

exon 2

Jk

PMA

inclusion

(Martinez et al. 2012)

Fyn

mutually
exclusive

Jk

PMA

inclusion
of exon 7b

(Rothrock et al. 2003)

Fyn

exon 9

Jk

PMA

skipping

(Martinez et al. 2012)

FR4

intron 3

CD4, Tregs

resting

retention

(Jia et al. 2009)

IRAK1

exon 11

CD4, Tregs

α-CD3/28

skipping

(Birzele et al. 2011)

IRAK1

exon 12

Thy

total

variable

(Jensen and Whitehead 2001)

MAP2K7

exon 2

Jk, CD4

PMA, PHA

skipping

(Martinez et al. 2012)

MAP3K7

exon 13

Jk, CD4

PMA, PHA

skipping

(Martinez et al. 2012)
e

MAP4K2

exon 9

Jk, CD4

PMA, PHA

variable

PPP1R12
A
REPS1

exon 15

Jk

PMA

skipping

(Martinez et al. 2012)

exon 10

Jk

PMA

skipping

(Martinez et al. 2012)

TRAF3

exon 7

Jk

PMA

skipping

(Martinez et al. 2012)

VAV1

exon 6

CD4, CD8

PHA

skipping

(Ip et al. 2007)

Ion channels/binding
ITPR1
exon 54

CD4

HIV-1

inclusion

(Imbeault et al. 2012)

K(Ca)3.1

mutually
exclusive

Thy

Con A

inclusion
of exon 3

(Ohya et al. 2010)

TRIM26

exon 2

Jk, CD4

PMA, PHA

variable

e

(Martinez et al. 2012)

TRIM65

exon 3

Jk, CD4

PMA, PHA

inclusion

(Martinez et al. 2012)
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(Ip et al. 2007)

Table 1.2: (con’t)
a

Gene

Exon

Cell Type

Cytoskelet
al
CCDC14

exon 5

Jk

CLASP1

exon 9

EVI5

exon 18

FAM21C
FAM33A

b

Condition

c

Change

Reference

PMA

skipping

(Martinez et al. 2012)

CD2

α-CD3/28

skipping

(Grigoryev et al. 2009)

CD4

HIV-1

inclusion

(Imbeault et al. 2012)

exon 5

Jk

PMA

skipping

exon 3

Jk

PMA

skipping

(Martinez
et al. 2012)
one
(Martinez et al. 2012)

MACF1

exon 47

Jk

PMA

skipping

(Martinez et al. 2012)

MAP7D1

exon 6

Jk

PMA

inclusion

(Martinez et al. 2012)

MYL6

exon 3

Jk

PMA

inclusion

(Martinez et al. 2012)

SLMAP

exon 22a

Jk

PMA

skipping

(Martinez et al. 2012)

Tau

exon 2

Jk

PMA

inclusion

(Waterman et al. 1991)

ARMC10

exon 15

Jk

PMA

skipping

(Martinez et al. 2012)

FAM36A

exon 3

Jk, CD4

PMA, PHA

variable

TID1

exon 11

Th2

α-CD3

skipping

(Syken et al. 2003)

TIMM50

exon 6

CD2

α-CD3/28

inclusion

(Grigoryev et al. 2009)

Mitochondrial
d

Other

(Martinez et al. 2012)

LRRC28

exon 9

Jk

PMA

inclusion

Oncogene
(Martinez et al. 2012)
one

DDH1

exon 12

Jk

PMA

skipping

(Martinez et al. 2012)

FKBP1A

exon 3

CD8

PHA

inclusion

(Ip et al. 2007)

GALT

exon 3

Jk

PMA

inclusion

(Martinez et al. 2012)

GZMB

exon 1

CD2

α-CD3/28

(Grigoryev et al. 2009)

HSPA14

exon 4

CD2

α-CD3/28

intron
removal
skipping

NGLY1

exon 9

Jk, CD4

PMA, PHA

skipping

(Martinez et al. 2012)

PIGQ

exon 10

Jk

PMA

inclusion

(Martinez et al. 2012)

hTERT

exon 7&8

T

various

inclusion

(Jalink et al. 2007)

UGCGL1

exon 6

Jk

PMA

skipping

(Martinez et al. 2012)

(Grigoryev et al. 2009)

Notes:
a Exon numbers may vary depending on convention, numbers were either taken as reported in the
references or deduced from ENSEMBL. Refer to the primary article for confirmation
b Codes for cell types are as follows: (Jk) Jurkat, (T) Total primary T cells, (CD4) CD4+ primary T cells,
(CD8) CD8+ primary T cells, (CD2) CD2+ primary T cells, (Thy) thymocytes, (PBMC) peripheral blood
mononuclear cells PBMCs, CD4+ primary Th2 cells (Th2)
c Codes for stimuli are as follows: (PMA) phorbol myristate acetate, (PHA) phytohaemagglutinin, (a-CD3/28)
anti-CD3 and CD28 antibodies, (ConA) conclavin A, (LPS) lipopolyssacharide, (HIV-1) human
immunodeficiency virus 1, (P2I) PHA+IL2+Ionomycin. "Various" is used when more than 2 stimuli have been
used.
d Increased skipping (Jurkat)/Increased inclusion (CD4+ T cells)
e Increased inclusion (Jurkat)/Increased skipping (CD4+ T cells)

9

Cell Surface Receptors
CD3ζ - The T cell receptor-CD3 complex is responsible for recognition of antigens
presented on MHC molecules (Smith-Garvin et al. 2009). In particular, it is the CD3ζ
chain that couples antigen recognition with intracellular signaling pathways. Thus, the
level of CD3ζ expression determines the ability of a T cell to be activated. Strikingly, AS
of exon 8 of CD3ζ is a primary control point of CD3ζ expression (Moulton and Tsokos
2010; Tsuzaka et al. 2003; Nambiar 2001). The 3’ UTR of the CD3ζ gene contains
several AREs (AU-rich elements) that regulate mRNA stability, as well as a sequence
that enhances translation (Chowdhury et al. 2006). Intriguingly, this 3’ UTR contains an
intron that is preferentially removed in resting cells, whereas upon T cell activation the
intron is retained (Moulton and Tsokos 2010). Removal of the intron leads to a shortened
3ʹ′ UTR, which does not affect the coding region of the protein, but lacks two ARE motifs
(ARE2 and ARE3) and a translation regulatory sequence (Chowdhury et al. 2006). Thus,
the stability and translation of the intron-removed form of CD3ζ is reduced as compared
to the intron-retained version (Chowdhury et al. 2006; 2005) while intron retention upon
T cell activation allows for increased CD3ζ protein expression and increased T cell
signaling (Tsuzaka et al. 2003).
Defects in CD3ζ intron retention have been linked to autoimmune disease
(Nambiar 2001). T cells from patients with systemic lupus erythematosus (SLE)
preferentially express the short (intron removed) form of CD3ζ (Nambiar 2001).
Consistently, there is a decrease in CD3ζ protein associated with the TCR, and T cells
are impaired in their signaling capacity and production of the proliferation cyokine
interleukin-2 (IL-2) (Tsuzaka et al. 2003). Strikingly, not only is expression of CD3ζ
inversely correlated with severity of SLE disease, but restoring CD3ζ in cells results in a
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rescue in IL-2 production (Nambiar et al. 2003). Thus correcting the splicing defect in
CD3ζ provides a potential therapeutic opportunity for the treatment of SLE.
CD45 - One of the best-documented examples of AS in response to T cell activation is
that of the transmembrane tyrosine phosphatase CD45. In hematopoietic cells CD45 is
involved in regulating proximal antigen receptor mediated signaling, as well as integrinand cytokine- mediated signaling (Hermiston et al. 2003). Several CD45 isoforms that
result from regulated pre-mRNA AS have been documented (Lynch and Weiss 2000).
CD45 AS is differentially regulated in distinct cell types, developmental stages and in
response to signaling such as antigen receptor-mediated signaling (Hermiston et al.
2003). In peripheral T cells three variable exons 4, 5 and 6 that encode for CD45
extracellular domains are preferentially skipped following antigen receptor-mediated
signaling, resulting in increased expression of the smallest isoform (Hermiston et al.
2003). The regions of the CD45 protein encoded by these variable exons are heavily
glycosylated, and thus prevent CD45 homodimerization. Upon T cell activation, skipping
of the CD45 variable exons leads to homodimerization at the cell surface, which leads to
an inactive form of the phosphatase and decreased signaling through the TCR (Dornan
et al. 2002; Xu and Weiss 2002). Thus AS of CD45 serves as a feedback mechanism for
the maintenance of T cell homeostasis.
Interestingly, a single nucleotide polymorphism (SNP) in CD45 exon 4 (C77G)
has been described that leads to aberrant inclusion of this exon (Lynch and Weiss 2001;
Zilch et al. 1998). Consistent with the above model, in which loss of exon 4 skipping
leads to loss of T cell attenuation, studies have shown a correlation between this
polymorphism and susceptibility to multiple sclerosis (MS) and HIV infection (Hemmer et
al. 2000; Tchilian et al. 2001) as would be anticipated from a hyperactive T cell
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response. Furthermore, HIV infection itself induces exon skipping in CD45 and CD4+ T
cells expressing the smallest isoform of CD45 (CD45 RO), which have been found to
preferentially be infected by HIV-1 (Imbeault et al. 2012), suggesting a HIV-induced
positive feedback loop in which CD45 AS promotes infection.

Cytokines
IL-7Rα - AS of cytokine receptors such as those in the interleukin family typically results
in the generation of a soluble receptor that antagonizes or synergizes with the
membrane bound receptor for ligand binding (Lynch 2004). One such example is the
Interleukin 7 receptor alpha chain (IL-7Rα), in which differential skipping of exon 6
excludes the transmembrane domain resulting in a soluble form of the receptor that is
secreted in the plasma (Goodwin 1990). IL-7Rα is expressed almost solely in cells of
lymphoid origin, and mice and humans deficient in the IL-7 signaling pathway develop
lymphopenia (Mazzucchelli and Durum 2007). IL-7Rα is particularly critical in the
survival of peripheral CD4+ and CD8+ and in the generation of a memory phenotype
(Schluns et al. 2000; Kondrack et al. 2003).
Consistent with a functional importance for IL-7Rα AS in CD4+ T cells, HIV-1
infected individuals have lower concentrations of soluble IL-7Rα in their plasma (Rose et
al. 2009). Moreover, similar to the example of CD45 mentioned above, there is a genetic
association of a SNP located within exon 6 of IL-7Rα and multiple sclerosis (Gregory et
al. 2007). Notably, the SNP located within exon 6 results in increased exon skipping and
decreased expression of the membrane-bound IL-7Rα mRNA in PBMCs from MS
patients harboring the SNP (Gregory et al. 2007). By contrast, the soluble IL-7Rα mRNA
was overrepresented in SNP-containing patients relative to healthy individuals (Gregory
et al. 2007; McKay et al. 2008). Interestingly, AS appears to regulate IL-7 signaling at
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multiple layers since a splice variant of IL-7 cytokine itself lacking exon 5 was shown to
promote T cell survival and thymocyte maturation (Vudattu et al. 2009).

Intracellular signaling
Fyn - Fyn is a protein tyrosine kinase (PTK) of the Src family involved in intracellular
signaling of various cellular processes including T cell development and activation
(Palacios and Weiss 2004). The gene encoding Fyn generates two isoforms by
differential inclusion of mutually exclusive exon 7s denoted 7a and 7b (MP and RM
1989). The two exon 7s encode distinct versions of the SRC homology (SH2) domain
and part of the kinase domain of Fyn; therefore AS of exon 7 is predicted to impact
substrate recognition and phosphorylation (see below). The FynT isoform uses exon 7b
and is the primary isoform expressed in T cells. FynT more efficiently mobilizes calcium
and produces IL-2 during TCR signaling than the alternate isoform FynB, which is
primarily expressed in the brain (Brignatz et al. 2009a; Davidson 1992; Davidson et al.
1994). Infection with human T cell leukemia virus type 1 (HTLV-1) induces the
expression the FynB isoform in T cells, which could serve to attenuate T cell effector
functions (Weil et al. 1999). By contrast, T cell activation induces an even further bias
toward inclusion of exon 7B, which may serve as a mechanism for sustaining and
enhancing TCR signaling (Rothrock et al. 2003).
Recently it was demonstrated that FynT more efficiently interacts with and
phosphorylates the RNA-binding protein Sam68 than FynB (Brignatz et al. 2009b). The
differential interaction between FynT and FynB with SAM68 was mapped to part of the
distinct SH2 kinase linker encoded by exon 7 (Brignatz et al. 2009b). Swapping of the
linker region of the FynT to the FynB isoform granted it the ability to strongly interact with
and phosphorylate Sam68 (Brignatz et al. 2009b). Notably, Sam68 has previously been
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shown to modulate AS of Bcl-x, in which it promotes use of the alternate upstream 5’
splice site in exon 2 to generate the pro-apoptotic Bcl-x(s) form (Paronetto et al. 2007).
Phosphorylation of Sam68 by Fyn switches the activity of Sam68 to enhancing
production of the Bcl-x(L) isoform (Paronetto et al. 2007). Consistent with the previous
observations, expression of FynT but not FynB favors the expression of the Bcl-x(L) antiapoptotic isoform through phosphorylation of Sam68 (Brignatz et al. 2009b). These
results suggest functional importance of the regulated Fyn AS in tuning the activity of an
RNA-binding protein than in turn regulates AS of downstream target genes.

Transcription Factors
LEF1 - Lymphocyte enhancer factor 1 (LEF1) is an HMG-box transcription factor that is
broadly expressed during embryonic development, and during adulthood is expressed in
a tissue specific manner in certain lymphocyte subsets (van Genderen et al. 1994; Arce
et al. 2006). LEF1 promotes expression of the T cell antigen receptor alpha chain (TCRalpha) through binding to the TCR-alpha enhancer (Travis et al. 1991; Waterman et al.
1991). We have shown that inclusion of LEF1 exon 6 is increased during thymic
development specifically during the double negative 3b (DN3b) to double positive (DP)
transition (Mallory et al. 2011). Exon 6 encodes part of the context-dependent regulatory
domain of the LEF1 protein, which allows its TCR-alpha enhancer activity. During the
DN3a stage the mature TCR beta is expressed at the cell surface in complex with a
surrogate TCR alpha chain called the pre-TCRα chain (Leiden and Thompson 1994).
One of the critical consequences of pre-TCR signaling is the rearrangement and
transcription of the TCR-alpha chain to give rise to the expression of the mature
alpha/beta TCR complex by the DP stage. We found that increased TCR-alpha
transcript levels correlate with increased LEF1 exon 6 inclusion during the DN3b to DP
14

transition (Mallory et al. 2011). Similarly, activation of the Jurkat T cells with PMA results
in increased LEF1 exon 6 inclusion with a corresponding increase in TCR-alpha
expression. Importantly, the ability of LEF1 to enhance TCR-alpha transcription is a
direct result of LEF1 exon 6 splicing, as blocking of the LEF1 exon 6 splice site results in
a substantial decrease in TCR alpha mRNA (Mallory et al. 2011). These results suggest
that during pre-TCR signaling regulated splicing of the LEF1 transcription factor
contributes to the control of TCR-alpha transcription to produce functional TCR
complexes at the cell surface.

RNA Processing Factors
CELF2 – Many RNA binding proteins regulate their own expression by an autofeedback
loop which maintains protein expression in a particular range. The splicing factor CELF2
accomplishes this by binding to one of its own introns to induce skipping of exon 6. This
AS event results in a premature stop codon and loss of subsequent translation of full
length protein when the levels of CELF2 are sufficient (Dembowski and Grabowski
2009). Interestingly, activation of peripheral CD4+ T cells leads to an increase in CELF2
exon 6 inclusion (Martinez et al. 2012; Ip et al. 2007; Mallory et al. 2011). Although this
change in CELF2 splicing has not directly been linked to functional changes in T cells,
CELF2 is known to regulate the functionally-relevant splicing of LEF1 (see above and
below) as well as many other signal-responsive genes (Mallory et al. 2015). Therefore,
one can readily imagine a cascade of AS events initiating with autoregulatory splicing of
CELF2. Similarly, Sam68 and TIA-1 are RNA binding proteins that have been implicated
in regulated AS in T cells (see below) and have themselves been validated to undergo
changes in isoform expression following antigen stimulation of T cells (Ip et al. 2007;
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Izquierdo and Valcárcel 2007). It remains to be shown, however, whether these proteins
truly trigger splicing cascades following T cell activation.

Pathways and RNA-binding proteins that regulate splicing
Importance of understanding splicing mechanism
Surprisingly, despite the interest in AS in immune responses, we only have mechanistic
insights as to how a handful of the AS events listed in Table 1.2 are regulated (see
below). This means that we have very little understanding of what signaling pathways,
trans acting splicing factors and sequences are mediating AS programs in immune
responses. Understanding the mechanisms by which splicing is regulated in normal
immune responses is critical to understanding and treating diseases of the immune
system. As implied above, emerging research is providing an ever growing list of misregulated splicing events that correlate with autoimmune diseases and other immune
defects (Cooper et al. 2009). Understanding how SNPs cause splicing changes,
predicting the effects of newly identified SNPs and ultimately designing therapies to
correct splicing defects, all require a detailed knowledge of the mechanisms that control
particular splicing decisions.
A second motivation for understanding the mechanisms that control splicing in
immune cells is so that we can better predict co-regulation and functional consequences
of AS. AS is often thought of as a fine-tuning mechanism because it allows for tweaking
of specific functions of a protein while maintaining others. In some instances such
tweaking is sufficient to exert a major functional change in the cell (Licatalosi and Darnell
2010; Nilsen and Graveley 2010). More often, however, concerted changes in the
splicing of a family of related genes is expected to be of greater functional impact than
that generated by individual AS events (Licatalosi and Darnell 2010; Nilsen and
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Graveley 2010). For this reason, a major step in understanding the role of splicing
regulation in modulating immune responses is the identification of signaling pathways,
trans-acting factors and mechanistic commonalities that orchestrate networks of
regulated splicing. By analogy, knowledge of the binding sites and activity of
transcription factors has allowed researchers to predict what genes are expressed
downstream of an event such as NF-kB activation (Hoffmann and Baltimore 2006).
Similarly, the ultimate goal of splicing research is to gain sufficient knowledge of what
regulatory factors are activated during an immune response to be able to predict from

Figure 1.2 General mechanism of splicing and its regulation. (A) Spliceosome assembly. The 5’ end of
introns are defined by the 5’ splice site (GUAAGU) and the 3’ end of introns are defined by the branch point
sequence (BPS), polypirimidine tract (PPT) and the 3’ splice site AG dinucleotides. The U1, 2, 4, 5 and 6
represent the snRNPs which assemble with substrate and each other as shown. The NTC is an additional
snRNA-free spliceosomal subunit. For more details see ref 58. (B) Regulation of alternative splicing.
Enhancer auxiliary elements are denoted in green for exonic (ESE) or intronic (ISE) splicing enhancers.
Silencer auxiliary elements are denoted in red for exonic (ESS) or intronic (ISS) splicing silencers. The
activities of these auxiliary elements are often mediated through binding of SR and hnRNPs, two common
families of proteins described in the text, among other RNA binding proteins.
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the genetic sequence what genes and gene families undergo antigen-induced changes
in splicing patterns.

Basic concepts in the regulation of alternative splicing
At the most basic level the decisions of what sequences of a gene are included in the
final mRNA rely on the ability of the spliceosome to recognize and process the splice
sites located at the intron-exon boundaries of a pre-mRNA. The spliceosome is the
enzymatic complex that catalyzes intron removal and exon joining. Instead of being a
preformed enzyme, the spliceosome is built de novo on pre-mRNA transcripts through
sequential interactions between the substrate and subunits of the spliceosome (Figure
1.2A). The major subunits of the spliceosome are the 5 so-called snRNPs, which each
contain a single non-coding RNA (snRNA) and multiple proteins (Wahl et al. 2009).
Exons are targeted to be spliced together by binding of the snRNPs to the splice sites, a
process which is driven primarily through basepairing interactions between the snRNA
component of the snRNPs and the splice site sequences (Figure 1.2A; (Wahl et al.
2009)). Importantly, however, most mammalian splice sites only weakly basepair with
the snRNAs. Therefore, auxiliary sequence elements play a crucial role in regulating
splice site selection by modulating snRNP-substrate interactions (House and Lynch
2006; Chen and Manley 2009).
Cis-elements that control splicing include sequences within exons such as exonic
splicing enhancers (ESEs) and exonic splicing silencers (ESSs) as well as sequences
within introns such as intronic splicing enhancers (ISEs) and intronic splicing silencers
(ISSs) (Figure 1.2B). These elements either promote (enhancers) or suppress
(silencers) proper assembly of the snRNP on the substrate, typically by recruiting
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regulatory proteins which then interact with spliceosomal components (House and Lynch
2006; Chen and Manley 2009). Two protein families that often function as splicing
regulators are the serine/arginine rich (SR) proteins and heterogeneous nuclear
ribonucleoproteins (hnRNPs) (Long and Caceres 2009; Martinez-Contreras et al. 2007).
When bound within exons, SR proteins tend to enhance splice site usage, whereas
hnRNPs typically induce exon skipping (Figure 1.2B); although there are exceptions to
this generalization (House and Lynch 2006; Chen and Manley 2009; Motta-Mena et al.
2010). Moreover, both families of proteins, as well as other RNA binding proteins, can
have both enhancing and silencing activity when bound to an intron. The location of
binding relative to the splice sites, the presence of neighboring regulatory proteins, and
the relative strength of the splice site-snRNA interactions all influence the ultimate
consequence of a particular regulatory protein on the pattern of splicing. Finally, most
transcripts are bound by multiple regulatory proteins such that the final decision of which
alternative splice patterns will be used and how many distinct isoforms will be expressed
from a single gene and pre-mRNA relies on a balance of competing regulatory factors
(Licatalosi and Darnell 2010; Nilsen and Graveley 2010; House and Lynch 2006; Chen
and Manley 2009).
Another important aspect of splicing regulation, particularly in thinking about
immune responses, is how signaling pathways can influence splicing factor activity.
There are many ways by which cell signaling pathways can modulate the function of
splicing regulatory factors (reviewed in (Heyd and Lynch 2011a)). First of all, T cell
activation induces widespread transcriptional changes that can lead to differences in
splicing factor protein expression (Martinez et al. 2012; Grigoryev et al. 2009; Ip et al.
2007). Similarly, AS of RNA-binding and spliceosomal proteins, such as has been
identified in studies listed in Tables 1.1 and 1.2 (see CELF2 above), is likely to influence
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the activity of these factors and thus influence AS of downstream targets.
Phosphorylation of splicing regulatory proteins can alter their activity, localization and
ability to interact with other proteins. Phosphoproteomic analyses of TCR signaling have
found that proteins involved in all aspects of T cell signaling become phosphorylated,
including splicing factors and components of the spliceosome (Mayya et al. 2009).
Notably, TCR-induced phosphorylations within splicing proteins was preferentially
observed in domains that are predicted to mediate protein-protein and/or protein-RNA
interactions (Mayya et al. 2009). Other mechanisms of signal-induced changes in the
splicing machinery include different modes of differential protein-protein interactions,
protein-RNA interactions, protein stability and localization (Heyd and Lynch 2011a).
Strikingly, despite the abundance of AS in immune responses, relatively little is
know regarding the factors, mechanisms and signaling pathways by which such changes
in gene expression are controlled. The identity of signaling molecules and how they
regulate the activity of splicing factors and RNA binding proteins to regulate AS have
been elucidated in only a few of the validated genes listed in Table 1.2. Moreover, even
in the cases where regulators have been characterized on individual genes, the breadth
of the AS program mediated by such factors have not been well defined. Over the past
decade the primary focus of our laboratory has been to begin to identify the proteins,
pathways and mechanisms by which AS is regulated in human T cells. Below I describe
the distinct proteins and mechanistic paradigms that have thus far been described by our
lab and others to regulate splicing during T cell development and function (Figure 1.3). I
emphasize what is known, as well as what remain critical future areas of research as we
seek to gain a complete understanding of how splicing shapes immune function in
normal and disease states.
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hnRNP L
From a mechanistic perspective most of what we know about regulated splicing in T
cells comes from decades of detailed analysis of CD45, the first gene well-documented
to undergo splicing changes during T cell response to antigen (see above). We initially
demonstrated that regulation of the three CD45 variable exons is mediated by a
sequence motif, contained within each of the exons, which we designated the activationresponsive sequence [ARS= (A/CYYGCA)] (Rothrock et al. 2003; Tong et al. 2005). In
exons 4 and 6 the ARS motif lies within a 60 nt exonic splicing silencer (ESS1) that is
necessary and sufficient to confer repression of exons 4 and 6. Mutation of key residues
within the ARS has demonstrated that this sequence is critical for the partial repression
of exons 4 and 6 that is observed in resting T cells; as well as the activation-induced

Figure 1.3. Splicing factors known to regulate AS in immune responses. Domain schematics for each
factor are displayed. The abbreviations are as follows: RRM – RNA recognition motif, RRM – pseudo RRM,
G – glycine-rich region, P – proline-rich region, RGG – arginine/glycine/glycine repeat region, P, Q –
proline/glutamine rich, RS – arginine/serine-rich, KH – K homology domain. Binding preferences for each
factor are specified for hnRNP L, hnRNP LL, PSF, CELF2, TIA-1, SRSF1, Sam68.
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hyper-repression of these exons and exon 5 upon antigen stimulation (Rothrock et al.
2003; Tong et al. 2005). Furthermore, introduction of the CD45 exon 4 ESS1 element
into a heterologous unregulated exon imparts basal and TCR signaling-mediated exon
repression (Rothrock et al. 2003).
Definition of the ARS has allowed for the identification of proteins that regulate
CD45 splicing through this element. Arguably, the most essential factor in the regulation
of CD45 AS is hnRNP L. Our lab first identified hnRNP L as the major ARS-binding
activity in biochemical studies (Rothrock et al. 2005), and subsequently have confirmed
hnRNP L to be the primary mediator of basal repression of the CD45 variable exons
both in vitro and in cells (Figure 1.4) (Motta-Mena et al. 2010; Tong et al. 2005; Rothrock
et al. 2005; Melton et al. 2007; Topp et al. 2008). More recently, tissue specific knockout studies in mice revealed that thymocytes depleted of hnRNP L exhibited aberrant
inclusion of the CD45 exons, confirming the in vivo relevance of hnRNP L for CD45 exon
repression (Gaudreau et al. 2012).
HnRNP L is a highly abundant member of the hnRNP family of splicing factors
and contains four RRMs (Figure 1.3). It has both splicing silencer and enhancer
activities, depending on the context in which it binds, and functions in introns or exons to
regulate inclusion of cassette exons, intron retention and poly(A) site choice (MottaMena et al. 2010; Rothrock et al. 2005; Hui et al. 2005; Hung et al. 2008). HnRNP L
binds preferentially to CA-rich sequences, although it can associate with CA dipeptides
located in a wide range of contexts (Hui et al. 2005; 2003). Interestingly, the ARS itself is
comprised of only a few, widely scattered, CA elements. Correspondingly, hnRNP L has
only a moderate affinity for the ARS element. This use of moderate affinity is likely
essential for appropriate regulation of CD45 as it allows some exon inclusion in resting T
22

cells. Finally, the expression of hnRNP L is unchanged during T cell responses,
consistent with it largely setting a constant basal level of CD45 exon repression in both
resting and activated T cells. However, hnRNP L may become hyperphosphorylated in
response to antigen which may alter some of its activities (Melton et al. 2007; Liu et al.
2012).
As discussed below, there is increasing evidence of wide-spread activity of
hnRNP L in regulating T cell splicing. The hnRNP L T cell specific knockout mice
revealed that hnRNP L is critical for thymocyte development. In the absence of hnRNP
L, the DN4 to DP transition is blocked causing a decrease in thymic cellularity
(Gaudreau et al. 2012). HnRNP L was also implicated in migration of single postive
thymocytes to the periphery. The hnRNP L T cell specific knockout mice revealed that
hnRNP L mediates regulation of widespread AS as an RNA-seq comparison between
hnRNP L deficient and wildtype thymocytes identified many potential hnRNP L regulated
exons (Gaudreau et al. 2012). Our lab has recently combined CLIP-seq analysis of
hnRNP L binding with RNA-seq of hnRNP L knockdown in Jurkat Tcells and identified
hundreds of hnRNP-regulated cassette exons (Shankarling et al. 2014) and (Cole et al
2015 RNA) in press. Binding maps revealed that hnRNP L can repress when bound
upstream, downstream or within a cassette exon. Furthermore, the lab showed that
hnRNP L enhanced exons do not present enrichment for hnRNP L binding suggesting
this function is through an indirect mechanism ((Shankarling et al. 2014) (Cole et al 2015
RNA)). The hnRNP L enhanced exons are flanked by short GC introns with decreased
nucleosome occupancy, proposing a role for hnRNP L in epigenetic regulation (Cole et
al 2015 RNA).
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hnRNP LL
Upon activation of T cells, hnRNP L is joined in binding the CD45 ARS by two additional
proteins (Figure 1.4) (Melton et al. 2007; Topp et al. 2008). One of these is a paralogue
of hnRNP L called hnRNP L-like (hnRNP LL), which is preferentially expressed in
activated and memory T cells (Figure 1.3). HnRNP LL was identified as a regulator of
CD45 splicing simultaneously by our group and two others (Topp et al. 2008; Wu et al.
2008; Oberdoerffer et al. 2008). Two of us discovered hnRNP LL through a cell-based
screening approach (Topp et al. 2008; Oberdoerffer et al. 2008), while the third took
advantage of mouse genetics (Wu et al. 2008).
The screen through which our lab identified hnRNP LL consisted of analyzing
Jurkat T cell clones that exhibited an altered “activation-like” phenotype under resting
conditions (Topp et al. 2008). We utilized a novel reporter construct in which CD45 exon
4 was inserted between exons encoding the synthetic transcription activator Gal4-VP16,
such that expression of the active form of Gal4-VP16 was dependent on skipping of
exon 4. The expression of Gal4-VP16 was, in turn, monitored by its ability to activate
transcription of a reporter construct encoding GFP allowing for a read-out that was highly
sensitive to relatively small changes in CD45 exon 4 inclusion (Levinson et al. 2006).
Cells containing this dual-reporter scheme were then infected with a retroviral-encoded
cDNA library, and resting cells exhibiting increased levels of GFP (indicative of
increased exon 4 skipping) were isolated. Strikingly, the one commonality among
several of the resulting GFP-high cell clones was aberrantly high expression of hnRNP
LL (Topp et al. 2008). We confirmed the activity of hnRNP LL in the Jurkat T cell line by
demonstrating that direct overexpression of hnRNP LL resulted in increased exon 4
repression, while knockdown abolishes activation-induced repression (Topp et al. 2008).
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We also demonstrated that hnRNP LL mRNA and protein expression are normally
upregulated in response to T cell activation, as is direct binding of hnRNP LL to the
CD45 exon 4 ESS1 (Topp et al. 2008). Similar results were obtained from the work of
Oberdoerffer et al who isolated hnRNP LL in an shRNA screen for factors required for
repression of exon 4 in the endogenous CD45 gene in the JSL1 cell line (Oberdoerffer et
al. 2008).
The in vivo relevance of the studies regarding hnRNP LL in human T cell lines
were supported by subsequent analysis of primary human cells (Oberdoerffer et al.
2008) and by a ENU (N-ethyl-N-nitrosourea) mutagenesis study in mice (Wu et al.
2008). In the mouse study, a mutant mouse line was identified that exhibited fewer
CD4+ Th T cells. T cells from these mice, named “Thunder” mice for “Th under normal”,
were found to have altered expression of CD45 isoforms (Wu et al. 2008). Specifically,
memory T cells in the Thunder mice, which normally express the smallest isoform of
CD45, aberrantly express isoforms that include the variable exons (Wu et al. 2008). This
altered expression of CD45 was mapped to an ENU-induced missense mutation in
hnRNP LL (V136A), which abolished hnRNP LL binding to the ARS motif in CD45 by
destabilizing one of the RNA binding domains (RRMs) of the protein (Wu et al. 2008).
Despite the similarity and overlapping functions between hnRNP L and hnRNP
LL, these proteins have distinct binding requirements (Topp et al. 2008). Although both
CD45 exons 4 and 5 contain the ARS motif and are repressed by hnRNP L, hnRNP LL
does not bind to exon 5 or have a functional effect on its activation-induced repression
(Motta-Mena et al. 2010; Oberdoerffer et al. 2008). By contrast, the affinity of hnRNP LL
for the ARS element in exon 4 is actually higher than that of hnRNP L. However in naïve
T cells hnRNP LL is expressed only at ~ 1/100th the level of hnRNP L, thus there is no
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significant binding or repression of exon 4 by hnRNP LL in T cells until the expression of
this protein is induced by antigen stimulation (Topp et al. 2008). Notably, induction of
binding of hnRNP LL to the ARS in CD45 exon 4 results in a significant increase in exon
skipping over that observed from the binding of hnRNP L alone. Why association of
hnRNP LL together with hnRNP L achieves more efficient repression of exon 4 than
hnRNP L alone remains an open question, and will require further mechanistic studies.
However, it is clear that both proteins can bind simultaneously and independently to the
ARS motif, and both proteins are capable of exon repression on their own (Topp et al.
2008).
A second open question with regards to hnRNP LL and T cell function is how
broadly this protein regulates splicing, and how commonly hnRNP L and hnRNP LL work
in conjunction with one another. Although some targets of hnRNP LL splicing have been
suggested by exon array studies in T cells (Wu et al. 2008; Oberdoerffer et al. 2008)
none of these splicing events have been validated so no conclusions can be made
regarding the scope of hnRNP LL function. Studies from the Goodnow lab have
demonstrated that the regulation of CD45 by hnRNP LL is not sufficient to account for all
the phenotypes of the hnRNP LL mutant mouse, implying the existence of additional
physiologic targets of hnRNP LL activity (Wu et al. 2008). However, it is not known what
such targets may be or even if all of the activity of hnRNP LL is at the level of splicing
regulation rather than other steps of RNA processing that can be affected by hnRNP
proteins such as mRNA stability, translation, 3’ UTR processing and even transcription.
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PSF
The other factor that cooperates with hnRNP L in the signal-responsive repression of
CD45 is PTB-associated splicing factor (PSF) (Melton et al. 2007; Heyd and Lynch
2010). PSF is not considered one of the canonical hnRNP proteins, but like the hnRNPs
contains 2 RNA binding motifs as well as additional domains of low-complexity and
unknown function (Figure 1.3). PSF was initially identified as an essential splicing factor,
and has subsequently been implicated in regulating many aspects of mRNA processing
and nuclear processes (Shav-Tal and Zipori 2002). The first direct connection of PSF to
AS was our identification of PSF as one of the factors necessary for activation-induced
repression of all three of the CD45 variable exons (Melton et al. 2007). We initially
implicated PSF in the regulation of CD45 through biochemical purification of proteins
bound to the ESS1 element in CD45 exon 4. Similar to hnRNP LL, PSF associates with
the ARS element specifically in activated T cells (Figure 4) (Melton et al. 2007). This
binding of PSF to the ESS1 is independent of hnRNP L or hnRNP LL, and involves
sequences outside of the core part of the ARS motif (Melton et al. 2007; Topp et al.
2008). However, PSF is required for maximal activation-induced repression of the CD45
variable exons as indicated by the fact that mutation of the PSF-recognition element
increases CD45 exon inclusion in activated cells without affecting binding of hnRNP L or
LL (Motta-Mena et al. 2010; Melton et al. 2007; Topp et al. 2008).
Strikingly, unlike hnRNP LL whose transcription and protein expression are
increased following activation, PSF mRNA and protein expression remain constant
during an immune response (Melton et al. 2007; Topp et al. 2008; Heyd and Lynch
2010), This finding suggested that the preferential binding of PSF to the CD45 premRNA in activated T cells is controlled at the post-translational level. Interestingly, PSF
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is a direct substrate of glycogen synthase kinase 3 (GSK3) in naïve T cells, in which
GSK3 is active and phosphorylates PSF at threonine 687 (Heyd and Lynch 2010).
Phosphorylated PSF interacts with a protein called TRAP150, which prevents PSF from
binding the CD45 pre-mRNA. Upon engagement of the TCR, GSK3 is inactivated
leading to reduced PSF phosphorylation. The loss of T687 phosphorylation on PSF
releases it from TRAP150, allowing PSF to bind CD45 splicing regulatory elements and
repress exon inclusion (Heyd and Lynch 2010). Conceptually, this is one of the first
direct links between a signaling molecule and a splicing factor in T cells. Moreover, the
accumulation of unphosphorylated PSF following T cell activation requires de novo
protein synthesis, which explains the observed kinetics of activation-induced CD45 exon
repression.
Importantly, the mechanism by which TRAP150 regulates PSF is not by a simple
phospho-site recognition, since deletion of part of the C-terminus of PSF which includes
T687, does not prevent its interaction with TRAP150 (Heyd and Lynch 2010). This
observation supports a model in which phosphorylation of PSF drives a conformational
change that regulates the interaction between PSF and TRAP150. Our lab recently
showed that TRAP150 binds a region of the PSF RRMs and directly blocks PSF from
binding the CD45 pre-mRNA which is contacted by RRM2 (Yarosh et al. 2015).
Futhermore, the lab showed that the PSF/TRAP150 complex is a means of regulation for
a broader set of alternatively spliced pre-mRNAs. Specifically, they found that PSF and
TRAP150 co-regulate a set of ~40 T cell activation induced splicing events (Yarosh et al.
2015). PSF may also have additional activities in T cells as a T cell specific knockdown
of PSF in mice results in thymic apoptosis (Heyd and Lynch 2011b). While the extent of
knock-down in these studies was not sufficient to induce changes in AS, we did observe
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altered stability of several mRNAs including those encoding histones (Heyd and Lynch
2011b).

CELF2
Another hnRNP-related protein involved in regulated splicing in immune cells is CELF2
(Mallory et al. 2011). CELF2 is a member of the CELF family of RNA processing factors,
which have been extensively documented to regulate splicing during heart and skeletal
muscle development (Dasgupta and Ladd 2012). The CELF proteins all contain multiple
RRMs and typically bind UG rich sequences to promote or repress exon recognition
(Figure 1.3) (Faustino and Cooper 2005). We have recently determined CELF2 to
function as a signal-responsive splicing regulator during T cell development, as well as
in response to activation of mature T cells (Mallory et al. 2011).
Biochemical assays initially identified CELF2 as binding to two UG-rich ISEs that
control inclusion of LEF1 variable exon 6 (see above; (Mallory et al. 2011)). The
concentration of CELF2 protein, and its corresponding binding to the LEF1 ISEs,
increases during the transition from DN and DP cells in thymic development, consistent
with increased inclusion of LEF1 exon 6 following pre-TCR signaling. A similar change in
CELF2 expression, function and LEF1 splicing is also observed upon activation of JSL1
T cells. Knock-down of CELF2 in the JSL1 cells results in loss of LEF1 exon 6 inclusion
with a concomitant decrease in TCR-alpha mRNA, consistent with the functional
consequence of regulated LEF1 splicing (see above) and confirming the role of CELF2
in the regulation of LEF1 (Mallory et al. 2011).
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Furthermore, our lab has recently shown that the increase in CELF2 protein in
response to T cell signaling is driven by an increase in transcription and an increase in
the stability of the CELF2 mRNA (Mallory et al. 2015). The initial increase in CELF2
transcription is dependent on NF-kB while the increase in stablilty is mediated by an
unknown mechanism. Importantly, they uncovered that in addition to the alternative
splicing of LEF1 many additional splicing events are dependent on the increase in
CELF2 protein following T cell activation (Mallory et al. 2015). These studies
demonstrating CELF2-dependent regulation of a group of alternative splicing events
emphasize the biological importance of CELF2 as a lymphocyte splicing factor in
addition to its activities as a brain and muscle specific regulator. Interestingly the related
factor CELF1 has been shown to regulate cytoplasmic mRNA stability during immune
responses (Beisang et al. 2012). Although CELF1 has no activity in LEF1 splicing, it is
expressed in the nucleus of T cells and may regulate additional splicing events.

TIA-1
T cell-restricted intracellular antigen 1 (TIA-1) was first identified by monoclonal
antibodies that reacted with intracellular antigens in T cells, but not in B-cells (Anderson
et al. 1990). Cloning of TIA-1 revealed it to be an RNA binding protein with three RNArecognition motifs (Figure 1.3). Interestingly, this protein is homologous to a splicing
factor in the yeast S. cerivisae, Nam8, which is known to bind uridine-rich sequences in
introns (Puig et al. 1999; Förch et al. 2000; Gottschalk et al. 1998; Förch et al. 2002).
Further studies confirmed that TIA-1 functions as a splicing factor, as well as exhibiting
other RNA-processing functions such as silencing translation of TNF-alpha (Piecyk et al.
2000; Del Gatto-Konczak et al. 2000).
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TIA-1 is the primary splicing factor responsible for regulation of FAS alternative
splicing. As shown in Table 2, Fas exon 6, which encodes the transmembrane domain of
the protein, is inducibly included upon T cell activation (Liu et al. 1995). Skipping of Fas
exon 6 produces a soluble version of the receptor, which can inhibit Fas signaling and
therefore control apoptosis (Cheng et al. 1994; Cascino et al. 1995). Knockdown of TIA1, or the realated TIAR (TIA-1 related protein), results in increased exon 6 skipping
(Izquierdo et al. 2005). A uridine-rich sequence located downstream of the exon 6 5’
splice site was identified as an ISE required for the ability of TIA-1 to enhance exon 6
inclusion (Izquierdo et al. 2005).
In an interesting case of positive feedback regulation, TIA-1 is phosphorylated by
Fas-activated serine/threonine kinase (FASTK) which, as its name implies, is a kinase
that becomes activated in Jurkat T cells in response to Fas engagement with ligand
(Tian et al. 1995). Strikingly, knockdown in Jurkat cells or overexpression in HeLa cells
of FASTK phenocopies modulation of TIA-1 expression with regards to Fas exon 6
inclusion (Izquierdo and Valcárcel 2007). In addition, FASTK has little effect on Fas
splicing in cells in which TIA-1 and TIAR were depleted or the uridine-rich ISE was
mutated (Izquierdo and Valcárcel 2007). Together, these results suggest that
phosphorylation of TIA-1 by FASTK promotes the ability of TIA-1 to enhance exon 6
inclusion. Moreover, these studies propose that Fas signaling can use AS to enhance
itself in a feedforward manner in which initial Fas signaling activates FASTK and TIA-1
to increase expression of membrane-bound receptors. Whether, this pathway is involved
in the T cell activation-induced exon 6 inclusion remains unanswered. Furthermore it is
unknown whether the many other targets of TIA-1 function that have been identified are
likewise alternatively spliced in response to Fas or TCR signaling (Dember et al. 1996;
Aznarez et al. 2008; Wang et al. 2010).
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SRSF1
Alternative Splicing Factor/Splicing Factor 2 (ASF/SF2 now called SRSF1) is a member
of the ubiquitous SR family of splicing factors that promote constitutive and alternative
splicing (Long and Caceres 2009). Like all SR proteins, SRSF1 contains N-terminal
RRM type RNA binding motifs and a C-terminal domain rich in Arg-Ser dipeptides
(Figure 1.3) (Long and Caceres 2009). The C-terminal Arg-Ser (RS) domain provides
the SR protein family their name and is thought to function primarily as a protein-protein
interaction domain that promotes recruitment of the snRNPs and enhancement of exon
inclusion (Long and Caceres 2009). The splicing of most exons is controlled in at least
some manner by SR proteins. Therefore it is not surprising that, where investigated, SR
proteins have activities in controlling splicing in immune cells.
One example of SR protein function in immune-related AS comes, not
surprisingly, from studies of CD45. Specifically, we implicated SRSF1 in regulation of
CD45 exon 5. Like the other CD45 variable exons, CD45 exon 5 contains the two copies
of the ARS motif, however, they are separated by a strong ESE (Tong et al. 2005).
Although hnRNP L and PSF mediate exon 5 repression through binding to the ARS, the
ESE is also important for regulation and specifically for promoting the relatively high
level of inclusion of this exon (Motta-Mena et al. 2010; Tong et al. 2005). We identified
SRSF1 as a protein that binds to the exon 5 ESE and promotes exon inclusion in an
ESE-dependent manner (Motta-Mena et al. 2010). Furthermore, we demonstrated that
hnRNP L counters the SRSF1 enhancer activity, by directly competing for binding exon
5. Therefore, although it is now apparent that the ESE also functions at the level of
transcription (see CTCF below), we conclude that the balance of hnRNP L and SRSF1
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contributes to the degree of CD45 exon 5 inclusion, consistent with the notion that the
balance of hnRNP and SR activities plays a fundamental role in many splicing decisions.
We also note that several other SR proteins, including SRSF2 (SC35), SRSF3 (SRp20)
and SRSF7 (9G8) have also been correlated to changes in CD45 AS (Dam et al. 2000;
Wang et al. 2001), although the mechanism of activity and even whether these are direct
or indirect effects has not been determined.
SRSF1 also mediates the activation-induced CD3ζ AS highlighted in Table 2
(Moulton and Tsokos 2010). As described above, following T cell activation there is a
shift toward the CD3ζ isoform that retains an intron within the 3’ UTR, thus promoting
protein expression. SRSF1 regulates CD3ζ AS by binding to the ARE2 element within
the 3’ UTR and promoting intron retention at the 3’ UTR (Moulton and Tsokos 2010).
Consistent with the intron-retained version of the CD3ζ message being the functional
version of this mRNA, depletion of SRSF1 resulted in decreased CD3ζ protein
expression while overexpression resulted in increased intron retention and CD3ζ protein
production (Moulton and Tsokos 2010). Furthermore, during T cell activation, increased
levels of SRSF1 correlate with an increase in the intron-retained CD3ζ 3’UTR. SRSF1
protein levels has been further linked to CD3ζ protein levels in T cells from SLE patients
(Moulton and Tsokos 2010). Interestingly, several SR proteins in addition to SRSF1
show altered expression (both increased and decreased) in response to antigen
stimulation of T cells. Given the abundant functional role of SR proteins, such changes in
SR protein expression are likely to affect widespread changes in splicing efficiency and
AS patterns (Screaton et al. 1995).
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SAM68
Sam68 is a member of the Signal-Transduction and RNA (STAR) family of proteins that
contain a KH type RNA-binding domain as well as binding sites for signaling proteins
(Figure 1.3) (Lukong and Richard 2003). STAR family proteins typically have activities in
mRNA stability and translation; however, Sam68 has been shown to regulate several AS
events including the T cell activation-induced regulation of CD44 splicing (Matter et al.
2002). CD44 is a cell surface adhesion molecule involved in T cell homing, and some of
its splice variants have been correlated with tumor malignancy (reviewed in (Lynch
2004)). The CD44 gene contains 10 variable exons that are differentially included in T
cells in various combinations. Whereas naïve T cells express the shortest CD44 isoform
that lacks all of the variable exons, antigen stimulation induces the inclusion of various
combinations of the additional 10 variable exons (Arch et al. 1992; König et al. 1998). AS
of exon v5 is the most investigated of the CD44 variable exons. Deletion experiments of
CD44 exon v5 identified both an ESS and an ESE that regulate its inclusion (König et al.
1998). Activation-induced inclusion of CD44 exon v5 in T cells was also shown to be
dependent on the Ras-Raf-MEK-ERK signaling pathway (Weg-Remers et al. 2001). The
Ras signaling cascade leads to interactions between Sam68 and the SR-related protein
SRm160 to form a complex which binds the ESE and promotes exon inclusion (Matter et
al. 2002; Cheng and Sharp 2006). Furthermore, Sam68 can also interact with the Brm
subunit of SWI/SNF a complex involved in chromatin-remodeling (Batsche et al. 2006).
Upon activation by the ERK pathway Sam68 binds to CD44 exon v5 and then interacts
with or signals to Brm, to promote Pol II stalling (Matter et al. 2002; Batsche et al. 2006).
As part of a growing recognition of the mechanistic interplay between transcription and
splicing, it is known that slowing Pol II elongation rates can promote inclusion of variable
exons, by providing the spliceosome time to recognize and assemble on weak splice
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sites (Kornblihtt 2006). Consistent with this model, recruitment of Brm to CD44 through
Sam68 promotes inclusion of the variable v5 exon of this gene through transcriptional
pausing (Batsche et al. 2006). Thus, Sam68 regulation of CD44 is an example of how an
RNA-binding protein can influence AS by modulating transcription rates. A recent report
shed light on the link between Erk signaling and the change in activity of SAM68. They
showed that when Erk is activated it phosphorylates a nuclear matrix associated protein
SMAR1 that mediates a complex between HDAC6 and Sam68 (Nakka et al. 2015). This
phosphorylation of SMAR1 dissociates the complex and prevents HDAC6 from
deacetylating Sam68 and allows acetylated Sam68 to promote CD44 variant exon
inclusion (Nakka et al. 2015).

CTCF
Another excellent example of AS mediated by regulation of transcription comes from
recent studies on the DNA-binding protein CCCTC-binding factor (CTCF) (Shukla et al.
2011). CTCF binds DNA and has classically been thought of as an insulator that binds in
intergenic chromosomal regions (Singh et al. 2012). However, recently, CTCF was
shown to bind extensively within genes, where it correlates with sites of Pol II pausing.
Remarkably, CTCF binding sites are also enriched in or near alternative exons, raising
the possibility that binding of CTCF regulates elongation of Pol II to favor exon inclusion.
Proof of this model was provided for CD45 exon 5 (Shukla et al. 2011). Specifically, it
was shown that B-cell lines with high expression of CD45 exon 5 (CD45RB high)
exhibited greater CTCF binding to exon 5 than cells that were CD45RB low. Surprisingly,
the binding site for CTCF was shown to encompass the ESE previously identified as
essential to high inclusion of exon 5 (Figure 1.4) (Motta-Mena et al. 2010; Tong et al.
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Figure 1.4. Mechanism for the regulation of CD45 alternative splicing. The CD45 ARS is depicted in
orange/red and the ESE in green. In resting cells hnRNP L (L) regulates basal levels of exon 4 repression,
while SRSF1 mediates basal levels of exon 5 inclusion. Exon 5 inclusion is further regulated at the level of
transcription. CTCF binds to the exon 5 ESE at the DNA level and promotes Pol II pausing around that
region to promote exon 5 inclusion. Upon activation hnRNP LL and PSF join hnRNP L at the exon 4 and 6
ARSs to promote further repression, while only hnRNP L and PSF associates to exon 5.

2005). In cells and in vitro CTCF binding to exon 5 promoted Pol II pausing upstream of
CTCF binding sites (Shukla et al. 2011). Importantly, CTCF depletion results in loss of
CD45 exon 5 inclusion, as does mutation of the CTCF binding site, providing a direct
causal link between CTCF binding and AS (Shukla et al. 2011).
Importantly, CTCF promoted exon 5 inclusion is independent of hnRNP LL,
which does not influence CD45 exon 5 skipping in the transition from naïve to activated
T cells (Oberdoerffer et al. 2008; Shukla et al. 2011). Instead, CTCF binding to exon 5 is
inhibited by DNA methylation, and this correlates with loss of exon inclusion (Shukla et
al. 2011). Notably, memory T cells, which express reduced amounts of CD45 exon 5,
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have increased DNA methylation and decreased CTCF binding at exon 5 relative to
naive T cells (that show high levels of exon 5 inclusion) (Shukla et al. 2011). RNA-seq of
CTCF depleted B-cell lines combined with CTCF ChIP-seq, revealed genome wide
effects of CTCF regulated AS (Shukla et al. 2011). Furthermore, comparison of the
CTCF binding sites identified by ChIP-seq in B-cells with publicly available studies in
primary CD4+ T cells revealed conservation of CTCF binding sites. Therefore, regulation
of CTCF binding is likely to contribute broadly to the regulation of AS.

Splicing networks and the importance of identifying regulatory features
Although the detailed dissection of the regulation of individual genes is essential, to
ultimately understand the full functional consequence of AS in immune responses we
need to have a broader understanding of the networks of genes that are coordinately
regulated to achieve a concerted functional outcome. This is particularly true given the
concept of AS as a fine-tuning mechanism discussed above. While the RNA binding
proteins discussed above are good candidates for directing programs of coordinated
splicing, predicting targets of these proteins is not simple. While, some of the known
splicing factors have stringent binding specificity, others bind more promiscuously to premRNAs (Figure 1.3). Furthermore, combinatorial control of splicing by multiple RNAbinding proteins that bind to pre-mRNAs independently, or in complex with one another,
adds many layers of control, as seen in the example of CD45 regulation (Figure 1.4).
Such modular binding and/or function of proteins allows tight control of the extent to
which a given AS event is expressed (Motta-Mena et al. 2010; Preussner et al. 2012;
Motta-Mena et al. 2011), but precludes straightforward prediction of functional targets.

37

Global mRNA profiling during various immune responses, or in cells depleted of
various regulatory proteins, is an increasingly common method to identify co-regulated
AS events. In the case of protein depletion, such profiling studies combined with
transcriptome-wide binding maps generated by approaches such as CLIP-seq, are an
important first step toward differentiating between direct and indirect effects of various
regulatory proteins. Such genome-wide analyses also aids in defining binding signatures
that are predictive of particular splicing patterns. However, even when predicted events
are validated, profiling studies are simply a starting place for deeper understanding.
Detailed analysis of individual genes and/or biochemical analysis of particular regulatory
factors is ultimately required in order to truly understand the mechanisms by which
genes are regulated and how specific combinations of proteins lead to changes in
splicing during immune responses.
The recent analysis of CTCF function in B cells described above is an example of
a thorough comparison of factor binding with functional effects on splicing in
lymphocytes (Singh et al. 2012). RNA-seq and microarray analysis of mRNAs following
depletion of a splicing factor in T cells has also been applied to hnRNP L and hnRNP LL
(Gaudreau et al. 2012; Wu et al. 2008; Oberdoerffer et al. 2008). For hnRNP L, mRNA
from thymocytes of hnRNP L depleted versus wild type mice was analyzed by RNA-seq
(Gaudreau et al. 2012). Importantly, this study detected no major changes in gene
transcription upon hnRNP L depletion, suggesting that the observed differences in
mRNA profiles were due solely to AS (Gaudreau et al. 2012). The investigators found
that hnRNP L target genes were enriched in microtubule and cytoskeletal functions.
Although upwards of 200 AS events were predicted by RNA-seq, only 4 events were
validated (Gaudreau et al. 2012). More recently our lab has utilized two techniques:
RNA-seq and RASL-seq to identify splicing changes triggered by hnRNPL knockdown in
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T cells with a high validation by RT-PCR. They have combined these with an analysis of
hnRNP L binding sites determined by CLIP-seq to thoroughly catalogue of hundreds of
direct hnRNP L regulated AS events and indirect events as decribed above (Cole et al
RNA 2015). Furthermore, they find a negligible role for hnRNP L in regulating gene
expression levels in Jurkat T cells, in agreement with its function in thymocytes (Cole et
al RNA 2015).
For hnRNP LL, exon array analysis of resting and activated hnRNP LL depleted
T cells suggested several hnRNP LL dependent AS events (Oberdoerffer et al. 2008), as
did analysis of naïve and memory T cells from hnRNP LL mutant mice (Wu et al. 2008).
Both studies propose that hnRNP LL regulates a set of AS events upon T cell activation;
although in neither case were any of the array predictions confirmed by RT-PCR, so the
validity of the predictions remains unknown. Two other regulatory proteins known to
exhibit increased activity during T cell response are PSF and CELF2 (see above;
(Mallory et al. 2011; Heyd and Lynch 2010)). Both of these proteins have been shown in
other cell types to regulate the splicing of multiple genes (Dembowski and Grabowski
2009; Faustino and Cooper 2005; Ray et al. 2011; Kim et al. 2011; Ladd et al. 2005;
Kalsotra and Cooper 2011). Recent work from our lab indicates that CELF2 and PSF
regulate a substantial program of activation-induced splicing events in T cells (Mallory et
al. 2015; Yarosh et al. 2015). Consistent with this finding, many of the exons that we
have identified as undergoing activation-responsive AS in T cells are flanked by
sequence motifs that match the binding consensus for CELF2 (Martinez et al. 2012). For
PSF, the binding site is less well defined and thus less predictive (Shav-Tal and Zipori
2002). Genome wide analysis of PSF binding during T cell activation could help to define
a consensus PSF binding site.
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Of the other proteins thus far implicated in T cell splicing, various studies have
shown that TIA-1 preferentially binds U-rich elements, and that alternative exons with Urich intronic sequences downstream of 5’ splice sites are frequently regulated by TIA-1
(Dember et al. 1996; Wang et al. 2010). Whether some of the TIA-1 regulated AS events
identified in other cell types are also regulated in T cells or whether there are others
remains an open question. Similarly, Sam68 and SRSF1 have been implicated in the
regulation of many AS events including during the processes of adipogenesis, neuronal
development, apoptosis and heart development (Paronetto et al. 2007; Huot et al. 2012;
Iijima et al. 2011; Xu et al. 2005). However, thus far there are no studies inquiring the
broad scope of either Sam68 or SRSF1 in AS regulation in immune responses.
In addition to defining the scope of genes that are substrates of various
regulatory proteins in lymphocytes, much remains to be learned about the connections
between signal transduction and splicing factors during immune responses. Several
canonical signaling pathways are activated downstream of the T cell receptor and costimulatory receptors (Smith-Garvin et al. 2009). Future studies will be needed to
discover signaling axes involved in the coordinated regulation of AS. Attributing
regulatory control of splicing to signaling pathways will provide a higher resolution
understanding of how signal transduction is coupled to splicing. Signaling pathways that
modulate the activity of splicing factors in T cells remain largely undescribed. For the
regulatory proteins described above we know only a few of the upstream signaling
molecules that regulate their activity such as GSK3 for PSF, ERK for Sam68 and FASTK
for TIA-1 (Figure 1.5). Importantly, a single signaling pathway may regulate the activity of
multiple factors, and various pathways may impinge on the same factor. For example, a
particularly interesting question with regards to PSF is whether all activities are regulated
by its phosphorylation by GSK3 and/or interaction with TRAP150 described above. As
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Figure 1.5. Networks of signaling pathways that regulate AS in T cells. Summary of several
known kinases (blue/purple diamonds) and RNA binding factors (orange/red ovals) that have
been shown to be regulated in response to antigen (Ag) stimulation or Fas Ligand (FasL)
signaling in T cells, and the genes (text) that they regulate. Solid arrows and lines indicate direct
activities, dotted arrows/lines indicate known relationships that are likely indirect. “other” indicates
the fact that there are likely many other signaling pathways that are also involved in mediating
antigen-induced changes in AS that are yet to be discovered. Question marks are meant to
emphasize that although each signaling pathway so far has only been linked to regulation of 1-2
genes, each branch likely regulates a program of co-regulated genes. Cross-coordination
between branches is also anticipated, as observed for CD45. See text for detailed description of
each pathway.

the cellular phenotype of PSF knock-down is distinct from the TRAP150-inhibited
condition (Heyd and Lynch 2011b), it is strongly predicted that PSF has both
GSK3/TRAP-dependent and independent activities
To begin to define networks of AS we have compared the responsiveness of
specific signal-induced AS events to various stimuli in cultured and primary T cells
(Martinez et al. 2012). We classified distinct networks of signal-induced AS events by
their responsiveness to ionomycin relative to PMA. Strikingly we found the different
networks identified in this way are enriched for distinct sequence features (Martinez et
al. 2012) and see chapter 2. Among the enriched motifs we identified the ARS motif as
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present in several exons that respond to PMA signaling alone in addition to CD45
(Martinez et al. 2012). Some of the additional motifs identified in this study may likewise
regulate specific networks of genes distinct from CD45; however, individual experiments
will be required to test the functionality of these motifs. Mapping regulatory motifs also
serves to predict splicing outcome of other AS events that contain particular motifs. For
examples, our initial definition of the ARS motif allowed us to predict T cell activation
responsive exons in the Tau and Fyn genes that we subsequently validated (Rothrock et
al. 2003).
Finally, motif mapping is important to enhance our predictive capacity of disease
causing SNPs. For example, our group has made important contributions to
understanding how the SNP in CD45 exon 4 (C77G) affects AS. Despite the link
between the C77G SNP and susceptibility to MS and HIV infection (see above), the
molecular consequences of this disease relevant SNP had remained unexplored. The
C77G disrupts the ESS1 and confers aberrantly high exon 4 inclusion without affecting
the protein coding capacity (Lynch and Weiss 2001; Zilch et al. 1998). We recently found
that the C77G polymorphism weakly affects the binding of hnRNP L to exon 4 and
dramatically abrogates the binding of two additional hnRNP proteins, hnRNP E2 and
hnRNP K (Motta-Mena et al. 2011). Even though hnRNP K and hnRNP E2 make little
contribution to CD45 exon splicing under normal conditions, upon depletion of hnRNP L
these proteins play a compensatory role (Rothrock et al. 2005; Melton et al. 2007; MottaMena et al. 2011). The C77G mutation both reduces the binding of hnRNP L and
prevents the compensatory function of hnRNP K and E2, to result in a significant overall
loss of splicing repression. Therefore, a thorough biochemical understanding of the
essential regulatory element controlling exon 4 expression, and the proteins that
associate with this sequence, permitted a mechanistic explanation for the phenotype of
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the C77G SNP. Such a detailed appreciation of the molecular basis of disease is the first
step toward predicting the consequences of similar polymorphisms and designing
approaches to correct or override such genetically encoded defects.
In summary, several lines of evidence suggest broad regulation of AS during
immune responses. A handful of cases have been described in which AS serves to
modulate lymphocyte activity. Furthermore, a few of the signaling pathways, splicing
factors, and auxiliary elements that drive these AS events in immune effector functions
have been characterized. However, many more genes and regulatory factors have yet to
be investigated, and even the full spectrum of AS regulation in lymphocytes during
different phases of an immune response remains to be rigorously explored. My
dissertation has addressed the extent to which splicing is regulated during one phase of
immune response, that of T cell activation. Through profiling studies of Jurkat T cells and
primary human CD4+ T cells in unstimulated and activated states using next-generation
sequencing, we have identified hundreds of alternative splicing events that have altered
splicing pattern in response to T cell activation. I find that signal-responsive AS events
are enriched in genes involved in many aspects of T cell biology and effector functions
(Martinez et al. 2012; Grigoryev et al. 2009). Enriched activities include canonical T cell
signaling pathways, MAPK kinase signaling and cell proliferation, highlighting the
potential impact of AS on immune responses. I also find no overlap between
differentially expressed genes and genes that are alternative spliced, suggesting that
these two process have distinct roles in controlling T cell activation responses.
Furthermore, I find that not all activation-induced alternative splicing events are sensitive
to the same activation stimuli, including calcium signaling, suggesting that several
distinct signaling pathways regulate alternative splicing in T cells.
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Given the potential for AS to broadly shape cellular function and the growing
number of instances in which aberrant splicing is known to contribute to defects in
immune function, future studies will undoubtedly continue to uncover new and exciting
connections between AS and immune responses and suggest novel approaches to the
treatment of human disease. Finally, defining novel cis-regulatory elements and transacting factors that may function to co-regulate networks of genes in response to T cell
activation will further our understanding of how alternative splicing can shape T cell
functions. Given our limited knowledge regarding the mechanisms and consequences of
splicing regulation in T cells, studies on individual genes that are subject to alternative
splicing have the potential to reveal unprecedented insight into T cell regulation.
In this dissertation I describe the new mechanistic insight that we have gained
based on the MKK7 gene as a case study for studying signal-induced splicing regulation.
Through the study of MKK7 splicing regulation I identify intronic cis-regulatory elements,
factors that interact in trans with these sequences and describe a new connection
between a T cell signaling pathway and a splicing factor. First, I performed a screen for
functional differences between the two isoforms of each of 5 of the genes that are
regulated similarly in Jurkat T cells and primary T cells (see above). The results from this
screen led to the selection of the JNK kinase MKK7 for further study. The last chapters
of my dissertation focus on MKK7, as it was alternatively spliced in response to T cell
activation signaling in a manner that I predicted would change MKK7 protein function
and it was amenable to splicing mechanistic studies. Furthermore, MKK7 is a kinase
within the JNK signaling cascade, allowing me to explore the interplay between signaling
and splicing. I find that alternative splicing of MKK7 in response to T cell activation
produces an isoform of MKK7 with increased docking activity for its substrate, the kinase
JNK. This enhances JNK signaling, leading to a downstream increase in the activity of
44

the transcription factor c-jun and upregulation of the c-jun target gene and immune
cytokine, TNF-a. Moreover, the splicing of MKK7 is regulated by JNK itself. Thus I
demonstrate a positive feedback loop in JNK signaling that involves the JNK-dependent
alternative splicing of MKK7. I further show that the regulation of MKK7 splicing is
dependent on intronic regulatory sequences flanking its exon 2 and a JNK-dependent
increase in the protein expression of the splicing factor CELF2. Finally, I show that the
JNK/CELF2 signaling module is a major pathway controlling TCR-induced alternative
splicing.
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CHAPTER 2: PROFILING OF ALTERNATIVE SPLICING DURING T CELL
ACTIVATION	
  

Introduction
As discussed in Chapter 1, a hallmark of the human adaptive immune system is the
ability of T cells to detect foreign antigen and direct an appropriate functional response.
The detection of foreign antigen occurs through the T cell receptor (TCR), and triggers
an extensive array of receptor-proximal signaling proteins that in turn initiate a broad
network of signaling cascades (Smith-Garvin et al. 2009). These antigen-activated
signaling pathways coordinate effector activities (Smith-Garvin et al. 2009).

Not

surprisingly, many of these antigen-induced changes in cellular activity are conferred
through changes in gene expression (Naito et al. 2011). Thus, the activity of the human
immune system relies on the ability of T cells to undergo extensive changes in protein
expression in response to antigen-triggered signaling pathways.
Although many protein expression changes upon T cell activation are mediated
by transcription (Smith-Garvin et al. 2009; Beurel et al. 2010; Naito et al. 2011),
increasing evidence suggests that post-transcriptional gene control is also an important
feature of T cell activation (Lynch 2004; Sandberg et al. 2008). Relatively little is known
about the regulation and biological roles of alternative pre-mRNA processing following
stimulation of the immune system. A few genes such as CD45, CD3, IL-7Ralpha, Fyn
and LEF1 have well characterized alternative splicing events that undergo pronounced
changes in response to T cell activation, in a manner that has important physiological
consequences for immune function (as described in Chapter 1). The examples of
functionally relevant alternative splicing provide precedent for it’s importance in immune
responses, and suggests that determining the full profile of alternative splicing changes
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induced by T cell stimulation is critical for a complete understanding of the cellular
consequences of antigen challenge. Other studies querying alternative splicing in T cells
have utilized exon arrays thus not exploring the full transcriptome (See Table 1.1).
In collaboration with the Blencowe lab our lab utilized high-throughput RNA
sequencing (RNA-seq) to investigate global changes in alternative splicing in a cultured
T cell line and in primary human T cells. In collaboration with colleagues from the Lynch
and Blencowe labs I identified 178 genes that are predicted to exhibit robust signalinduced changes in isoform expression in cultured T cells, and provide independent
confirmation of such changes for ~40 of these genes. Importantly, at least 80% of these
signal-induced splicing changes have not previously been described as regulatory
events. A large percentage of these genes are enriched in functions related to
immunobiology, including components of several of the critical signaling pathways that
mediate T cell effector function, thus underscoring the likely importance of these
alternative splicing events for proper T cell function. Finally, by comparing alternative
splicing induced by different stimuli in the cultured cell line with that in primary cells, I
provide evidence for several distinct signaling pathways leading from cell stimulation to
alternative splicing. One of these pathways is shared between the primary and cultured
T cells; while I also identify alternative splicing events that are unique to primary human
peripheral T cells or the cultured T cell line. Collectively, our results significantly expand
knowledge of genes that are regulated at the level of alternative splicing in response to
cellular signaling, and also the signals that lead to such changes.
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Results
Global analysis of signal-induced alternative splicing and gene expression changes in a
Jurkat T cell line
Given previously reported examples of the physiological relevance of signal-induced
changes in gene expression to T cell activity ((Smith-Garvin et al. 2009; Lynch 2004;
Sandberg et al. 2008; Naito et al. 2011) and see Chapter 1), it is important to gain a
more comprehensive view of how alternative splicing is used to control protein
expression downstream of TCR-mediated signaling. To accomplish this we used RNASeq to quantify differential expression of alternate mRNA isoforms using the Jurkat
human T cell line (JSL1). Stimulation of JSL1 cells with PMA triggers signals that mimic
aspects of mature TCR signaling ((Lynch and Weiss 2000) and see below). Total RNA
was harvested from three independent samples each of resting and PMA-stimulated
JSL1 cells; these samples were pooled, polyA+ mRNA was then isolated and used to
generate cDNA libraries for RNA-Seq analysis which was performed by our collaborators
Qun Pan and Benjamin Blencowe (see Materials and Methods). Between 45 and 48
million reads were obtained from the resting and PMA-stimulated samples and were
mapped to genomic DNA sequence. Non-mapping reads were then aligned to a
reference database comprising a comprehensive set of cDNA/EST-supported splice
junction sequences ((Pan et al. 2008), Fig 2.1A). By counting the relative ratios of reads
that map uniquely to junctions representing exon inclusion and exon-skipping, estimates
for the percentage of transcripts with alternative exon inclusion (%In) were derived.
By applying minimal RNA-Seq read coverage levels required to derive reliable
estimates for alternative splicing levels, %In values could be determined for
approximately 11,000 exons in both the resting and stimulated cell samples (Table S1
from Martinez et al. 2012). Approximately 10% (929 of 10637) of these exons exhibited
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at least a 10-point change in predicted %In between the resting and stimulated cells
(Table S1 from Martinez et al. 2012). This rate of predicted differential inclusion is
consistent with a previous, smaller scale analysis in which changes in %In were
detected in 5-10% of profiled alternative exons upon T cell stimulation (Ip et al. 2007).

Figure 2.1. RNA-Seq and RT-PCR validation of alternative splicing in resting and PMAstimulated JSL1 cells. (A) Work flow of RNA-Seq analysis of isoform expression in JSL1 cells. (B)
Representative RT-PCR of genes newly predicted by RNA-Seq analysis to exhibit differential isoform
expression in resting (-PMA) versus stimulated (+PMA) JSL1 cells. % inclusion of variable exon
shown is an average of at least three independent experiments. (C) Plot of differential in % exon
inclusion in resting versus stimulated cells as calculated by RNA-Seq (Y-axis) and RT-PCR (X axis).
Pearson coefficient is calculated as 0.894.
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To focus on the most pronounced signal-dependent alternative splicing events,
we identified a set of 178 exons in 168 genes that have at least a 20-point differential in
%In between resting versus stimulated cells (Table A1.1). Among these signal-induced
changes in alternative splicing, 90 (51%) of the exons displayed increased inclusion and
88 (49%) of the exons displayed increased skipping upon PMA stimulation. Notably, this
list of “top candidates” captures previously defined and biologically important signalresponsive exons, including all three of the immune-regulated alternative exons in the
CD45 gene, and also exons in the FYN, CUGBP2, and MAP4K2 genes (Lynch and
Weiss 2000; Rothrock et al. 2003; Ip et al. 2007; Mallory et al. 2011).
Next, my colleagues from the Lynch lab and I used low cycle RT-PCR to validate
predicted changes in the levels of inclusion of 46 additional exons among the list of 178.
These events were chosen at random to represent a range from largest to smallest
predicted changes in %In, and included sets of exons that display either increases or
decreases in %In upon stimulation. For 32 of these exons, we observe differential %In
values between resting and stimulated cells that are largely consistent with the RNA-Seq
predictions, while an additional five genes exhibited smaller yet statistically significant
differential %In values (Table 2.1, Fig 2.1B, C; p<0.05 for all; paired student’s t-test).
Together with the six exons validated in previous studies, the results from the RT-PCR
validation experiments confirmed changes in %In levels between resting and stimulated
cells for 80% (43/52) of the tested events (Table 2.1, A1.1), with a Pearson correlation
coefficient of 0.894 between %In values derived from the RNA-Seq and RT-PCR-based
measurements (Fig 2.1C). As further validation of the RNA-Seq predictions, 11 of 12
exons predicted to have no notable change in %In (<5-point differential) between resting
and activated JSL1 cells also showed a lack of signal-responsiveness by RT-PCR
analysis (Table A1.2).
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Table 2.1: Signal-Responsive Exons in JSL1 Cells Validated by RT-PCR (n=>3).
Gene

%Inc
-PMA
RT-PCR

StDv

%Inc
+PMA
RT-PCR

StDv

RT-PCR
Differential

% Inc
-PMA
RNA-seq

% Inc
+PMA
RNA-seq

RNA-seq
Differential

SLMAP
FAM36A
CELF2
TRAF3
BRD8
NGLY1
ZC3H14
SEC16A-E1
PPP1R12A
MACF1
REPS1
AKAP9
CD45-E6
H2AFY
TRIM26
EHMT2
DDHD1
MAP4K2
TIR8
LUC7L
CD45-E4
PIGQ
SEC16A-E2
CD45-E5
MAP2K7
CARD8
Fyn
ZNF384
ERP29
TRIM65
CKB
FAM21C
UGCGL1
MAP7D1
FIP1L1
LRRC28
MYL6
CCDC14
GALT
MAP3K7
ATF2
ARMC10
FAM33A

74
69
84
95
70
70
56
32
27
28
89
55
31
94
46
73
29
52
49
12
20
23
61
94
47
21
30
64
66
85
39
36
21
57
33
77
79
51
71
12
56
56
44

2
2
5
1
2
6
2
1
2
2
2
1
2
1
5
2
3
4
4
3
2
2
3
1
5
2
3
2
2
3
4
3
1
1
1
2
4
2
3
1
1
1
1

11
31
48
59
37
43
81
8
3
5
67
33
11
74
64
91
12
68
64
27
5
37
75
80
33
8
18
76
77
96
50
25
10
67
23
87
89
41
80
4
63
49
38

2
2
1
3
1
2
3
2
1
1
2
2
2
2
4
3
4
6
4
3
1
3
3
4
2
4
1
2
1
3
4
2
2
1
2
2
3
1
1
0
2
1
1

-63
-38
-36
-36
-33
-27
25
-24
-24
-23
-22
-22
-20
-20
18
18
-17
16
15
15
-15
14
14
-14
-14
-13
-12
12
11
11
11
-11
-11
10
-10
10
10
-10
9
-8
7
-7
-6

81
90
92
98
71
94
55
53
68
41
95
72
80
83
77
56
55
65
55
48
33
67
71
94
61
88
100
47
49
76
65
78
62
64
71
73
73
94
54
35
44
89
90

7
48
63
78
29
59
84
17
9
12
75
41
52
52
97
87
16
90
91
88
8
94
91
69
39
58
76
87
95
100
86
46
16
84
31
94
93
75
93
8
68
68
63

-74
-42
-29
-20
-42
-35
29
-36
-59
-29
-20
-31
-28
-31
20
31
-39
25
36
40
-25
27
20
-25
-22
-30
-24
40
46
24
21
-32
-46
20
-40
21
20
-19
39
-27
24
-21
-27
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In general, predictions based on fewer than 20 reads per splice junction, or
based on %In changes between resting and stimulated JSL1 cells of <15%, were not
supported by RT-PCR results (data not shown). Therefore, I focused subsequent
analyses on the set of 178 exons that are associated with a high rate of validation. Given
the number and length of the RNA-Seq reads analyzed in this study, we estimate that
the list of 178 regulated exons we have detected are represented by the top ~40% most
highly expressed genes in JSL1 cells (Blencowe et al. 2009).

However, given the

unbiased nature of RNA-Seq and our subsequent analysis (see below), we anticipate
that these 178 alternative splicing events are representative of the larger set of signalresponsive cassette alternative exons in JSL1 cells.
To address whether signal-induced changes in mRNA expression levels may
have affected our detection of %In changes, I next compared changes in total mRNA
expression with changes in alternative splicing. In our previous, smaller-scale analysis of
mRNA expression in JSL1 cells we determined that upon PMA treatment a similar
percentage of genes exhibited alternative splicing changes as transcriptional changes.
However there was no significant overlap between the sets of genes affected by each
process (Ip et al. 2007). In the present study, of 10,374 genes for which we obtained
reliable sequence coverage in either resting or stimulated cells (10 or more reads per 50
basepairs of gene length), 312 exhibit a change of 2-fold or greater in mRNA expression
between resting and stimulated cells (Table S3 from Martinez et al. 2012). As observed
in previous studies profiling gene expression in T cells (Lin et al. 2003; Ip et al. 2007),
I observe that a larger number of genes are upregulated upon stimulation than are
repressed (207 vs. 115). Importantly, further consistent with our previous studies (Ip et
al. 2007), none of the 178 differentially spliced exons are located within this set of 312
transcriptionally-regulated genes. Therefore, while alternative splicing and transcriptional
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Figure 2.2. Genes that undergo signal-responsive alternative splicing in JSL1 cells are enriched for
activities required for T cell function. (A) The 178 exons identified as signal-responsive in this study were
analyzed by IPA (Ingenuity Systems,www.ingenuity.com) for functional categories. Categories graphed
show above-threshold significance (-log(p-value) > 1.5) in enrichment relative to the 11,000 exons which
were detectable in the RNA-Seq analysis. Numbers above the bar graph represent the number of genes
that score for each category. (B) Same as (A) but genes were analyzed for their involvement in canonical
signaling pathways.
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changes affect a similar percentage of genes, in general these regulatory processes do
not directly impact one another in the context of signal-induced changes in JSL1 cells.
Interestingly, by performing an ingenuity pathway analysis, I find that the signalresponsive exons we have identified are significantly enriched in genes involved in many
aspects of cellular development and activity relevant to T cell function, including cell
signaling and gene expression; as well as functions that are specifically related to
lymphocyte biology such as Immune Cell Trafficking, Inflammatory Response,
Immunologic disease and Cell-mediated Immune Response (Fig 2.2A, Table A1.3A;
p<0.03; Fischer’s exact test). Importantly, when I scored the genes containing the set of
178 exons for involvement in specific signaling pathways, I observe enrichment in many
of the signaling cascades that are triggered in response to T cell activation and which
are required for T cell effector functions, such as NF-kB, JNK and MAP kinase signaling,
as well as Rho-mediated changes in cell migration (Fig 2.2B, Table A1.3B; (SmithGarvin et al. 2009)). Together, these results strongly suggest that alternative splicing
likely plays a major role in shaping the T cell response to stimulation. Moreover, in light
of previous work demonstrating important functional roles for a few alternative splicing
events in T cells (Hemmer et al. 2000; Lynch 2004; Mallory et al. 2011), I predict that
many of the new examples of regulated exons we identify here also contribute to an
optimal immune response.
Genes that displayed differential expression at the transcript level were also
significantly enriched for functions related to T cell biology, including almost all of the
functional categories enriched among the genes with regulated alternatively splicing
events (Table A1.4AB; Fig 2.3; p<0.03). Interestingly, only “RNA Trafficking” was
identified as a function uniquely enriched among the alternatively spliced genes (A1.4B).
By contrast, transcription appears to regulate a broad spectrum of functions not
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impacted by alternative splicing, including general functions such as protein synthesis
and trafficking, cellular morphology and mobility, and functions related to metabolism
(Table A1.4A,B; Fig 2.3B). Functions enriched among transcripts up-regulated by cell
stimulation were largely overlapping those enriched among repressed genes (Fig 2.3A).
Strikingly, however, the pathways enriched among the up-regulated and down-regulated
genes are entirely distinct (Table A1.4C,D; Fig 2.3C). Moreover, only one signaling
pathway (NF-kB) includes genes regulated at both the level of transcription and
alternative splicing (Fig 2.3D). Therefore, whereas both transcriptional and splicing
regulation have the ability to influence T cell biology, these mechanisms appear to do so
through distinct signaling or functional pathways.

Figure 2.3: Comparison of IPA analysis of gene expression (GE) changes upon stimulation of JSL1
cells. (A) Functional categories enriched in genes up-regulated (red) vs. down- regulated (blue) upon
stimulation. (B) Functional categories enriched in all genes that change expres- sion (GE, red) vs. splicing
(AS, blue). (C) Signaling pathways enriched in genes up-regulated (red) vs. down-regulated (blue) upon
stimulation. (D) Signaling pathways enriched in all genes that change expression (GE, red) vs. splicing (AS,
blue).
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A subset of signal-responsive exons in Jurkat T cells have similar behavior in primary T
cells
I next asked whether the signal-responsive exons detected in JSL1 cells are also
regulated in response to antigen challenge of mature, peripheral T cells. CD4+
peripheral T cells were isolated from multiple donors and stimulated in culture with the
lectin PHA, which functions as a surrogate antigen to stimulate the canonical T cell
receptor signaling pathways. I then assayed alternative splicing changes for the top 25
genes in Table 1 by RT-PCR analysis of RNA harvested from resting or stimulated T
cells from multiple independent donors. This revealed that 68% (17/25) of the tested
exons show a statistically significant change in %In following PHA stimulation, whereas
the remaining eight exons did not detectably respond to antigen stimulation (Table 2.2;
Fig 2.4A-D). Similar results to those observed in the CD4+ T cells were obtained in
CD8+ peripheral T cells, and also when either CD4+ or CD8+ T cells were stimulated
with anti-CD3/CD28 antibodies instead of PHA (data not shown).
Although the majority (10/17) of the PHA-dependent changes in alternative
splicing in CD4+ primary cells were in the same direction (i.e. more or less exon
inclusion) as the changes seen upon PMA treatment of JSL1 cells (Table 2.2, Fig 2.4A,
B), some of the PHA-responsive exons (7/17) showed an opposite change in the PHA
stimulated primary cells compared to the PMA-stimulated JSL1 cells (Table 2.2, Fig
2.4A, C). Similar reciprocal changes in alternative splicing between JSL1 and CD4+ cells
has been noted in previous studies (Ip et al. 2007; Mallory et al. 2011). This difference in
directionality of the splicing change suggests cell type specific differences in T cell
signaling.
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Figure 2.4. Analysis of activation-induced splicing in CD4+ primary cells relative to JSL1 cells. (A)
Graphical representation of the change in % exon inclusion between resting and PHA-stimulated CD4+
cells (purple bars) compared to the change observed between resting and PMA-stimulated JSL1 cells (gray
bars). % exon inclusion differential was calculated by RT-PCR from at least 3 independent experiments
(JSL1) or donors (CD4+). Exons were further grouped in one of three categories: (I) responding similarly in
both cell types (red tint), (II) responding in an opposing manner in the two cell types (blue tint), or (III)
showing no statistically significant change upon PHA-treatment of CD4+ cells. See also Tables 1 and 2 for
details. (B-D) Representative RT-PCR of isoform expression in resting (-PHA) versus stimulated (+PHA)
CD4+ primary T cells, for genes in categories I (B), II (C) or III (D). % inclusion of variable exon shown is an
average of at least three independent experiments.

A PMA-sensitive pathway in Jurkat T cells uniquely mimics TCR-signal induced
alternative splicing in primary T cells
The classical model of T cell signaling posits that antigen-challenge and pre-TCR
engagement activate Ras and Calcium-dependent signaling pathways that synergize to
achieve an optimal response (Smith-Garvin et al. 2009). PMA is thought to primarily
trigger the Ras-dependent branch of this signaling cascade, while the calcium ionophore
Ionomycin induces calcium signaling. However, there is much evidence suggesting
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overlap or cross-talk between these pathways in JSL1 cells. Most conspicuously, PMA
alone triggers maximal expression of TNFa in JSL1 cells with no synergy observed upon
the addition of Ionomycin (Fig 2.5A). This result is striking since transcription from the
TNFa promoter has been well-documented to require Ca+2 signaling along with Ras
stimulation (Tsai et al. 1996b; López-Rodríguez et al. 2001). Moreover, treatment of
JSL1 cells with Ionomycin results in at least partial expression of the cell-surface protein
CD69 (Fig 2.5B), which is traditionally considered a marker of Ras activation
(D'Ambrosio et al. 1994). Therefore, PMA and Ionomycin stimulation of JSL1 cells does
not fit a clear-cut model of independent Ras and Ca+2 signaling respectively.
Given the apparent nonconventional signaling in JSL1 cells I wished to better
delineate the pathways through which the various “PMA responsive” genes are
regulated. In particular I sought to determine the relative contribution of Ionomycininduced signaling in the alternative splicing events we have identified. Notably, I find that
10 of the top 25 PMA-responsive genes show at least 50% of the maximal PMAresponse when stimulated with Ionomycin alone (Table 2.2, Fig 2.5C, left most 10
genes). By contrast the other 15 genes did not display statistically significant or robust
changes in alternative splicing upon Ionomycin treatment ((Fig 2.5C), gene names
between dotted lines). In no case did I observe any synergy following co-stimulation with
PMA and Ionomycin (data not shown). Therefore, I conclude that there are at least two
distinct signaling pathways leading from PMA stimulation to alternative splicing, one of
which is triggered by both PMA and Ionomycin and another, which is responsive only to
PMA.
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Figure 2.5. Analysis of signaling pathways in JSL1 cells and their effect on alternative splicing. (A)
Induction of TNF-alpha expression in response to PMA and/or Ionomycin treatment of JSL1 cells. TNF-alpha
mRNA was measured by RT-PCR and the average of 2 experiments is shown. (B) Cell-surface expression
of CD69, as measured by flow-cytometry, in JSL1 cells grown under resting (gray), PMA stimulated (red) or
Ionomycin stimulated (blue) conditions. (C) Analysis of Ionomycin-induced alternative splicing of the top 25
PMA-responsive genes. Ionomycin responsiveness was quantified by RT-PCR from at least three
independent experiments and the difference in exon inclusion between resting and Ionomycin-stimulated
cells was graphed as a % of splicing changed observed upon PMA stimulation (PMA differential set to
100%). (D) Model of signaling pathways in JSL1 versus CD4 cells as indicated by alternative splicing
responsiveness.

To ask whether differential signaling pathways might explain the distinct classes
of alternative splicing response patterns observed when analyzing different cell types, I
directly compared the Ionomycin-response data with the data from CD4+ T cells.
Strikingly, I observe that all (10/10) of the exons displaying the same directionality of
change in splicing upon stimulation of CD4+ and JSL1 cells are responsive only to PMA,
while 6 of the 7 genes that had an opposite splicing pattern in CD4+ and JSL1 cells are
also responsive to Ionomycin. To investigate whether this correlation might be predictive,
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I next assayed three additional genes that we have previously found to be anti-correlated
in response to stimulation of JSL1 and CD4+ cells (Lck, LEF1, Pyk2; (Ip et al. 2007)).
Remarkably, each of these genes displays a change in splicing in response to Ionomycin
that is similar to the response to PMA in JSL1 cells (Fig 2.5C). By contrast, the one
additional gene (TRIM65) we have thus far found to be spliced similarly in both PHAstimulated primary cells and PMA-stimulated JSL1s, is entirely unresponsive to
Ionomycin (Fig 2.5C).
Taken together, these results suggest that for 40% (10/25) of the genes initially
characterized as “PMA-responsive” in JSL1 cells, the signaling pathway that leads to
splicing modulation overlaps with an Ionomycin-triggered cascade (Fig 2.5D). Moreover,
this Ionomycin-triggered or “overlapping” pathway in JSL1 cells is distinct from signaling
cascades triggered by antigen-stimulation of CD4+ cells, and in some cases is even
counter to the effects of TCR signaling, at least in terms of alternative splicing regulation
(Fig 2.5D). These differences in alternative splicing of some genes may account for
important cell type specific splicing regulation. By contrast, we conclude that there is a
PMA-induced pathway in JSL1 cells that mimics, at least at the level of alternative
splicing, antigen-stimulation of mature peripheral T cells. Such a model is further
consistent with the fact that I observe full TNF-alpha expression with PMA alone,
demonstrating that PMA is sufficient in JSL1 cells to induce at least some transcriptional
events that typically require both a Ras and Ca+2 signal. However, I note that not all
PMA-only-induced alternative splicing events in JSL1s are seen in CD4+ T cells,
suggesting that at least one PMA-induced mechanism in JSL1 cells is not functional in
primary T cells (Table 2.2, Fig 2.4D).
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Table 2.2: Exon expression in mature human T cells (n=>3)
Gene

CD4+
Resting

CD45-E5
CD45-E6
MAP2K7
CD45-E4
NGLY1
BRD8
TIR8
SEC16A-E2
EHMT2
ZC3H14

53
25
39
10
64
47
30
59
58
76

LUC7L
MAP4K2
TRIM26
CELF2
FAM36A
SEC16A-E1
AKAP9

64
78
88
40
51
11
67

DDHD1
SLMAP
H2AFY
PPP1R12A
REPS1
MACF1
PIGQ
TRAF3

47
56
94
7
76
12
82
90

CD4+
PHA
13
8
3
2
7
4
12
4
2
3
8
3
4
4
6
1
2
7
9
4
5
3
3
5
3

27
5
26
1
56
41
70
70
67
82
16
47
58
75
61
17
72
52
61
98
10
77
12
81
88

P< 0.05

CD4+
Differential

JSL1
Differential

Ionomycin
responsive?

*
*
*
*
*
*
*
*
*
*

-26
-20
-13
-9
-8
-6
40
11
9
6

-14
-20
-17
-15
-27
-33
15
14
18
25

N
N
N
N
N
N
N
N
N
N

*
*
*
*
*
*
*

-48
-31
-30
35
10
6
5

15
16
18
-36
-38
-24
-22

Y
Y
Y
Y
N
Y
Y

5
5
4
3
1
0
-1
-2

-17
-63
-20
-24
-22
-23
14
-36

Y
Y
N
Y
N
Y
N
N

6
2
3
2
7
1
12
2
2
4
8
4
6
9
6
3
3
4
5
1
1
6
3
3
0

Distinct sequences correlate with discrete signal-responsive categories of alternative
splicing
Finally, to begin to address whether the different sets of signal-induced alternative
splicing events detected in our transcriptomic analysis are regulated by distinct factors,
we investigated whether they are significantly enriched in specific sequence motifs
indicative of binding sites of splicing regulators. An implication of the model in Figure
2.5D is that exons that are regulated by a common signaling pathway (i.e. one of the
colored arrow in Fig 2.5D), are likely regulated by similar or overlapping mechanisms.
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Figure 2.6. Motif enrichment among signal-responsive alternative exons. (A) Logos of motif identified
as enriched among category I exons and e-value of the enrichment (left) along with the location and p-value
of the motif in each of the 5 exons in which it was identified (right). (B) Logos and corresponding e-values of
the five motifs identified within the flanking introns of exons from categories I, II and III, along with the
names of the genes in which each motif is found. Detail of motifs and locations are provided in Figure 2.7.

As most alternative splicing relies on the binding of regulatory proteins to cis-acting
control sequences (Chen and Manley 2009), and in light of previous observations that
co-regulated sets of alternative exons tend to be regulated by one or more common
regulatory factors, we reasoned that exons which fell into a given regulatory category
might share specific regulatory motifs. Brian Cole a graduate student in the Lynch lab
queried each of the three categories of genes in Table 2.2 using the motif finder MEME
(Bailey et al. 2009) to search for sequences that are significantly enriched in the
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regulated exons or their flanking intron sequences (see Materials and Methods). For the
exons we only found a single statistically-enriched motif among the “category I” exons
regulated similarly in JSL1 and CD4 cells (Fig 2.6A). Strikingly, this enriched motif
identified by MEME encompasses the “activation-response sequence” (ARS =
(A/C)YYGCA) that we have previously demonstrated to be critical for the regulation of
each of the three CD45 variable exons (Rothrock et al. 2003; Motta-Mena et al. 2011).
MEME indeed identifies two copies of the enriched motif in each of the CD45 variable
exons, as we have previously identified (Rothrock et al. 2003), and also identifies
previously unrecognized occurrences of this sequence motif in two additional exons in
category I (Fig 2.6A). This motif is not found in categories II or III, nor is it enriched in the
validated “non-responsive” exons.
In contrast to these results, we observe significantly enriched sequence motifs
within intronic sequences flanking the regulated exons belonging to each of the three
categories (Fig 2.6B, Fig 2.7). For categories I and II, two distinct sequence motifs are
enriched. Matches to these motifs were found in the intron both upstream and
downstream of the variable exons. We also were able to identify a single motif in
category III, however this motif is present in only two of the eight genes in the category
and has a relatively low e-value.

Notably the sequence motifs flanking the signal-

responsive exons are similar but not identical between the three categories, suggesting
functional differences between the regulatory factors that mediate signal-induced
alternative splicing of these sets of genes. This observation is consistent with the distinct
signaling requirements for the regulation of alternative exons belonging to classes I, II
and III. In sum, we conclude that there are likely multiple, distinct connections between
signaling pathways and the regulatory factors that control splicing in T cells.
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Figure 2.7. Details of enriched motif analysis. Exact sequences and locations thereof for the
sequences which match enriched motifs identified in Figure 2.6. Data presented as provided by
MEME suite analysis (Bailey et al., 2009).

Discussion
Alternative splicing is an important but under-investigated mechanism of regulation of T
cell function during immune responses. In this study we use RNA-Seq to identify genes
that express distinct isoforms in response to stimulation of a human T cell line. We
identified 178 exons in 168 genes that are subject to signal-induced alternative splicing.
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The vast majority of these genes also exhibit differential isoform expression in naive and
activated primary T cells.
Importantly, only a few of the 178 exons belong to genes previously described to
undergo signal-induced alternative splicing in T cells or in any other system. For
example, only 25 of these exons were among the high-confidence set of alternative
splicing level predictions generated by our previous quantitative alternative splicing
microarray profiling study (Ip et al. 2007). Conversely, many of the signal-induced
alternative splicing changes predicted to occur based on our previous microarray
profiling study were not detected by RNA-Seq analysis. This can be attributed to the
observations that a substantial number of the microarray-profiled exons lack sufficient
read coverage required to generate reliable predictions for splicing changes, that the
microarray platform is associated with a higher false-positive detection rate for splicing
changes than is RNA-Seq analysis, and possibly also because of false-negative
detection in the RNA-Seq analysis (data not shown). Thus, while both systems are
capable of generating reliable predictions for alternative splicing changes on a largescale, RNA-Seq has the main advantage of affording relatively unbiased detection of
exons within expressed transcripts and, based on comparisons of relative RT-PCR
validation rates (this study and (Ip et al. 2007)), is generally more quantitative.
Regardless, our results greatly expand the repertoire of known signal-regulated splicing
events. Moreover, because of the unbiased nature of RNA-Seq analysis, these events
are likely to be representative of the total spectrum of alternative exons that are
regulated during T cell activation. This is further reflected by the enrichment of the set of
178 exons in gene function categories that are specifically associated with the immune
response.
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Strikingly, the 178 exons are significantly enriched in genes involved in mediating
critical T cell effector functions, such as cell signaling, proliferation and development and
immune cell trafficking. For example, MKK7 is a MAP kinase that controls the activity of
the c-Jun transcription factor that is essential for expression of immune cytokines (see
chapter 4), EHMT2 is a methyl transferase that has been implicated in regulating gene
expression and controlling apoptosis (see chapter 3), and TIR8 regulates Toll-like
receptor signaling and the inflammation response (Hoffmann et al. 2008; Drexler et al.
2010; Huang et al. 2010; Wang et al. 2007). Therefore, although the precise functional
impact of most of the splicing events we have uncovered remain unexplored, alternative
splicing is predicted to play a significant role in shaping the ability of T cells to mount a
robust and appropriate immune response.
Finally, in addition to providing novel examples of signal-induced alternative
splicing, our data reveal important insight into the diversity of signaling pathways that
control splicing. Specifically, comparison of the responsiveness of splicing to various
stimuli in the cultured versus primary T cells enabled grouping of the signal-responsive
exons into at least three distinct networks. Importantly, we find that each regulatory
network is characterized by distinct sequence features, further suggesting independent
regulatory mechanisms including multiple signaling pathways.
The relevance of our motif analysis is strongly suggested by the unbiased
identification of the known ARS regulatory motif among the category I genes. We have
previously shown that the ARS motif functions by recruiting hnRNP L, LL and PSF to
regulate the category I exons in the CD45 gene (Rothrock et al. 2005; Topp et al. 2008;
Melton et al. 2007; Motta-Mena et al. 2010; Tong et al. 2005). Our identification of the
ARS motif in EHMT2 and TIR8 suggests that hnRNP L, LL and/or PSF may also
regulate at least a subset of additional category I exons. Interestingly, however, a G-rich
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motif was also identified in the introns of EHMT2 and TIR8, implying potential cross-talk
between signaling pathways and/or regulatory factors in mediating the final outcome of
splicing of these genes. Moreover, the fact that the ARS motif was not enriched in exons
outside category I underscores the likelihood that the category II and III exons are
regulated by pathways and factors other than those described for the ARS-containing
CD45 gene. Further identification of the regulatory factors will be required to fully
delineate the signaling networks that control diverse alternative splicing events;
however, our studies clearly demonstrate the presence of distinct regulatory pathways.
Therefore, in summary, the data presented in this chapter provide a valuable basis for
the future characterization of the function and mechanisms of alternative splicing
networks controlled by distinct signal-induced pathways during T cell stimulation. Indeed,
chapter 3 uses the information gained from this study to select one of the identified
candidate genes (MKK7) for further analysis. Finally, chapters 4 and 5 describe the
biological impact of MKK7 alternative splicing and reveal the mechanism by which MKK7
splicing is regulated. Specifically, I identify a network of alternative splicing controlled by
a new signaling connection between a canonical T cell signaling pathway and a splicing
factor.
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CHAPTER 3: SELECTION OF AN ALTERNATIVE SPLICING EVENT FOR
FUNCTIONAL AND MECHANISTIC STUDIES

Introduction
Our global analysis of alternative splicing during T cell activation identified over 178
alternative splicing events in 168 genes (Table 2.1). For most of these genes, the effect
of differential isoform expression on T cell function and the molecular mechanism
controlling alternative splicing is unexplored. In order to understand the impact of
alternative splicing on lymphocyte biology, performing detailed studies of alternative
splicing of individual genes is critical to reveal novel paradigms of splicing regulation and
its functional implications. To identify experimentally tractable models to further dissect
the functional role of T cell activation-induced alternative splicing, I focused my effort on
the list of alternative splicing events that we validated as being regulated similarly upon
activation of both Jurkat T cells and primary human CD4+ T cells (Table 2.7). The
conserved regulation of these events suggests potential functional importance for T cell
function, and the availability of a model T cell line facilitates biochemical analysis. I then
narrowed this list to novel alternative splicing events that have not been previously
explored: the JNK kinase MKK7; the histone methyltransferase EHMT2; the
transcriptional

co-activator

BRD8;

the

RNA-binding

proteins

ZC3H14;

the

deglycosylating enzyme NGLY1. This chapter describes the data I accumulated on
these genes and the selection process that identified MKK7 among the five candidates
as the focus of further studies described in Chapters 4 and 5.
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Results
Screen for T cell activation-induced alternative splicing events for further studies
As a starting point for selecting a candidate gene I aimed to identify alternative splicing
events that impacted protein expression and T cell functions. The criteria that I tested to
select a candidate gene for further study were as follows: functional differences between
splice variants including (1) expression of T cell activation markers, (2) cell viability, (3)
known protein activities and (4) minigenes that recapitulate endogenous regulation.
First, I transfected

splice

site

blocking

antisense

morpholino

oligos

(AMOs)

complementary to a splice site of the cassette exon in each of the 5 candidate genes
MKK7, EHMT2, BRD8, ZC3H14 and NGLY1 to force skipping of this exon (Fig 3.1).
Most of the AMOs were able to force skipping of their target exons in both unstimulated
and PMA-activated conditions. However, the AMO targeted to the NGLY1 cassette exon
did not force exon skipping, but instead had a limited effect on enhancing exon inclusion
(Fig 3.1).

Figure 3.1 Antisense splice site blocking morpholino olgos (AMOs) force skipping of cassette
exons. Percent inclusion determined by RT-PCR analysis of RNA from cells that were transfected with
AMOs (15 nmol) targeting either the 5’ or 3’ss of alternative exons in EHMT2, MKK7, ZC3H14, NGLY1and
BRD8 compared to a control AMO in unstimulated and PMA activated Jurkat T cells.
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Figure 3.2 Analysis of cell surface activation markers in AMO-transfected cells. (A) Jurkat T cells
transfected with AMOs (5 and 15nmol) to modulate splicing of EHMT2, MKK7, ZC3H14, NGLY1 and BRD8
left unstimulated or activated with PMA were stained with anti-CD25 FITC (top) or anti-CD69 PE (bottom)
and fluorescence analyzed by flow cytometry.

I then asked whether modulating isoform expression with these AMOs affected
the expression of well-established markers of T cell activation such as the cell surface
receptors CD69 and CD25 (Fig 3.2) (Fazekas De St Groth et al. 2004). I found that the
induced expression of CD69 and CD25 on the cell surface, as measured by flow
cytometry, following T cell activation by PMA for 24h was unchanged following treatment
with the AMOs compared to a control AMO (Fig 3.2). Similarly, treatment with the AMOs
did not affect basal expression of these T cell activation markers.
Another hallmark and consequence of T cell activation is increased T cell
proliferation (Smith-Garvin et al. 2009). Having found no differences in cell surface
expression of two canonical T cell activation markers, I determined whether alternative
splicing of any of the five genes impacted the cell viability of Jurkat T cells. I performed a
MTS cell viability assay in cells that were treated with the splice site blocking AMOs.
MTS is converted by cells to formazan and the amount of formazan, as measured by
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Figure 3.3 Analysis of cell viability in AMO-transfected cells. (A) Calibration curve of absorbance versus
cell number showing linear range of the MTS assay used to analyze cell viability. (B) Growth curves plotting
cell number, as determine by absorbance at 490nm MTS assays, as a function of time after transfection with
the AMOs targeting each splicing event at a low dose (5 nmol). (C) Same as B, but at a high dose (15
nmol).

absorbance at 490nm, is proportional to the number of living cells. I first performed a
calibration curve of absorbance (490nm) versus cell number to demonstrate the linear
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range of the assay (Fig. 3.3A). I plated cells transfected with a control AMO or with
AMOs at a low dose (5 nmol) and a high dose (15 nmol) to the cassette exons in either
MKK7, EHMT2, BRD8, ZC3H14 and NGLY1 and monitored absorbance at 490nm with
the MTS assay every ~12h up to 72h (Fig 3.3B,C). I did not observe marked differences
in the cell growth curves for cells transfected with the splicing modifying AMOs relative to
a control AMO. I concluded that alternative splicing of MKK7, EHMT2, BRD8, ZC3H14,
or NGLY1 does not have a considerable effect on cell viability of T cells.
Another important criteria in the selection of a candidate gene for further study
was the ability to generate a minigene that recapitulates the endogenous activationinduced splicing regulation. Minigenes allow for mutational analysis to identify splicing
regulatory sequence elements and associated trans-acting factor. A minigene contains
the genomic sequences of interest typically including the alternative exon and a portion
of the flanking introns placed in the context of heterologous flanking exons in a plasmid.
Cis-regulatory elements usually reside within a few hundred nucleotides of the
alternative exon. Thus, inclusion of 100-500nt of introns is a generally sufficient
sequence to encompass the regulatory elements. With the help from Chris Yarosh and
Sam Allon, I made minigenes containing the alternative exons in MKK7, BRD8, NGLY1
and ZC3H14 and a few hundred nucleotides of the upstream and downstream introns
flanked by Beta-globin sequences (Fig 3.4). For the EHMT2 alternative exon we made a
minigene containing the entire upstream and downstream intron and constitutive exons
since they were all <1kb (Fig 3.4). Out of these minigenes only the EHMT2 and BRD8
minigines recapitulated the activation-responsive regulation of the variable exons
observed in the endogenous gene as quantified by RT-PCR with minigene specific
primers (Fig 3.4). However, shortening of the MKK7 intron sequences to about 100nt
resulted in a signal-responsive minigene, presumably through the loss of a strong
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silencer that was preventing the exon from being included at all in the minigene context.
These minigenes allowed me to narrow down my candidate list to MKK7, EHMT2 and
BRD8 because we were able to produce minigenes that recapitulate the signalresponsive alternative splicing observed in T cells to enable mechanistic and
biochemical studies. The function of BRD8 as a transcriptional co-activator is not well
characterized, therefore there was no hypothesis on which to design further analysis of
functional differences in the isoforms. However, MKK7 and EHMT2 have clear, important
biological functions that allowed me to hypothesize about the functional implications of
regulated splicing of these genes. I evaluated MKK7 and EHMT2 in parallel, but the rest
of the chapter discusses EHMT2 since MKK7 is the topic of Chapters 4 and 5.

Preliminary analysis of the mechanism and function of EHMT2 alternative splicing
As described in Chapter 2, EHMT2 (also called G9a) contains two of the motifs that were
bioinformatically identified as enriched among genes that are regulated similarly in
Jurkat T cells and primary human T cells (Fig 2.6A,B). One of these motifs is the
activation-responsive sequence (ARS) that has been previously shown by the Lynch
laboratory to be required to confer signal-responsive splicing of CD45 and its consensus
sequence has been experimentally validated to be MCYYGCA (Rothrock et al. 2003;
Motta-Mena et al. 2010). Basal repression of CD45 variable exons is mediated by
binding of hnRNP L to the ARS motif located within the CD45 variable exons. The ARS
in CD45 lies in an exonic splicing silencer element termed (ESS1), upon T-cell activation
the splicing factors PSF and hnRNP LL are recruited to the ESS1 in a manner that is
dependent on the ARS to confer signal-responsiveness (Rothrock et al. 2003; Melton et
al. 2007; Tong et al. 2005; Oberdoerffer et al. 2008). In addition to the ARS motif we also
found a second enriched motif in the flanking EHMT2 introns, resembling a CTCF
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binding site (Fig 2.6B). As discussed in Chapter 1, CTCF can promote inclusion of
alternative exon by enhancing Pol II pausing (Shukla et al. 2011).
Given the precedence for the ARS and CTCF motifs as splicing regulatory
sequences I decided to test the importance of these elements by replacing the ARS and
CTCF motif sequences with a heterologous sequence in the context of the EHMT2
minigene stably transfected into Jurkat T cells. Indeed replacing both the ARS and the
CTCF motif impacted inclusion of EHMT2 exon 10 (Fig 3.5A, left). However,

Figure 3.4 Evaluation of minigene signal-responsiveness. Left, schematic of MK7, BRD8, EHMT2,
NGLY1 and ZC3H14 minigenes. Sequences derived from candidate genes are shown in color and betaglobin sequences are shown in gray. Right, representative RT-PCR gel of exon inclusion in unstimulated
and PMA activated conditions for each minigene. Below the RT-PCR gel is the quantification of the
average percent inclusion for each case (n=3 independent clones).
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replacement of either sequence affected only basal inclusion of EHMT2-E10, but left the
activation responsiveness unaffected (Fig 3.5A, right). Given the differences in basal
inclusion upon substitution of the ARS motif, I analyzed EHMT2 splicing in hnRNP L
knockdown samples from a technician in the lab, Michael Mallory, to evaluate whether
hnRNP L is responsible for promoting EHMT2-E10 inclusion. I found that knockdown of
hnRNP L decreased basal inclusion of this exon (Fig 3.5B). The effect of hnRNP L as an
enhancer of exon inclusion is consistent with the minigene mutational analysis that

Figure 3.5 Identification of sequences and factors involved in EHMT2 splicing regulation. (A). Top,
schematic of EHMT2 minigene annotated with the locations of the ARS and downstream CTCF sites that
were substituted in the minigene mutational analysis. Left, graph of average % inclusion as determined
by RT-PCR with minigene specific primers of the parental EHMT2 minigene and minigenes with either
the CTCF or ARS sequences swapped for heterologous sequences. Right, graph of average fold
activation (ratio of included to skipped isoform in stimulated over unstimulated conditions) as determined
by RT-PCR (n=3 clones). (B) Left, western blot showing mock treated or knockdown of hnRNPL (from
Cole et al. 2015). Right, corresponding graph of endogenous percent EHMT2-E10 inclusion as
determined by RT-PCR in cells left unstimulated or activated with (PMA 48h). (C) Same as (B), but with
CTCF knockdown (n=3).
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demonstrated the ARS in EHMT2 serves as an enhancer, suggesting that hnRNP L may
act through the ARS as in the case of CD45.
Next I knocked down CTCF to establish whether CTCF regulates EHMT2
splicing given the functional role of the CTCF binding motif. Knockdown of CTCF caused
only a minor decrease in exon 10 inclusion (Fig 3.5C). It is possible that the achieved
levels of CTCF knockdown were not sufficient to see major changes in exon inclusion.
This mutational analysis of EHMT2 identified sequences that were required for basal
exon 10 inclusion and identified at least one splicing factor that contributes to overall
basal levels of inclusion. However, neither motif impacted the activation-induced
inclusion of EHMT2-E10 in T cells.
In parallel to the minigene sequence analysis I tested the biological
consequences of alternative splicing of exon 10 on EHMT2 protein. The Euchromatic
histone lysine N-methyltransferase (EHMT2) preferentially methylates Histone 3 at
Lysine 9 (H3K9) via its catalytically active SET domain. EHMT2 thus plays a role in
regulating gene expression by rearranging and controlling chromatin structure. Among
the functional roles for EHMT2 are gene silencing of developmental and neuronal genes
(Tachibana 2002; Roopra et al. 2004). EHMT2 is critical during embryogenesis as mice
lacking EHMT2 are early embryonic lethal (Feldman et al. 2006). The role of EHMT2 in
lymphocytes has been less explored. It was found that although EHMT2 was not
essential for T-cell development as CD4+ and CD8+ T-cell numbers were unaffected in
lymphocyte specific EHMT2-deficient mice (Thomas et al. 2008). However, a recent
report highlighted that EHMT2 plays a critical role in the differentiation of adult peripheral
CD4+ T-cell into Th cell lineages (Lehnertz et al. 2010). Specifically, Th cells lacking
EHMT2 are impaired in their ability to differentiate into a Th2 phenotype and in their
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ability to express cytokines IL-4, IL-5, and IL-13 that are markers of the Th2 subset of T
cells. EHMT2

mediated

activation

of these

cytokines

is

independent of its

methyltransferase activity. Furthermore, EHMT2-deficient CD4+ T-cells were unable to
protect against infection with a pathogen requiring Th2 responses. Together this
evidence suggests that EHMT2 plays a role in modulating effector functions of adult
peripheral blood T-cells.
To begin to characterize the functional differences between EHMT2 isoforms, I
analyzed EHMT2 protein expression to determine if the splicing change was manifested
at the protein level. Western blot analysis of EHMT2 protein in unstimulated and PMAactivated Jurkat T cells shows a shift toward the longer isoform of EHMT2 upon PMA
treatment (Fig 3.6A) consistent with increased exon 10 inclusion upon PMA treatment as
quantified by RT-PCR (Fig 3.6B).
Since EHMT2’s most prominent role is as a lysine methyl transferase, we
hypothesized that although the alternative exon 10 of EHMT2 lies at N-terminus, distal
from the SET domain it could impact catalytic activity. To test this prediction, I utilized a
splice site-blocking AMO to force EHMT2-E10 skipping, followed by PMA activation or
left unstimulated (Fig 3.6C). The EHMT2 AMO forces robust exon skipping (Fig 3.6C),
however has no specific effect on global H3K9 tri-methylation compared to a control
AMO, as assessed by Western blot analysis with an H3K9me3-specific antibody (Fig
3.6D). The analysis of H3K9 methylation was performed by Jiajun Zhu in Shelly Berger’s
lab at Penn.
EHMT2 was shown to be required for appropriate expression of Th2 cytokines,
the most prominent being IL-4 in a catalytically-independent manner. To test whether
skipping of EHMT2-E10 altered IL-4 expression, I analyzed IL-4 mRNA levels by RT77

Figure 3.6 Analysis of functional impact of EHMT2 alternative splicing on known EHMT2 protein
activities. (A) Representative western blot showing shift in EHMT2 isoform expression at the protein level
upon PMA activation of Jurkat T cells. (B) Corresponding, RT-PCR quantification of average percent
inclusion in unstimulated compared to PMA-activated Jurkat T cells. (C) Graph of average percent inclusion
for Jurkat T cells transfected with a low (5nmol) and high (15nmol) dose of a control AMO against a splice
site in an unrelated gene (Cont) or the AMO blocking the 3’ splice site of EHMT2 exon 10 (MKK7) in the
presence and absence of PMA (48h). (D) Corresponding, Western blot analysis showing H3K9 methylation
relative total H3. (E) RT-PCR analysis of IL-4 mRNA relative to actin mRNA in cells treated as in panel C
(PMA 48h).

PCR in the AMO-treated Jurkat cells in unstimulated and stimulated conditions.

As

shown in Fig 3.6E, treatment with the EHMT2 AMO does not significantly alter IL-4
mRNA levels compared to the control AMO in either condition.
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I did not pursue EHMT2 splicing regulation further as I was unable to see any
functional differences between EHMT2 splice variants in either global H3K9 methylation
or expression of Th2 cytokines in Jurkat T cells, two known activities of EHMT2. It is
possible that alternative splicing of EHMT2 impacts H3K9 methylation of specific genes
or that the splicing event alters other EHMT2 functions.

Discussion
The results presented in this chapter were critical in the decision to pursue the study of
MKK7 pre-mRNA splicing regulation. Importantly, I found that antisense splice site
blocking morpholino oligos were an effective strategy to manipulate isoform expression
and investigate the functional output of each isoform on protein activity and T cell
activation. I further found that alternative splicing of MKK7, EHMT2, BRD8, ZC3H14 and
NGLY1 did not alter the expression of known markers of T cell activation, including
expression of cell surface markers CD69 and CD25. Furthermore, manipulating the
isoform ratio of these events did not influence cell viability under unstimulated
conditions.
The prioritization strategy outlined in these studies for selecting alternative
splicing events allowed me to eliminate candidate genes and focus on alternative
splicing of EHMT2 and MKK7 that could be studied in model systems. Since I was
unable to find differences between EHMT2 isoforms in two known EHMT2 activities and
I did not identify signal-responsive sequences in EHMT2, I decided to focus my thesis on
the regulation of MKK7 alternative splicing. However, my findings support that alternative
splicing of EHMT2 could play a role in the regulation of H3K9 methylation around
specific genes or that it affects some of the other described functions of EHMT2 that are
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independent of catalytic activity. Consistent with my finding that EHMT2-E10 inclusion
does not affect global methylation levels, the Kornhblitt group observes no differences in
the catalytic activity of the EHMT2 splice variants in neuronal cells, but rather sees an
increase in the nuclear localization of the EHMT2 isoform that includes exon 10
(personal communication). This EHMT2 isoform affects alternative splicing of EHMT2
itself perhaps through increased H3K9 methylation around EHMT2-E10. Similar to my
results in T cells, they observe an increase in EHMT2-E10 inclusion during neuronal
differentiation. Together, these results support that the splicing change in EHMT2
following T cell activation may also serve to redirect EHMT2 to the nucleus to alter some
of its regulatory activities.
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CHAPTER 4: JNK-INDUCED ALTERNATIVE SPLICING OF MKK7
GENERATES A POSITIVE FEEDBACK LOOP TO AMPLIFY JNK SIGNALING
IN ACTIVATED T CELLS.

Introduction
As described in chapter 2, antigen-induced signaling through the T cell receptor (TCR)
controls the splicing of hundreds of genes involved in a large array of T cell effector
functions, including the secretion of cytokines and cytotoxins. I also find in chapter 2,
that genes encoding signaling molecules are particularly enriched amongst targets of T
cell activation-induced alternative splicing, suggesting a complex interplay of signaling
and splicing. However, we still know little about the functional consequences of
regulated splicing on specific signaling pathways (Martinez and Lynch 2013; Lynch
2004).
A particularly intriguing, but unexplored, example of alternative splicing of a signaling
molecule is that of the gene encoding MAP kinase kinase 7 (MKK7, also called
MAP2K7) (Chapter 2). MKK7 activates the c-Jun kinases JNK1 and JNK2 in response to
T cell activation signals, leading to phosphorylation and activation of the c-Jun
transcription factor that mediates T cell gene expression programs and cytokine
expression (Fig 4.1A) (Tournier et al. 1997; Matsuda et al. 1998; Sasaki et al. 2001).
Consistently, CD4+ T cells from MKK7 and JNK deficient mice fail to differentiate into
appropriate T helper subsets or carry out appropriate effector functions (Dong et al.
1998; 2000). Beyond T cells, JNK and MKK7 are broadly important kinases involved in
cellular responses to stresses such as UV damage, oxidative stress, as well as cell
growth and apoptosis in a variety of cell types (Wang et al. 2007; Haeusgen et al. 2011;
Asaoka and Nishina 2010).
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In the global transcriptome analysis described in chapter 2, we detected that exon 2
of MKK7 is amongst the many exons that are differentially included in response to
activation of a cultured T cell line. As explained in chapter 3, I did not observe
differences in the expression of T cell activation markers or cell viability as a result of
modulating MKK7 splicing. However, MKK7’s best-described role is as a specific JNK
kinase, which led me to hypothesize that alternative splicing MKK7-E2 could alter
MKK7’s ability to activate JNK. MKK7 interacts with JNK1/2 through three canonical
MAPK docking sites (Ho et al. 2006). Interestingly, inclusion of exon 2 disrupts the
second, and highest affinity, docking site within MKK7 (Fig 4.3A,B). Based on our
understanding of docking sites I predicted that the long isoform including exon 2 (MKK7L) would be less effective in activating JNK than the short isoform (MKK7-S), although
the functional consequence of MKK7 exon 2 inclusion had not been directly studied,
Moreover, the mechanism by which the MKK7-S isoform is generated is also unknown.
In this chapter, I demonstrate that expression of MKK7-S increases upon activation
of both cultured and primary human T cells, and that increased expression of MKK7-S
enhances JNK docking interaction, JNK pathway activity and cytokine production.
Remarkably, we find that, in turn, JNK activity is both necessary and sufficient to
promote skipping of MKK7 exon 2 via TCR-initiated signaling. Thus, I identify a positive
feedback loop involving alternative splicing in which initial signaling through the MKK7JNK pathway induces alternative splicing of MKK7 to enhance JNK pathway activity.
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Figure 4.1. MKK7 is alternatively spliced in response to activation of primary human CD4+ T cells
and a model Jurkat T cell line. (A) Schematic of JNK pathway activation in the context of T cell receptor
signaling. (B) Left panel, representative RT-PCR gel and quantification of MKK7-E2 inclusion in
unstimulated and activated (anti-CD3/CD28, 48 h) primary human CD4+ T cells (n=9). Right panel,
representative RT-PCR gel and quantification of MKK7-E2 inclusion in unstimulated and activated (PMA,
48h) Jurkat T cells (n=14). Throughout all figures, error bars represent standard deviation. P < 0.005,
student’s t-test.

Results
MKK7 is alternatively spliced in response to activation of primary human CD4+ T cells
and a model Jurkat T cell line
I previously detected signal-induced skipping of MKK7 exon 2 (MKK7-E2) during a
transcriptome-wide analysis of splicing in a Jurkat T cell line stimulated with PMA, a
commonly used mimic for antigen signaling in T cells (chapter 2) (Fig 4.1B). To confirm
that MKK7 is also regulated in primary T cells I assessed inclusion of MKK7-E2 in
primary human CD4+ T cells following activation with antibodies that engage the
physiologic T cell surface receptors CD3 and CD28 (Fig 4.1B). Importantly, both the
extent and time course of the change in MKK7-E2 inclusion between stimulated and
unstimulated cells is highly similar in both Jurkat and primary T cells (Fig 4.1B, 4.2A),
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suggesting a common mechanism of regulation in these related cell types.

Alternative splicing of MKK7 positively regulates JNK signaling
Given the conserved regulation of MKK7 splicing upon activation of both primary and
cultured T cells, and the role of JNK signaling in T cell biology, I wanted to determine the
functional relevance of this isoform switch. I predict skipping of exon 2 increases MKK7’s
ability to activate JNK by generating a smaller isoform that contains a more optimal JNK
docking site (MKK7-S, Fig 4.2B, 4.3A,B). Consistently, I find that the MKK7-S coprecipitates with JNK1 more efficiently than MKK7-L in co-transfection studies (Fig
4.3C).

Figure 4.2. MKK7 is alternatively spliced with similar kinetics in primary human CD4+ T cells and a
model Jurkat T cell line. (A) Time course of average MKK7-E2 inclusion in response to (left) activation
(anti-CD3/CD28) in primary human CD4+ T cells or (right) activation (PMA) in Jurkat T cells as quantified by
RT-PCR (n=3). (B) MKK7 domain schematic displaying the predicted outcome of MKK7-E2 inclusion on its
MAPK docking site.
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Figure 4.3. Details of MKK7 docking site. (A) The nucleotide and encoded protein sequence of MKK7
Exon 2 (red brackets) and two halves of the second docking site (black boxes). (B) Consensus sequence of
MAPK docking sites. (C) Western blot of FLAG-tagged MKK7-L and MKK7-S co-associated with c-myctagged JNK1 following immunoprecipitation with anti-c-myc from lysates of co-transfected HEK293 cells.
Lysate input (IN) and precipitated material (IP) are both shown.

To directly test the functional consequence of MKK7-E2 skipping I used a splice site
blocking antisense morpholino oligo (AMO) complementary to the 5’ splice site of MKK7E2 (Fig 4.4A). Although the minimal size difference between MKK7-L and MKK7-S
proteins precludes their discrimination by Westerns, by RT-PCR I confirmed that
transfection of the AMO results in forced skipping of MKK7-E2 and preferential
production of the MKK7-S isoform (Fig 4.4B). To activate JNK signaling, MKK7 needs to
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be phosphorylated and activated by an upstream kinase, such as TAK1, before
activating JNK (Fig 4.1A) (Blonska et al. 2007; Wan et al. 2006). Consequently, I find no
phosphorylation of the JNK-target c-Jun in unstimulated cells, even in the presence of
the AMO (Fig 4.4C). However, AMO treatment results in a marked increase in c-Jun
phosphorylation when MKK7 has been activated by PMA (Fig 4.4C). Furthermore, I
observe a 3-fold increase in TNF-alpha mRNA, a target of c-Jun mediated transcription

Figure 4.4. Alternative splicing of MKK7 positively regulates JNK signaling (A) Schematic of the MKK7
5’ splice site blocking AMO on the pre-mRNA and it’s effect on the MKK7 protein. (B) Representative RTPCR gel of MKK7-E2 and average percent inclusion (n>3) for Jurkat T cells transfected with a control AMO
against a splice site in an unrelated gene (Cont) or the AMO blocking the 5’ splice site of MKK7 exon 2
(MKK7) in the presence and absence of PMA (48h). (C) Corresponding western blot of Jurkat T cells treated
as in panel b, blotted for phospho-c-Jun (Ser73), total c-Jun and total MKK7 (PMA 2h). (D) Quantification of
TNF-alpha mRNA normalized to B2M by RT-PCR (n=4) in cells treated as in panel b (PMA 48h). Error bars
represent standard deviation. * P < 0.005, student’s t-test.
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(Tsai et al. 1996b; 1996a; Lawrence et al. 2011), in activated cells that have been
treated with the MKK7 AMO (Fig 4.4D). Importantly, the increased c-Jun phosphorylation
and TNF-alpha expression cannot be attributed to increased MKK7 protein, as the AMO
does not alter total MKK7 protein levels (Fig 4.4C). Together, these data demonstrate
that skipping of MKK7-E2 generates an isoform that is more effective in activating JNK
and enhancing JNK pathway activity, including increased c-Jun activation and upregulation of the immune cytokine TNF-alpha.
	
  
JNK activity is necessary and sufficient for activation-induced MKK7-E2 skipping
Having determined the functional significance of MKK7 alternative splicing, I next sought
to identify the signaling pathway that triggers repression of MKK7-E2. Multiple signaling
pathways are activated both downstream of antigen engagement in T cells and upon
PMA stimulation of Jurkat cells, including those involving Erk, Akt, mTOR and JNK
(Smith-Garvin et al. 2009; Harris and Lawrence 2003; Zheng et al. 2007; Su et al. 1994).
Strikingly, amongst these signaling pathways, only inhibition of JNK signaling blocks
PMA-induced MKK7-E2 skipping (Fig 4.5A). By contrast, inhibition of the Erk (DeSilva et
al. 1998), Akt (Yang et al. 2004) and mTOR (Brown et al. 1994) pathways have no
significant effect on PMA-induced repression of MKK7-E2 (Fig 4.5A). Consistent with
previous reports (Jin et al. 2009), I do observe that the JNK inhibitor used (SP600125)
partially inhibits mTOR, as indicated by a decrease in phospho-S6K. However, since
direct inhibition of mTOR with rapamycin has no effect on MKK7-E2 repression (Fig
4.5A), I conclude that the effect of SP600125 on MKK7-E2 splicing is not mediated via
mTOR. I also find that inhibition of GSK3 signaling, previously shown to be responsible
for the PMA-induced regulation of CD45 alternative splicing in Jurkat and primary T cells
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(Heyd and Lynch 2010), has no effect on MKK7-E2 inclusion (Fig 4.6A).
Importantly, SP600125 blocks activation-induced MKK7-E2 skipping in a dose
dependent manner, plateauing near 50 µM, consistent with the cellular IC50 for this
compound (Fig 4.5B) (Bennett et al. 2001). Moreover, inhibition of JNK in primary human
CD4+ T cells is also sufficient to significantly block the anti-CD3/CD28 enhanced

Figure 4.5. JNK activity is necessary for activation induced MKK7-E2 skipping (A) Top, average
percent MKK7-E2 inclusion (n=3) in Jurkat T cells pre-treated with the following inhibitors prior to PMA
treatment: JNKi (SP600125 50µM), MEKi (U0126 20µM), Akti (Triciribine 1µM) or mTORi (Rapamycin
100nM). Bottom, western blot analysis of downstream substrates: phospo-c-Jun (JNK), phospho-Erk (MEK),
phospho-S6K (mTOR), the Akt activating auto-phosphorylation site Ser473 (Akt) and hnRNPL as a loading
control. Protein samples were harvested 2 h after PMA, while RNA was harvested after 48 h. Note that the
samples from mTOR inhibition were run on the same gels as the other samples but with a spacer lane that
has been removed. (B) Average MKK7-E2 inclusion (n=3) with 12.5µM, 25µM, 50µM and 100µM JNK
inhibitor SP600125 prior to PMA treatment (48h) (C) Average MKK7-E2 percent inclusion (n=2) of primary
human CD4+ T cells treated with JNK inhibitor SP600125 and/or anti-CD3/CD28 (48h). See also Fig S2B.
(D) Average percent MKK7-E2 inclusion (Top) and western analysis (Bottom) in two independent Jurkat T
lines depleted of JNK by an shRNA grown in the absence or presence of PMA (48h). * P < 0.005, student’s
t-test.
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repression of MKK7-E2 (Fig 4.5C, 4.6B). Finally, as an additional test of the requirement
for JNK in the regulation of MKK7 splicing Michael Mallory, a techinician in the lab,
helped generate stable Jurkat T cell lines expressing a small hairpin RNA targeting JNK.
As shown by Western blot, JNK2 and at least one isoform of JNK1 are dramatically
depleted from the cells expressing the JNK shRNA (Fig 4.5D, bottom). While I cannot
differentiate whether JNK1 or JNK2 are the primary drivers, I find that JNK depletion in
Jurkat cells largely abrogates MKK7-E2 repression in response to PMA activation (Fig
4.45, top). I thus conclude based on both genetic and pharmacologic studies, that JNK
signaling is necessary for antigen- promoted skipping of MKK7-E2.
To determine if JNK activity is also sufficient to promote MKK7-E2 skipping I
expressed constitutively active JNK1 or JNK2 (CAJNK1/2) (Lei et al. 2002) in HEK293
cells, as these cells are more amenable to transient transfection and protein expression
than Jurkat cells. Inclusion of MKK7-E2 in untransfected HEK293 cells is less than that
observed in unstimulated Jurkat cells, but is still readily detectable (Fig 4.7A). Strikingly,
the presence of either FLAG-tagged CAJNK1 or CAJNK2 is sufficient to completely
inhibit inclusion of MKK7-E2 (Fig 4.7A). Expression of CAJNK1 and CAJNK2 similarly

Figure 4.6. Further data on signaling requirements for MKK7 alternative splicing (A) Inclusion of MKK7
exon 2 in Jurkat cells left unstimulated (resting), stimulated with PMA, which inhibits GSK3, or in which GSK3
is directly inhibited with the small molecule SB216763. (B) Representative RT-PCR gel of splicing of MKK7 in
human CD4+ T cells treated with (+) and without (-) anti-CD3/CD28 stimulating antibodies in the absence (-)
or presence (+) of the JNK inhibitor SP600125.
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induce the expected activity as assessed by c-jun phosphorylation (Fig 4.7B). The
induced skipping of MKK7-E2 is observed even at the lowest amounts and activity of
CAJNK1 detectable (Fig 4.7C). Thus, I conclude that JNK signaling is both necessary
and sufficient for MKK7 alternative splicing. Moreover, the fact that JNK signaling is
sufficient to induce MKK7-E2 skipping in HEK293 cells highlights that the regulation of
MKK7 by JNK is not cell type specific, but rather is a general feature of this signaling
pathway.
	
  
Discussion
Previous studies have established that alternative splicing is widely regulated in
response to various cell stimuli, such as T cell activation (Martinez and Lynch 2013; Fu
and Ares 2014). Conversely, genes encoding signaling proteins are themselves subject
to such regulation (Martinez and Lynch 2013), implying reciprocal regulation between
signaling and splicing. However, specifics regarding the signaling pathways that connect

Figure 4.7. JNK activity is sufficient to induce activation induced MKK7-E2 skipping. (A)
Representative (n=3) RT-PCR gel of MKK7-E2 inclusion (Top) and corresponding western analysis of
FLAG-CAJNK expression (bottom) from HEK293 cells transfected with vector control or constitutively active
JNK1 and 2 (CAJNK1 or CAJNK2). (B) Western blot of phospho-c-Jun, as a marker for activity of CAJNK1
and CAJNK2 in transfections shown in panel A. (C) Same as panel E but with 0.01µg, 0.1µg and 1µg of
CAJNK1. Phospho-c-Jun, as a marker for CA-JNK activity, is also shown. Error bars represent standard
deviation.
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T cell activation to alternative splicing, and the functional consequences of signalinduced splicing changes, remain poorly characterized. In this chapter I identify one
target of JNK-dependent splicing, that of the JNK-kinase MKK7. Specifically, I show that
JNK activation is necessary and sufficient for MKK7 alternative splicing and that MKK7
alternative splicing, in turn, augments JNK signaling creating a positive feedback loop.
Negative feedback loops involving alternative splicing have previously been
reported. For example, activation of the IL-1 receptor promotes expression of a small
isoform of Myd88 that in turn negatively regulates IL-1 (Janssens et al. 2002; 2003).
There are also examples of indirect feed-forward loops, such as Ras-mediated inclusion
of CD44 exon 6 to generate an isoform that serves as a co-receptor for growth factors
that in turn trigger Ras signaling (Cheng 2006). By contrast, I have identified here a
direct positive feedback loop in which signaling through JNK promotes alternative
splicing of its upstream kinase MKK7. The increase in c-Jun phosphorylation and TNFalpha expression upon forced MKK7-E2 skipping, together with the fact that this splicing
event peaks at around 48 hours following T cell activation, strongly suggests a role for
alternative splicing of MKK7 in propagating JNK signaling and augmenting T cell effector
functions following initial activation. Thus, the interplay of JNK and MKK7 provides both
a new type of connectivity between signaling and splicing and one that is critical for full T
cell responses.
MKK7 alternative splicing also highlights the breadth of mechanisms through which
splicing can modulate kinase activity. In the examples of A-Raf, IRAK1, and TrkB/C, the
kinase domain itself is subject to alternative splicing (Tsuzaka et al. 2003; Rauch et al.
2011; Jensen and Whitehead 2001; Middlemas et al. 1991; Allen et al. 1994; Tsoulfas et
al. 1996; Esteban 2006; Palko et al. 1999). By contrast, inclusion of alternative exons
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encoding the C-terminus of ROCK2 during muscle differentiation causes inhibition of a
distal kinase domain (Singh et al. 2014). Moreover, cancer cells express a spliced form
of the MAP kinase MNK2 that lacks its docking domain (Maimon et al. 2014). This
docking domain deficient isoform of MNK2 was shown to be oncogenic as it is unable to
activate the downstream kinase p38 (Maimon et al. 2014). I now show that alternative
splicing of MKK7 favors MKK7-S, the isoform with an intact MAPK docking domain that
interacts more effectively with JNK and activates downstream signaling. The discovery
of alternative splicing to modulate MAPK docking sites in both MNK2 and MKK7
suggests that this may be a common mechanism to regulate MAPK activity.
In summary, in this chapter I show that an important functional consequence of JNK
signaling is amplification of its own activity through inducing alternative splicing of MKK7.
I demonstrate that during T cell activation the JNK signaling pathway has a new role, in
addition to its established role in transcriptional regulation, in the control of gene
expression through promoting alternative splicing.
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CHAPTER 5: JNK-DEPENDENT UPREGULATION OF CELF2 REGULATES
ALTERNATIVE SPLICING OF MKK7 DURING T CELL ACTIVATION

Introduction
In chapter 4, I demonstrate that in response to T cell activation, the JNK-kinase MKK7 is
alternatively spliced to favor an isoform that lacks exon 2. This isoform restores a JNK
docking site within MKK7 that is disrupted in the larger isoform. Consistently, I show that
skipping of MKK7 exon 2 enhances JNK pathway activity, as indicated by c-Jun
phosphorylation and up-regulation of TNF-alpha. Moreover, this splicing event is, itself,
dependent on JNK signaling. Thus, MKK7 alternative splicing represents a positive
feedback loop through which JNK promotes its own signaling. The mechanisms
controlling alternative splicing of MKK7 and hence the positive feedback loop in JNK
signaling is unknown.
Alternative splicing is typically controlled by cis-regulatory elements within the
alternative exon and/or flanking introns (Fu and Ares 2014). These regulatory elements
commonly serve as binding sites for trans-acting proteins that can promote or repress
alternative exon inclusion, including members of the SR and hnRNP families of proteins,
as well as additional RNA binding proteins such as CELF, MBNL and RbFox proteins
(Fu and Ares 2014). However, there have been no studies linking any of these proteins
to MKK7 splicing, nor information regarding how T cell signaling regulates this process.
In this chapter I further characterize the mechanistic basis for JNK-dependent
repression of MKK7 exon 2, demonstrating the critical role of the intronic sequences
flanking exon 2 and recognition of these regulatory elements by JNK-induced CELF2.
Finally, we show that JNK signaling mediates activation-induced alternative splicing not
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just of MKK7, but of approximately a quarter of TCR-induced splicing surveyed in
primary human CD4+ T cells, thus serving as a widespread mechanism for controlling
gene expression. Strikingly, JNK-induced splicing events are significantly enriched for
responsiveness to CELF2, supporting a pervasive role for the JNK-CELF2 signaling arm
in the regulation of gene expression in response to T cell activation.

Results
MKK7 intronic sequences are required for activation-induced skipping of exon 2
I next sought to determine the molecular mechanism by which T cell activation leads to
skipping of MKK7-E2. As a first step to identifying the sequences and trans-acting
factors by which MKK7 is regulated in response to T cell activation, I made a chimeric
MKK7 minigene containing MKK7-E2 and about a hundred nucleotides of the flanking
introns, inserted between exons from the heterologous beta-globin gene ((Fig 5.1A,
5.2A) and is also shown in chapter 3 (Fig 3.4)). The minigene was transfected into Jurkat
T cells and inclusion of MKK7-E2 was quantified by RT-PCR with minigene specific
primers. This minigene (MKK7) recapitulates the activation-induced MKK7-E2 skipping
observed in the endogenous gene (eMKK7, Fig 5.1A,B), and exhibits a similar level of
basal inclusion in unstimulated cells (Fig 5.2B). Swapping out the exonic or intronic
sequences from MKK7 with those from the beta-globin gene demonstrates that the
introns alone are sufficient for activation-induced skipping of a constitutive heterologous
exon, while the exonic sequence does not seem to contain any signal-responsive
element (Introns, Fig 5.1A,B). A control minigene containing the heterologous exon
placed between beta-globin introns shows that this exon does not contribute to the
signal-responsiveness (Control, Fig 5.1A,B). Strikingly, I find that replacing the upstream
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or downstream intron with a corresponding beta-globin intron abrogates MKK7-E2
skipping in activated cells, suggesting that the MKK7 introns act cooperatively (Up or
Down, Fig 5.1A,B). Together, these results demonstrate that ~100 nucleotides of the
upstream and downstream introns are necessary and sufficient to enhance MKK7-E2
skipping in activated cells.

Figure 5.1 MKK7 intronic sequences are required for activation-induced skipping of exon 2. (A)
Schematic of MK7 minigenes. MKK7 sequences are orange and beta-globin sequences are gray. (B) Graph
of average fold repression (ratio of included to skipped isoform in stimulated over unstimulated conditions)
as determined by RT-PCR of MKK7 minigenes with minigene specific primers.

Trans-acting factors recognize the regulatory intronic sequences
To identify proteins that bind in trans to the MKK7 introns I performed UV crosslinking
with radiolabeled in vitro transcribed RNA including MKK7-E2 and the flanking introns,
and nuclear extract made from unstimulated (-PMA) and activated (+PMA) Jurkat T
cells. Strikingly, I observe a dramatic difference between these two extracts in the
binding pattern of 4 protein bands on an SDS-PAGE gel (Fig 5.3A). Three of these
proteins exhibit stronger binding in the activated versus unstimulated extracts, while the
fourth protein is enriched in the unstimulated condition. At least one additional protein
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Figure 5.2. MKK7 sequences and minigene information. (A) Sequences of endogenous MKK7 that are
included in the various minigenes. In black are the sequences of the upstream ~100 nucleotides and the
downstream ~80 nucleotides introns flanking exon 2. In red are is the sequence of MKK7 exon 2. (B) Graph
of average percent basal exon inclusion of MKK7 minigenes as determined by RT-PCR, n=3 and error bars
represent standard deviation.

binds with similar intensity in activated relative to unstimulated nuclear extracts (Fig
5.3A). Importantly, UV crosslinking with the intronic sequences that are necessary and
sufficient for activation-induced skipping reveal the same binding pattern as with the
same construct that includes MKK7-E2, while a construct lacking these introns lacks the
binding pattern (Fig 5.3A). These results are consistent with our minigene data, showing
that both intronic sequences are important for signal-responsive regulation, while exon 2
is dispensable.
To determine the identity of the proteins associating with the MKK7 introns, I
performed the UV crosslinking assay followed by immunoprecipitation of candidate
proteins. Candidates were chosen based on the size of the crosslinked species and the
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sequences of the MKK7 introns (Fig 5.3A, 5.2A). By this method I identified the four
differential MKK7 intron binding proteins as CELF2 (50kD), hnRNPC (40kD), HuR
(30kD) and SRp20 (20kD) (Fig 5.3B). As predicted from the total binding pattern, binding
of CELF2 and SRp20 increases; binding of hnRNP C decreases; and binding of HuR is
similar in activated compared to unstimulated nuclear extracts (Fig 5.3B). Importantly,
antibodies to several additional potential candidates, including PSIP1, hnRNPA1,
hnRNPE, SRSF1 and 9G8 do not precipitate any bound species (Fig 5.3B and data not
shown).

Figure 5.3. MKK7 intronic sequences recruit RNA-binding proteins. (A) UV crosslinking with nuclear
extracts from Jurkat T cells (–/+ PMA, 60 h) to radiolabeled in vitro transcribed MKK7 RNAs, followed by
RNase digestion and resolution on an SDS-PAGE. Note that (+PMA) sample for the MKK7 construct was
run on the same gel as the (–PMA) sample but with a spacer lane that has been removed. (B)
Immunoprecipitation of UV crosslinking reactions of the introns construct in panel A after RNase digestion
with antibodies shown.
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As an additional approach to identify proteins bound to the MKK7 intronic sequences
I performed an RNA affinity purification experiment followed by mass spectrometry (Fig
5.4A). We filtered the list for proteins with at least 10 spectral counts across conditions
and sorted based on fold change in activated compared to unstimulated extract (Table
A2.1). Remarkably, the top induced binding protein from the mass spectrometry list is
CELF2, consistent with the observed binding pattern by UV crosslinking. Furthermore,
hnRNPC, HuR and SRp20 were also identified in this list. A western blot of the RNA
affinity purification experiment confirmed the increase in CELF2 protein in activated
nuclear extract compared to HuR which is not induced in activated nuclear extract,
supporting the mass spectrometry analysis (Fig 5.4B). Subsequent UV crosslinking IP
and western blot analysis of RNA affinity purification experiments failed to validate any
other proteins other than CELF2, hnRNPC, HuR and SRp20 (Table A2.1).

Figure 5.4. RNA affinity purification of MKK7 introns. (A) Schematic of RNA affinity purification
experiment. RNA containing the MKK7 introns or the control RNA (from Fig 4A) were biotinylated, incubated
with unstimulated or PMA stimulated nuclear extracts, and isolated by streptavidin-agarose. Following
washing the entire reactions were submitted for mass spectrometry. (B) Western blot of CELF2 and HuR
from RNA affinity purification of the MKK7 introns. See also Table 5.1.
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JNK induces CELF2 protein expression through mRNA stabilization, which drives
activation-induced skipping of MKK7-E2
Having identified several proteins that bind differentially to the MKK7 introns in
activated compared to unstimulated states, I sought to determine if any of these proteins
drives activation-induced skipping of MKK7-E2 in the endogenous gene. I therefore
knocked down each of the proteins that bind to the MKK7 intronic regulatory sequences
and examined endogenous MKK7-E2 inclusion levels by RT-PCR (Fig 5.5 A-D). We find
that depletion of HuR, SRp20 or hnRNP C result in only modest changes in the inclusion
of MKK7-E2 (Fig 5.5A-C). In stark contrast, knockdown of CELF2 with either of two
shRNAs targeted to distinct sequences dramatically increases basal inclusion levels of
MKK7-E2, and abolishes activation-induced skipping (Fig 5.5D, 5.7A).
As a complementary approach I tested if an increase in CELF2 protein is sufficient to
promote skipping of MKK7-E2 through the identified intronic binding sites, by coexpressing CELF2 cDNA and the MKK7 miningenes in HEK293 cells. Notably,
overexpression of CELF2 is sufficient to promote exon skipping of the parental MKK7

Figure 5.5. The MKK7 inton-binding protein CELF2 is necessary for activation-induced skipping of
MKK7-E2. (A-D) Top, western blot showing mock treated or knockdown of each MKK7 intron binding protein
left unstimulated or activated with (PMA 48h) n=3. Bottom, graph of endogenous percent MKK7-E2 inclusion
as determined by RT-PCR for corresponding knockdown. (A) HuR knockdown. (B) SRp20 knockdown. (C)
hnRNPC knockdown. (D) CELF2 knockdown.
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minigene (Figure 5.6A). Moreover, I find that the repressive activity of CELF2 is
mediated through the introns, with no effect on MKK7-E2 itself or the control minigene
(Figure 5.6A). We therefore conclude that CELF2 acts as a primary repressor of MKK7E2 inclusion.
We have previously shown that CELF2 protein expression increases following T cell
activation, and that inhibition of the Erk pathway does not impact this response (Mallory
et al. 2011; 2015). Strikingly, however, JNK knockdown or inhibition markedly diminishes
the increase in CELF2 protein expression that is observed upon activation with PMA,
with little or no effect on the protein levels of the other MKK7 intron binding proteins (Fig
5.6B, 5.7B). Importantly, the decrease in CELF2 upon JNK knockdown or inhibition
correlates with a decrease in CELF2 mRNA levels (Fig 5.8A). We have recently
published that the TCR-signaling induced expression of CELF2 is driven by two
mechanisms; an initial increase in transcription followed by an increase in the stability of
the CELF2 mRNA via a yet-unknown pathway (Mallory et al. 2015). We have also shown

Figure 5.6 JNK induces CELF2 protein expression, which drives activation-induced skipping of
MKK7-E2. (A) Top, RT-PCR analysis of MKK7 minigenes that were co-transfected with FLAG-CELF2 in
HEK293 cells. Bottom, corresponding western blot for CELF2 overexpression. (B) Representative western
blot analysis of proteins that bind MKK7 introns in wildtype Jurkat cells or Jurkat cells depleted of JNK by
shRNA grown under unstimulated conditions or activated with PMA (48 h). See also Figure 5.6.
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that the increase in transcription is not sensitive to JNK inhibition (Mallory et al. 2015).
Therefore, I hypothesized that JNK may be regulating CELF2 protein expression through
controlling stabilization of the CELF2 mRNA. Consistently, upon inhibition of
transcription with actinomycin, Michael Mallory observes that JNK depletion or inhibition
blocks the increase in message stability that is induced upon PMA activation of cells,
bringing CELF2 mRNA to unstimulated levels (Fig 5.8B). In sum, I conclude that upon T
cell activation a JNK-dependent increase in CELF2 mRNA stability results in an increase
in CELF2 protein. Moreover, this increase in CELF2 protein is sufficient to account for
increased binding of CELF2 to the MKK7 intronic regulatory sequences to repress
MKK7-E2 inclusion.

Figure 5.7. CELF2 protein expression. (A) RT-PCR analysis of independent Jurkat T lines depleted of
CELF2 with two distinct shCELF2 targeting sequences CELF2 A and CELF2 B. The averages from these
two targeting sequences are presented in Figure 5D. (B) Representative western blot analysis of total
expression of proteins that bind MKK7 introns in Jurkat T cells that have been left unstimulated, activated
with PMA or activated in cells that have been pre-treated the JNK inhibitor SP600125. See also Figure 5F.
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JNK signaling mediates a network of TCR-induced alternative splicing in primary T cells
The JNK-dependent control of MKK7-E2 skipping raises the question of whether JNK
signaling is a dedicated pathway for regulated splicing of MKK7 in the context of the
positive feedback loop, or whether JNK has a broader role in regulating TCR-induced
splicing. I thus wanted to test JNK-dependent splicing changes in the physiological
context of signal transduction initiating at the TCR in primary human T cells. As these
cells are not readily amenable to genetic manipulation I took advantage of the widelyused JNK inhibitor SP600125 (Bennett et al. 2001) to identify antigen-induced alternative
splicing events that require JNK signaling in primary human T cells. To query
widespread JNK-dependent splicing changes I used RNA-mediated oligonucleotide
annealing, selection and ligation coupled with sequencing (RASL-seq) (Zhou et al. 2012;
Li et al. 2001) on RNA from primary CD4+ T cells that were unstimulated, stimulated with
anti-CD3 and CD28 or pretreated with the JNK inhibitor prior to stimulation with anti-CD3
and CD28. The RASL-seq protocol was performed on my CD4+ T cell samples by our
collaborators Jinsong Qiu and Xiang-dong Fu. This method uses primers complementary

Figure 5.8 JNK signaling stabilizes CELF2 mRNA. (A) Quantification of total CELF2 mRNA normalized to
actin in Jurkat T cells that have been left unstimulated, activated with PMA (48h) or activated in cells in
which JNK is depleted (shJNK) or inhibited (JNKi, SP600125). Quantification was done by RT-PCR, n=3. (B)
Quantification of CELF2 mRNA following actinomycin-induced inhibition of transcription in Jurkat T cells that
have been left unstimulated, activated with PMA (48h) or activated in cells in which JNK is depleted (shJNK)
or inhibited (JNKi, SP600125).
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to sequences at ~5600 alternative spliced junctions to quantify changes in isoform ratio
between two conditions. Focusing on the events for which we obtained an average of
>10 reads across samples (~3000 events, Table S2 from Martinez et al. 2015 in press),
we identified those that have an absolute differential inclusion (change in percent spliced
isoform or ΔPSI) of greater than 10 comparing unstimulated to anti-CD3/CD28
stimulated conditions (|PSIunstim-PSI CD3/CD28|>10, p<0.05, paired t-test). This analysis
α

yielded 420 anti-CD3/CD28-responsive alternative exons (Table A1.2, Fig 5.7A, B). This
number of antigen-induced splicing events in primary human CD4+ T cells is consistent
with our previous reports that ~10-15% of known alternative exons exhibit altered
splicing upon activation of Jurkat cells (Ip et al. 2007; Martinez et al. 2012), and greatly
expands our knowledge of the overall scope of alternative splicing in normal human T
cells.
To quantify the effect of JNK inhibition on anti-CD3/CD28-induced alternative splicing
I next identified from among the list of 420 anti-CD3/CD28-responsive events those that
showed a significant difference (|ΔPSI| >10, p<0.05) when treated with anti-CD3/CD28 in
the absence versus presence of the JNK inhibitor. This led to the identification of 99
alternative splicing events for which JNK inhibition significantly reduces stimulationresponsive changes in splicing (“JNK dependent”; Fig 5.9A, Table A2.2). For the majority
of these 99 events the magnitude of the JNK-dependence is similar to the magnitude of
the CD3/CD28-induced change (Fig 5.9B, Table A2.2, pearson’s r=0.94, p<1.3e-51).
Thus, I conclude that approximately 25% of the splicing changes induced upon TCR
signaling are primarily driven through the JNK signaling pathway. The specific
dependence of these events on JNK signaling is underscored by a parallel analysis with
the GSK3 pathways that we have previously implicated in T cell signal-induced splicing
(Heyd and Lynch 2010), in which we find that only a fifth of the JNK-dependent exons
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are also responsive to GSK3 (Fig 5.9C, Table A2.2).
Gene ontology analysis reveals that JNK-dependent alternative splicing events are

Figure 5.9. JNK signaling mediates a network of TCR-induced alternative splicing in primary T cells.
(A) Venn diagram and (B) Heat map of total significant alternative splicing events induced by antiCD3/CD28 (48h) and those dependent on JNK. Anti-CD3/CD28 sensitivity and JNK dependence are as
defined in text. Color scale for heat map is on left. See also Table S3. (C) Pie chart comparing JNKdependent versus GSK3-sensitive anti-CD3/CD28 induced events. See also Table S3. (D) GO terms and
KEGG Pathways enriched (p-value < 0.05) in significant JNK-dependent alternative splicing events as
determined by DAVID analysis. (E) Scatter plot comparing RASL-seq calculated changes in isoform
expression versus that determined by RT-PCR. (F) Representative RT-PCR gel of RASL-Seq identified
JNK-dependent alternative splicing events upon inhibition of JNK with either SP600125 and IN-8. Percent
inclusion (% inc) is the average of three independent experiments. See also Figure S7.
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enriched for spliceosomal components and mRNA binding/processing activity, as
compared to the ~3,000 genes queried by RASL-Seq. Additional categories involved in
gene regulation, such as chromatin-related factors, metal ion binding proteins and
transcription factors, are also enriched amongst JNK-dependent genes (Fig 5.9D, Table
A2.3, A2.4A). This “JNK-dependent” gene ontology enrichment is distinct from the
“GSK3-dependent” enrichment (Table A2.4A,B), consistent with JNK and GSK3
controlling different target genes. Importantly, 11 of 14 RASL-seq identified JNKdependent alternative splicing events were also observed in RT-PCR assays (Fig
5.9E,F, Fig 5.8); while the other three events show a more modest JNK-dependence by
RT-PCR but still trending with the RASL-seq data (Fig 5.10A,B). I performed these RTPCR assays with help from my summer student Laura Agosto. This high correlation
between RASL-seq and RT-PCR (R2= 0.80, Fig 5.7E) is consistent with other studies
employing RASL-seq (Zhou et al. 2012; Shao et al. 2014). We further confirmed the
JNK-dependence of these events with a second highly selective JNK inhibitor (JNK-IN-8)
that covalently inhibits JNK through a distinct mechanism than SP600125 (Zhang et al.
2012). Importantly, we find that for 10 of the 10 JNK targets tested, the antigen-induced
splicing change is equally inhibited by either SP600125 or JNK-IN-8 (Fig 5.9F, Fig
5.10C). Michael Mallory performed RT-PCR analysis of the JNK target genes in samples
from Jurkat T cells treated with JNK-IN-8. Together our data demonstrate that JNK
serves as a broad regulator of alternative splicing in T cells, which is likely to influence a
wide range of cellular functions in addition to amplification of its own signaling pathways
through the alternative splicing of MKK7.
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Figure 5.10. RASL-Seq and RT-PCR data on JNK-dependent splicing in primary human CD4+ T cells.
(A) Isoform expression change of 14 genes upon treatment of primary human CD4+ T cells with antiCD3/CD28 in the presence or absence of the JNK inhibitor SP600125. Delta PSI values are calculated as
the difference between percent expression of the longest isoform relative to total in cells treated with antiCD3/CD28 alone minus that in cells treated with anti-CD3/CD28 in the prencese of the JNK inhibitor. The
absolute inclusion values calculated by RT-PCR are also given. (B) Representative RT-PCR gels for data
shown in panel A. Final numbers presented in panel A are derived from triplicate RT-PCR experiments.
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Figure 5.10. RASL-Seq and RT-PCR data on JNK-dependent splicing in primary human CD4+ T
cells. (C) Graphs show the average percent inclusion and standard deviations from 3 primary human CD4+
T cell donors treated with anti-CD3/CD28 in the presence or absence of the JNK inhibitor SP600125 or
JNK-IN-8.
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JNK signaling and CELF2 co-regulate alternative splicing in T cells
Interestingly, I noticed that among the JNK-dependent alternative splicing events
were genes that we have previously found to be regulated by the splicing factor CELF2
((Mallory et al. 2015), Fig 5.11A). In particular, I find that about a third of JNK-dependent
splicing events overlap with our recently published set of CELF2-regulated exons
((Mallory et al. 2015), Fig 5.11A). Our published set of CELF2-regulated exons used a
high threshold for CELF2-dependence to limit false-positives (Mallory et al. 2015);
therefore, we recognize that we may be under-estimating the number of JNK-responsive
exons that are sensitive to CELF2. We thus asked our collaborators Matthew Gazzara
and Yoseph Barash to utilize the AVISPA algorithm (Barash et al. 2013; Gazzara et al.
2014) to identify motifs enriched among all JNK-responsive events (Table A1.2) relative
to the alternative cassette exons queried by RASL-seq that are not responsive to JNK
(|ΔPSI|<3 and p>0.5, Table 5.2). Remarkably, we find CELF2 binding sites to be highly
enriched in both the upstream and downstream introns (Fig 5.11B), consistent with the
pattern of CELF2 binding in MKK7. Indeed, CELF2 binding sites are the top- scoring
motif in the downstream introns of JNK-responsive events (Fig 5.11B). The functional
significance of these CELF2 motifs were validated in two JNK-dependent splicing events
in DDR1 and MTHFD2L (Fig 5.11C), which exhibit altered splicing upon knockdown of
CELF2 despite not having met the threshold for CELF2-responsiveness in our previous
RASL-seq study (Mallory et al. 2015). Together, our data demonstrate that CELF2 not
only regulates MKK7, but also mediates a substantial proportion of JNK-dependent
splicing in T cells.
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Figure 5.11. JNK signaling and CELF2 co-regulate alternative splicing in T cells. (A) Pie chart of overlap
of significant JNK-dependent alternative splicing events from Figure 6 with published CELF2-dependent
alternative splicing events (Mallory et al. 2015), and list of genes containing alternative exons that are coregulated by JNK and CELF2. (B) Enriched motifs around JNK responsive exons in primary CD4+ T cells as
determined by the AVISPA algorithm. (C) Analysis of two cassette exons in two JNK-dependent alternative
splicing events that are predicted to be co-regulated by CELF2 on the basis of containing an AVISPA
determined CELF2 motif. Representative RT-PCR gel quantifying percent inclusion in wildtype (WT) versus
CELF2 knockdown (KD) samples from Jurkat T cells.

Discussion
Through the work presented in chapter 4 and this chapter (5) I demonstrate that JNK
signaling is a major pathway through which T cell activation induces alternative splicing,
and provide the first link between JNK signaling and a splicing factor (CELF2) that
regulates a sizeable fraction of JNK-responsive exons. Moreover, I find that one of the
targets of JNK/CELF2-dependent splicing is the JNK-kinase MKK7. While it remains
possible that other signaling pathways fine-tune the regulation of MKK7, I show that JNK
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activation is necessary and sufficient for MKK7 alternative splicing and that MKK7
alternative splicing, in turn, augments JNK signaling.
In addition to providing insight into the functional impact of splicing on signaling, my
studies of MKK7 have also revealed novel mechanistic insights on how JNK signaling
impacts splicing. First, I define intronic regulatory elements within the upstream and
downstream introns that promote activation-induced skipping of MKK7-E2. These
intronic sequences are highly conserved across vertebrates, implying these are
important for proper regulation of MKK7 in other cell types. Secondly, I identify several
proteins that bind to the intronic regulatory sequences and contribute to overall inclusion
levels of MKK7-E2, including HuR, SRp20, hnRNPC and CELF2. I note that while the
effects of HuR, SRp20 and hnRNPC knockdown are subtle, these changes are at least
consistent with their binding patterns in activated compared to unstimulated nuclear
extracts. However, while these and additional factors may influence MKK7-E2 inclusion,
we find that CELF2 is a major repressor of MKK7-E2 inclusion upon T cell activation. It
also remains to be determined how CELF2 promotes MKK7-E2 skipping, however, we
note that CELF2 regulates at least one other target in T cells, LEF1 exon 6, through
binding to both of the flanking introns (Mallory et al. 2011). Therefore, cooperativity or
competition across an exon may be a common theme through which CELF2 functions.
Consistent with the role of CELF2 in regulating MKK7, a JNK-dependent increase in
CELF2 protein following T cell activation correlates with an increase in CELF2 protein
binding to the MKK7 intronic regulatory elements. We have recently published that TCRsignaling induced expression of CELF2 protein is driven by two mechanisms; an initial
increase in transcription that is driven by NF-kB (JNK-independent) and an increase in
the stability of the CELF2 mRNA contributes to the increase in the stability of the CELF2
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mRNA by an uncharacterized mechanism. We now show that in response to T cell
activation JNK signaling stabilizes CELF2 mRNA, to increase CELF2 protein expression
and directly impact alternative splicing. Thus, I provide a novel mechanism by which
extracellular signals can be transmitted from the TCR through the JNK signaling
cascade to the splicing factor CELF2 and result in changes in gene expression.
Coincident with regulation of MKK7, JNK signaling also controls about ~25% of
activation-induced alternative splicing events in primary T cells, with at least a third of
these events also responsive to CELF2. Because previous large-scale studies of
alternative splicing in primary human T cells only generated limited events, our
identification of ~400 TCR-responsive splicing events greatly expand our knowledge of
splicing regulation during the human immune response. Furthermore, the specific
identification that ~100 of these TCR-responsive events are dependent on JNK
activation adds new insight into the role of JNK signaling in biology. Through regulating
alternative splicing of factors involved in different aspects of gene expression, such as
mRNA processing, chromatin remodeling and transcription, JNK signaling potentially
affects a greater breadth of biological processes than previously appreciated. For
example, JNK-dependent alternative splicing of apoptosis regulators such as Cell cycle
and apoptosis regulator 1 (CCAR1) and of BCL2-associated X protein (BAX) may serve
to turn off apoptosis and promote T cell proliferation, a hallmark of T cell activation
(Czabotar et al. 2013)
The regulation of MKK7 and other target genes in response to JNK signaling is
unlikely to be restricted to T cells. I show in chapter 4 that activation of JNK regulates
MKK7 splicing in HEK293 cells as well as in T cells. Moreover, other studies have
implicated JNK in the regulation of Fibronectin splicing in epithelial cells, and have
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shown JNK to interact with and phosphorylate at least a few known splicing factors
although the impact of this regulation has not been linked to changes in splicing (Pelisch
et al. 2005; Habelhah 2001; Hutchins and Szaro 2013). As JNK is activated by many
cellular stress conditions, including oxidative stress and DNA damage, these data
suggest that JNK-mediated alternative splicing may play a much broader role in the
cellular response to a wide range of stress conditions and cell types. Whether CELF2
contributes to JNK-dependent splicing in other cell types remains to be determined.
Clearly proteins other than CELF2 additionally contribute to JNK-dependent splicing in T
cells, and may also do so in other cell types. However, we note that CELF2 is one of the
splicing factors most frequently downregulated in multiple cancer types (Sveen et al.
2015). Given the role of CELF2 in MKK7 splicing shown here, and the role of JNK in proapoptotic signaling (Dhanasekaran and Reddy 2008), these data suggest the possibility
that loss of CELF2 leads to decreased JNK activity in cancer.
In sum, in chapter 4 and 5 I demonstrate a broad role for JNK signaling in controlling
splicing in human T cells and specifically show that an important functional consequence
of JNK-induced splicing is amplification of its own activity through the alternative splicing
of MKK7. These data provide important precedent for the regulation of JNK signaling in
other cell types and for the reciprocal regulation of signaling and splicing in general

112

CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS

Conclusions
As discussed in Chapter 1, despite the pervasiveness of alternative splicing as a
mechanism of gene regulation and the profound impact that it can impart, there is a
shortage of proven examples of alternative splicing that lead to distinct changes in
protein expression. One advantage of alternative splicing is that it can change specific
regions of a protein to alter specific activities while leaving other activities intact, thereby
allowing fine tuning of protein functions in the cell. Another advantage of alternative
splicing is its ability to change gene expression in response to environmental signals. As
discussed in chapter 1, T cells must respond to invading pathogens and mount an
appropriate immune response, including proliferation and expression of cytokines and
other effector molecules. The process of how antigen is sensed at the T-cell receptor
(TCR) and how downstream signals are transmitted through intracellular signaling
cascades to transcription factors in the nucleus that upregulate the expression of
activation cytokines such as IL-2 and TNF-alpha is well characterized. However, how the
same signals are transmitted to nuclear splicing factors to change alternative splicing
and alter protein expression is largely unknown.
In Chapter 2, I describe how we have utilized transcriptome-wide profiling to
identify hundreds of alternatively spliced genes in response to T cell activation of a
Jurkat T cell line, revealing that alternative splicing has the potential to shape T cell
immune responses by affecting a host of genes (Martinez et al. 2012). I find that many
alternative splicing events are conserved upon activation of Jurkat T cells with PMA and
of primary human CD4+ T cells with antibodies to the TCR (anti-CD3/28), indicating that
this phenomenon is consistently observed in T cells. Furthermore, consistent with
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previous reports I find little overlap between genes that are regulated by altering mRNA
levels and genes that are regulated by alternative splicing. This suggests that these two
mechanisms to regulate gene expression may have distinct functions in protein
expression and immune response. Genes that are alternatively spliced in activated T
cells are enriched in categories related to immune function and cellular immune
signaling, suggesting potential interplay between TCR signaling and splicing regulation.
Furthermore, we find that splicing events are differentially sensitive to T cell activation
stimuli, implying that more than one of the TCR-triggered signaling cascades impact
splicing during activation. Detailed analysis of the functional consequences and
mechanism regulating the alternative splicing of any of the identified genes would be
valuable in gaining understanding on the impact of alternative splicing in T cells.
To select a gene that could serve as a model system, in chapter 3, I screened
five alternatively spliced genes (MKK7, EHMT2, BRD8, NGLY1 and ZC3H14), that were
identified in chapter 2, for events that showed isoform-specific differences in protein
function or T cell phenotypes. I utilized antisense morpholino oligos to manipulate
isoform expression and examined differences in cell viability and expression of canonical
T cell cytokines. Alternative splicing of any of these genes did not result in significant
differences in these parameters in Jurkat T cells. Next, I screened these genes for their
experimental tractability in minigene assays to be used in follow-up mechanistic studies
and also examined the literature to identify splicing events that affect domains with
known biological functions. With this approach, I selected MKK7 as the focus of chapter
4 & 5 since the MKK7 splice variants affected an exon encoding for a JNK docking
domain and had generated an activation-responsive minigene to study the sequences
and trans-acting factors responsible for the splicing change.
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In Chapter 4 I show that in response to T cell activation, the JNK-kinase MKK7 is
alternatively spliced to favor an isoform that lacks exon 2. This isoform restores the
integrity of the MAPK domain that is a JNK docking site within MKK7 that is disrupted in
the larger isoform. Consistently, we show that skipping of MKK7 exon 2 enhances
docking and JNK pathway activity, as indicated by downstream signaling hallmarks such
as c-Jun phosphorylation and up-regulation of TNF-alpha. Moreover, this splicing event
is itself dependent on JNK signaling. Thus, MKK7 alternative splicing represents a
positive feedback loop through which JNK promotes its own signaling: TCR stimulation
increases JNK signaling that promotes skipping of MKK7 exon 2, which further
enhances JNK signaling. This JNK signaling/MKK7 splicing feedback loop is one of few
examples of direct positive feedback due to alternative splicing. Furthermore, this
positive feedback appears to be a general property of JNK signaling, as we observe
skipping of MKK7-E2 in non-T cells as well.
MNK2 is one other example of alternative splicing of a MAPK domain that has
been described, but in this case the docking domain is encoded within the alternative
exon (Maimon et al. 2014). Therefore, alternative splicing results in complete inclusion or
exclusion of the MAPK domain. In contrast, with MKK7 I describe a new mode of
regulating kinase substrate interaction, in which inclusion of the alternative exon disrupts
the MAPK docking site. These two instances suggest that alternative splicing may serve
to broadly regulate MAPK docking sites, thus it would be interesting to identify other
cases of this type of regulation in other MAP kinases.
Chapter 5 provides mechanistic details on how the activation-induced skipping of
MKK7-E2 is achieved. I show that repression of MKK7 exon 2 is dependent on the
presence of flanking intronic sequences and the JNK-induced expression of the RNAbinding protein CELF2, which binds to these regulatory elements. Furthermore, we find
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that JNK induces CELF2 protein expression through message stabilization. The results
in chapters 4 and 5 describing the regulation and consequence of MKK7 alternative
splicing in JNK signaling are summarized in the model depicted in Fig 6.1. I also find that
~25% of T cell receptor-mediated alternative splicing events are dependent on JNK
signaling. Strikingly, these JNK-dependent events are also significantly enriched for
responsiveness to CELF2. Together, my results demonstrate a widespread role for the
JNK-CELF2 axis in controlling splicing during T cell activation, including a specific role in
propagating JNK signaling.

Figure 6.1. Model depicting the MKK7 positive feedback loop. A JNK-dependent increase in CELF2
protein promotes MKK7 exon 2 skipping and the generation of the MKK7-S protein, that in turn enhances
JNK signaling.
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Finally, results in the appendix demonstrate that alternative splicing also serves
as a mechanism of gene regulation during the critical developmental transition from the
maturation of double negative to double positive thymocytes. Furthermore, we expand
the number of genes known to undergo alternative splicing in thymocytes at this stage of
development that involves pre-TCR signaling. Strikingly, we find that about 30% of the
identified events are pre-mRNA that are sensitive to CELF2 protein levels in Jurkat T
cells. These results suggest that CELF2 may also regulate alternative splicing during
pre-TCR signaling. We had previously shown that there is also an increase in CELF2
expression in the double positive thymocyte populations relative to double negative
populations (Mallory et al. 2011). It is possible that JNK signaling also promotes CELF2
expression in developing thymocytes, further broadening the prevalence of this unique
mechanism of gene regulation.

Perspectives and Future Directions
Reflecting on the introduction in chapter 1, I provide an example of how multiple
signaling pathways converge on the same splicing factor to affect its activity.
Specifically, my work in combination with our previous work (Mallory et al. 2015) shows
that NF-kB and JNK signaling impinge on the same splicing factor CELF2 to orchestrate
an increase in this protein that results in major changes in alternative splicing.
Conversely, my work also demonstrates that one signaling pathway can affect multiple
splicing factors to diversify gene expression. I find that JNK signaling accounts for about
one fourth of TCR-induced alternative splicing and that 1/3 of the JNK-dependent events
are co-regulated by CELF2. Therefore, the remaining JNK-dependent events are likely
regulated by other splicing factors that we have yet to identify. JNK signaling could, in
parallel with regulating CELF2 protein, regulate the activity of other splicing factors. JNK
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is a kinase and therefore it is possible that it directly phosphorylates other splicing
factors to impact splicing. A phosphoproteomic mass spectrometric study in activated T
cells in the presence and absence of JNK inhibitors and/or JNK knockdown, would be a
useful strategy to evaluate this hypothesis. Importantly, the RNA-binding protein hnRNP
K has been shown to be a substrate of JNK, although this has not been linked to its
activities in splicing control (Hutchins and Szaro 2013). Similarly, mass spectrometry
analysis of total splicing factor protein levels under the same conditions could reveal
other instances in which JNK signaling regulates the expression of splicing factors either
transcriptionally, translationally or through message stability, as is the case with CELF2.
Another interesting question is what other signaling pathways shape alternative
splicing during TCR activation of T cells. My results indicate that JNK signaling controls
one fourth of TCR-induced splicing events, while GSK3 controls about another fourth.
This implies that other uncharacterized signaling/splicing factor branches mediate
alternative splicing in T cells. The model derived in this thesis may serve as a prototype
for the identification of new connections between signaling pathways and splicing
factors. Finally, whether several pathways converge to impact common alternative
splicing networks to impart an additional layer of regulation will be an interesting area of
investigation. Applying a similar approach to the one presented in chapter 5, where I
utilized JNK inhibitors and performed RASL-seq to determine the activation-induced
splicing events that are JNK-dependent could be performed. RNA isolated from primary
T cells left unstimulated or activated (anti-CD3/CD28) in the presence and absence of
inhibitors (Table 6.1) to the other canonical TCR-stimulated signaling pathways such as
p38, MEK, mTOR, NFAT, PKC, NF-kB and others (Smith-Garvin et al. 2009), could be
analyzed in parallel by RASL-seq. This approach would define other signaling pathways
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Table 6.1 Inhibitors to canonical T cell signaling pathways
Pathway

Inhibitors

References

GSK3

SB216763, Lithium

(Cohen and Goedert 2004)

JNK

SP600125, JNK-IN-8

(Bennett et al. 2001; Zhang et al. 2012)

PI3K

Wortmanin, LY294002

(Arcaro and Wymann 1993; Sanchez-Margálet et
al. 1994)

Akt

MK-2206, Triciribine

(Hirai et al. 2010; Yang et al. 2004)

PKC

Gö6976, Gö6983, R0-31-8220

(Way et al. 2000)

NFAT

Cyclosporin A, FK506

(Shaw et al. 1995)

MEK

U0126, PD98059

(Favata et al. 1998; Dudley et al. 1995)

p38

SB203580, SB202190, skepinone-L

(Ward et al. 1997; Young et al. 1997; Koeberle et
al. 2012)

NF-kB

IKK inhibitor VII, MG0132, Bay11-702
IkB-alpha

(Waelchli et al. 2006; Palombella et al. 1994)

mTOR

Rapamycin, Temsirolimus

(Brown et al. 1994; Dudkin et al. 2001)

that regulate alternative splicing in T cell and networks that are co-regulated by multiple
signaling pathways.
Regarding the biological implications of MKK7 alternative splicing, I showed that
the MKK7 isoform that lacks exon 2 (MKK7-S) contains an intact docking site for JNK
and exhibits enhanced downstream signaling relatively to the MKK7-L isoform. However,
it is of interest whether the MKK7-L isoform that contains an additional 16 amino acid
peptide in the docking site has any different activities. For example the inclusion of exon
2 in MKK7 may disrupt the JNK docking site, but make this MAPK docking site have
greater selectivity for a different substrate. Previous studies have shown that amino acid
residues surrounding the conserved docking site residues can greatly impact substrate
selectivity (Bardwell et al. 2009). A plausible hypothesis is that the MKK7-L isoform may
have distinct or additional substrates such as other kinases or scaffolding proteins. To
address this possibility one could ectopically express tagged MKK7-L versus MKK7-S in
T cells and/or other cell types and preform co-immunoprecipitation experiments such as
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the one presented in Fig 4.3C, but looking for co-association of known MKK7/JNK
scaffolding proteins, other kinases or subjecting immunoprecipitated complexes to mass
spectrometric analysis.
We show in this thesis that JNK signaling increases CELF2 protein expression
through an increase in the stability of the CELF2 mRNA. An avenue for further
investigation is how JNK signaling stabilizes the CELF2 mRNA. It is known that
elements in the 3’UTR can serve as binding sites for proteins to stabilize or destabilize
the target mRNA (Reznik and Lykke-Andersen 2010). JNK signaling could alter the
ability of a stabilizing or destabilizing proteins to interact with the CELF2 3’ UTR.
Furthermore, our previous study showed that the identity of the CELF2 3’UTR is also
itself altered in response to T cell activation (Mallory et al. 2015) that could insert or
eliminate binding sites for proteins that stabilize or destabilize mRNAs and may be
dependent on JNK signaling. Nevertheless, the regulation of CELF2 mRNA stability is
likely a process with many layers of complexity.
Altogether, the results presented in this thesis identifies novel alternative splicing
events in response to activation of both a T cell line and primary human T cells. These
events are enriched for genes that play roles in immune-related functions and cellular
signaling. Furthermore, I establish that multiple signaling pathways coordinately regulate
alternative splicing in activated T cells. Finally, I delineate a pathway that relays
information from the cell surface (TCR), through the cytoplasmic JNK signaling cascade
to the nuclear splicing factor CELF2 to have pronounced effects on alternative splicing.
At least one of the regulated splicing events, that of MKK7, has a direct impact on
immune signaling, including increased activity of the transcription factor c-jun and
upregulation of immune cytokines. In this positive feedback loop JNK signaling through
promoting alternative splicing of its upstream kinase MKK7, can amplify its own signaling
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after the initial induction of the pathway. This mechanism requiring the JNK/CELF2
signaling arms provides a new type of connectivity between signaling and splicing.
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CHAPTER 7: MATERIALS AND METHODS

Cell Culture
The JSL1 clonal population of Jurkat cells were cultured in RPMI supplemented with 5%
heat-inactivated fetal bovine serum (FBS) (Lynch and Weiss 2000). HEK293 cells were
cultured in DMEM with 5% heat-inactivated fetal bovine serum (FBS). For stimulations,
Jurkat T cells were cultured with PMA (20 ng/mL; Sigma-Aldrich) for 48h (RT-PCR), 2h
(western analysis of phosphoproteins) or indicated time points. CD4+ peripheral blood T
cells were obtained from the University of Pennsylvania Human Immunology Core (IRB
protocol #811028) with an average purity of 90%–95%. CD4+ cells were maintained in
RPMI supplemented with 10% heat-inactivated FBS for unstimulated conditions, or
additionally stimulated with anti-CD3 (BD Biosciences 555336) and anti-CD28 (BD
Biosciences 348040) for 48h. For stimulations, plate wells were coated with anti-CD3 at
2.5 µg/mL and additional soluble anti-CD3 and anti-CD28 were added to a final
concentration of 2.5 µg/mL. Stimulation of primary CD4+ T cells with PHA was at
10µg/mL (Sigma L9017) for 60 hours. For inhibition studies, cells were pre-treated with
inhibitors SP600125 (50µM, Calbiochem, 420119), JNK-IN-8 (3µM, Calbiochem,
420150), Triciribine (1µM, Calbiochem, 124012), Rapamycin (100nM, LC Laboratories,
R-5000) or U0126 (20µM, Invitrogen, PHZ1283) for 1 hour or 3 hours (JNK-IN-8) before
stimulating as described above. Transcription inhibition was achieved by incubation of
cells with actinomycin D at a final concentration of 5 µg/mL.

Transfections
Jurkat T cells (10x106) were transfected with 15 nmol of a 5’ splice site blocking
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antisense

morpolino

oligo

MKK7

AMO

(Gene-Tools)

5’-

CGATGATAAAAAGGCTGGTACCTGC-3’, ZC3H14 AMO against the 5’ splice site of
exon 12 5’-CTTGAAACATTACCAACCTTGACTC-3’, BRD8 AMO against the 5’ splice
site of exon 21 5’-CCTTGCAGCCATTCAATACTTACAA-3’, EHMT2 AMO against the 3’
splice site of exon 10 5’-CACTCCTGACACAGAGACAGAGAGA-3’ or control oligo
against the 3’ splice site of exon 11 of NGLY1 5’- CAGTTGCCTCTGTAATTCATGTTTT3’ by electroporation as previously described (Rothrock et al. 2003). Cells were
incubated with AMO for 24h after transfection and then stimulated with PMA as
described above. Knockdown of HuR, SRp20, hnRNPC,, CTCF and hnRNPL was done
by transfection with translation blocking morpholino oligos (Gene-Tools) hnRNPC 5’ATCGTGTTTGATGGTAAGGTTTCTC

-3’,

TGTGGTCTTCATAACCATTAGACAT

-3’,

HuR

5’-

SRp20

5’-

AAAATGCGGCGGCTCAAATCCACAC

-3’,

CTCF

5’-

CTTCGACTGCATCACCTTCCATTTC-3’

and

hnRNPL

5’-

CGCCCGCCGCCGCCATCTTCACCAT-3’ as described above.
HEK293 cells were transfected

by Lipofectamine 2000 (Invitrogen #11668-019)

transfection according to manufacturer’s instructions and harvested after 48h.
Constitutively active JNK1 and JNK2 (pCDNA3 Flag MKK7B2Jnk1a1and pCDNA3 Flag
MKK7B2Jnk2a2) were a gift from Roger Davis (Addgene plasmid #19726 & 19727).
HEK293 cells were co-transfected with 2µg of FLAG-CELF2 and 2µg of corresponding
MKK7 minigenes as above. The CELF2 expression vector pEFnFLAG-CELF2 was
generated previously (Mallory et al. 2015). Jurkat stable cell lines that were depleted of
JNK were generated using lentiviral transfection of a short hairpin RNA targeting
JNK2a2 cDNA (Gen Bank accession number NM_002752.4) corresponding to
nucleotides 462-480. Similarly, depletion of CELF2 was done by lentivirus encoding
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hairpins targeting nt 171-189 (A) or 966-990 (B).

Cell Viability
10 million Jurkat T cells were transfected with indicated AMOs as described above.
Plated in 10mL of RPMI without phenol red (Promega) and left to recover overnight at 37
degrees. Subsequently, cells were split back and 100uL of each transfection reaction
were plated into 96 well plates, one plate for each time point including a time point equal
to 0h. At the indicated time points 20uL of MTS one solution (Promega) was added to
each well and incubated for 2h at 37 degress (covered with foil). Absorbance was read
at 490 nm (subtracting background reference at 600 nm).

Flow cytometry
Jurkat T cells were transfected and stimulated under indicated conditions. 1 million cells
per condition were harvested and incubated with anti-CD69 PE antibody (BD
Pharmingen 560968) or anti-CD25 FITC (BD Pharmingen 560990) for 15 min on ice in
PBS. Cells were washed and resuspended in PBS (without calcium and magnesium)
supplemented with 1% FBS and analyzed by flow cytometry in corresponding
fluorescent channels relative to unstained control.

cDNA Expression Plasmids
For coimmunoprecipitation experiments, FLAG-MKK7-L (4µg) or FLAG-MKK7-S (1µg)
were co-transfected with c-myc-JNK1 (1µg) in HEK293 cells as described above. MKK7S cDNA was generated by PCR from plasmid pDONR223-MAP2K7 (addgene) with
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primers containing BamHI/EcoRI and inserted into the pEFnFLAG vector downstream of
an N-terminal FLAG tag. MKK7-L was generate by RT-PCR from unstimulated Jurkat T
cell RNA with the same forward primer as MKK7-S and a reverse primer in MKK7 exon 5
encompassing a natural BspE1 site. The PCR fragment was the inserted in the MKK-S
plasmid through digestion with BamH1 and BspE1. C-myc-JNK1 was generated by PCR
from pCDNA3-FLAG-JNK1a1 (addgene) and inserted into a pCDNA3-c-myc plasmid
using BamH1 and XbaI sites.

Minigenes
MKK7, BRD8, NGLY1, ZC3H14 minigenes were generated by using PCR with primers
to isolate the indicated sequences of the endogenous gene and the 5’ and 3’ ends were
flanked with NdeI and BglI/BAMH1 respectively (see Table 7.2). The genomic fragments
were then inserted into beta globin constitutive exons 1 and 2 in the SCglo parental
minigene as previously described (Rothrock et al. 2003). For the MKK7 intron only
containing construct each intronic seqment was amplified by RT-PCR with primers for
the endogenous gene containing an NdeI site at the 5’ end and a PstI site and the 3’ end
for the upstream intron and a PstI at the 5’ end and a BglII site at the 3’ end for the
downstream intron. These fragments were then inserted into the SCglo parental
mingene and finally a portion of constitutive CD45 exon 14 dropped in with flanking PstI
sites (Rothrock et al. 2003). Primer sequences are listed in Table 7.2. The EHMT2
minigene was generated by isolating the entire endogenous region encompassing the
alternative exon and flanking constitutive exons and flanked at the 5’ and 3’ ends with
KpnI and HindIII and inserted into the SCgloI plasmid. EHMT2 minigenes with
substituted CTCF and ARS sequence motifs were generated by using nested PCR
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reactions to swap out the 15 nucleotide CTCF or ARS sequence from the parental
EHMT2 minigene with a heterologous sequence CAGCATGACTCTCAG (Tong et al.
2005). This was generated by combining two PCR reactions: the first reaction is
generated with a forward primer that anneals to the flanking sequences and contain the
nucleotides to be substituted swCTCF EHMT2-F or swARS EHMT2-F with a reverese
primer to in beta-globin intron 3 (outsideIVS3-R). The second PCR reaction was
generated with a Forward primer upstream of the T7 promoter (outside T7 promoter-F)
and a reverse primer that anneals to the flanking sequences and contain the nucleotides
to be substituted swCTCF EHMT2-R or swARS EHMT2-R. Then both PCR reaction
were combined and the full length insert was amplified and cloned into the pcAT7 vector
using KpnI and HindIII sites. Primers are listed in Table 7.2. Jurkat T cell clones that
stably express the minigenes described above were created by transfecting 10 million
cells with 10 ug of minigene plasmid by electroporation and grown under zeocin drug
selection as previously described (Rothrock et al., 2003).

Coimmunoprecipitation
HEK293 cells co-transfected with FLAG-MKK7-L or FLAG-MKK7-S and c-myc JNK1
were resuspended in PBS with protease inhibitor cocktail (Roche). and lysed by three
freeze-thaw cycles, followed by centrifugation at 13,300 rpm for 10 minutes. 150µg of
cell lysate and 4µg of anti-c-myc were incubated in 200µL at 4 degrees with rotation for
1.5h, followed by incubation with 40µL pre-washed protein G Dynabeads for 1h.
Immunoprecipitated complexes were washed in PBS and eluted from beads in SDS
sample buffer.
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RT-PCR
RNA was isolated using RNABee (Tel-Test, Inc.) according to the manufacturer’s
protocol. Reverse transcription-PCR (RT-PCR) was performed as previously described
in detail (Lynch and Weiss 2000; Rothrock et al. 2003; Ip et al. 2007), using sequencespecific primers for individual genes and low cycle number. Primer sequences for all RTPCR events are provided in Table 7.1. Quantification was done by densitometry using a
Typhoon Phosphor Imager and Image Quant software. Percent spliced in or (PSI) was
calculated as the density of isoforms including the variable exon over total isoform
density. Quantification of TNF-alpha, IL-4 and CELF2 gene expression was determined
by RT-PCR and normalized to B2M for TNF-alpha and actin for IL-4 and CELF2 with
primer sequences in Table 7.2. A two-tailed Student’s t-test analysis was performed for
all treatment groups in Jurkat T cells (unpaired) and CD4+ peripheral blood T
lymphocytes (paired) using Microsoft Excel for at least 3 biological replicates. Conditions
with a p-value < 0.05 were considered significant.

Western Blots
Western blots were carried out as previously described (Melton et al. 2007). Briefly,10µg
of total protein lysates were loaded into 10% 37.5:1 bis-acrylamide SDS-PAGE gels.
Antibodies used for western blot were as follows: phospho-c-Jun (Ser73) #9164, c-Jun
(L70B11) #2315, MKK7 #4172, p44/42 MAPK (Erk1/2) (137F5) #4695, phosph-p70 S6
Kinase (Thr389) (108D2) #9234, phospho-Akt (Ser473) #9271, SAPK/JNK #9252, FLAG
#2368 and CTCF (D31H2) #3418 from Cell Signaling. Antibody to hnRNPL (ab6106)
and U2AF35 (ab86305) were from Abcam. Antibody to c-myc (9E10) was from Roche
and CELF2 antibody from the University of Florida Hybridoma Lab (HL1889). Antibody to
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EHMT2 was from Millipore (#09-071).

UV crosslinking
UV crosslinking assays were preformed as previously described (Mallory et al. 2011). In
brief, nuclear extract was made from unstimulated or PMA activated from Jurkat T cells.
MKK7 templates were PCR amplified from the MKK7 minigene using primers containing
the T7 promoter and gel purified. These MKK7 templates were then in vitro transcribed
with T7 polymerase (Promega) and body-labeled with
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P alpha-UTP. Nuclear extracts

were incubated with MKK7 RNAs, UV crosslinked, RNase digested and resolved on an
SDS-PAGE. For UV crosslinking followed by immunoprecipitation, UV crosslinking
reactions after RNase digestion were incubated with corresponding primary antibodies at
4 degrees overnight, followed by incubation with protein G sepharose beads (GE) and
elution. Antibodies used in immunoprecipiation were as follows: HuR (sc-5261) from
Santa Cruz, hnRNPC (ab10294) from Abcam, CELF2 provided by UFL Hybridoma Lab,
SRp20 (33-4200) from Thermo and PSIP1 (A300-847A) from Bethyl Laboratories.

RNA Affinity Purification
The MKK7 introns construct and Control construct were in vitro transcribed from a T7
promoter. The 50pmol of RNA were then biotinylated at the 3’ end using RNA ligase
according to manufacturers protocol (Pierce RNA 3' End Biotinylation Kit). The RNA
affinity purification was performed as previously described (Rothrock et al. 2005). Briefly,
biotinylated RNAs were incubated with unstimulated or PMA activated nuclear extract
from Jurkat T cells at 30 degrees for 30min, the RNA was then coupled to preblocked
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Streptavidin beads (Pierce) and incubated for 1h at 4 degrees. The pull downs were
washed 4X and eluted in 2X SDS sample buffer. The samples were ran on a 12% gel for
0.5cm, stained with colloidal blue and the entire lanes were cut out and trypsin digested.
Trypsin digests were analyzed by LC-MS/MS on an Q Exactive Plus mass spectrometer.
Table S1 contains the peptides identified by mass spectrometry with at least 10 spectral
counts across conditions and is sorted based on the fold increase upon PMA activation.

RNA-Sequencing and Analysis
Human UniGene sequences (Build #208) and human genomic sequences (Build #36)
were

downloaded

from

NCBI

(ftp://ftp.ncbi.nih.gov/repository/UniGene/Homo_sapiens/,ftp://ftp.ncbi.nih.gov/genomes/
H_sapiens/).

RefSeq

data

were

downloaded

from

UCSC

(http://hgdownload.cse.ucsc.edu/goldenPath/hg18/database/refGene.txt.gz).

Cassette

alternative splicing events (n=27,240) were mined from aligning EST/cDNA sequences
to genomic sequence essentially as described previously (Pan et al. 2004; 2005;
Saltzman et al. 2011).
RNA-seq reads analyzed were 50-mers. For each splice site junction sequence aligned
to sequence reads, a 90 nucleotide-long sequence was extracted with 45 nucleotides of
overlap in each upstream and downstream exon. RNA-Seq reads were mapped to exonexon junction sequences and the mapped reads were filtered as previously described
(Pan et al. 2008). Percent exon inclusion values (%In) were calculated by counting the
number of reads mapping uniquely (i.e. not mapping to another splice junction or
genomic sequence) to the three junctions formed by alternative splicing of a single
cassette skipping event. Specifically the ratio of the average count for reads mapping to
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the two splice junctions formed by exon inclusion (C1:A, A:C2), over the total count for
reads mapping both to the included exon junctions (C1:A, A:C2) and to the skipped exon
junction (C1:C2), was determined. Percent exon inclusion values predicted for cassette
AS events represented by 20 or more reads to at least one of these three junctions were
shown to have a high correlation (r=0.80) with independent AS microarray measurement
(Pan et al. 2008), and thus were considered as high-confidence RNA-Seq predictions for
%In levels.

RNA-seq Ingenuity Pathway Analysis
Functional and canonical signaling pathway analyses were performed with Ingenuity
Pathway Analysis software (Ingenuity® Systems, www.ingenuity.com) using the ~11,000
genes with detectable expression by RNA-seq. A core analysis was performed with this
dataset as the reference set and the test set as genes with a cutoff of >20 point
differential in % inclusion. This analysis includes the top 178 genes with an 80%
validation rate by RT-PCR. Annotations with a –log (p-value) > 1.5 were selected for
functional analysis and canonical signaling pathway analysis.

RNA-seq Motif Analysis
For exons in each of the three categories, sequences of the alternative exons and the
flanking 200nt of intronic sequence where extracted from the human genome
(NCBI36/hg18). These regions were scanned for enriched motifs using MEME v4.7.0
(Bailey et al. 2009), allowing for any number of repetitions of elicited motifs within the
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input sequences. Enriched motifs with an E-value below 5E0 were considered
significant and shown in Figure 5.

RASL-seq
RASL-seq was performed as previously described using a set of probes that interrogate
~5600 specific splicing events (Li et al. 2001; Zhou et al. 2012). In brief, total RNA was
harvested from human CD4+ T cells from six independent donors, each of which were
cultured in RPMI alone (unstimulated), or stimulated with anti-CD3/CD28. Cells from
three donors were also pre-treated with SP600125 prior to stimulation with antiCD3/CD28 or treated with the GSK3 inhibitor SB216763, to determine dependence on
JNK or sensitivity to GSK3, respectively. All RNA samples were individually hybridized to
the probe set and selected by oligo-dT. Juxtaposed probes annealed to selected RNAs
were then ligated and amplified and barcoded by PCR for subsequent multiplexed
sequencing on a HiSeq2000. On average 2 million reads were obtained for each RNA
sample. Splicing events were filtered for a minimum of 10 reads average across all
biologic replicates and conditions and then the percent long isoform (PSI = percent
spliced in of variable exon) for each event in each sample was calculated by comparing
number of reads representing the longest isoform to the number of total reads for that
splicing event. The change in PSI (ΔPSI) was then calculated as the difference in PSI
comparing CD3/CD28-stimulated cells versus unstimulated cells or versus cells treated
with SP600125 or SB216763. The ΔPSI method was used as this is a standard criteria
for large scale splicing analysis (Martinez et al. 2012) and corrects for any possible bias
in the absolute detection of one isoform to another as it relies on differences in the
isoform ratio between samples. The validity of this method is confirmed by the high
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correlation of our RASL-seq and RT-PCR derived ΔPSI values (Fig 4). CD3/CD28dependent splicing events were defined as those for which the ΔPSI was significant
(|ΔPSI|> 10, p< 0.05, paired student t-test) across at least three donors, with consistent
data amongst all six donors. JNK-dependent splicing events were identified amongst the
CD3/CD28-dependent splicing events as those for which the addition of the JNK inhibitor
significantly returned the CD3/CD28-induced PSI back toward the unstimulated pattern
(i.e. |PSICD3/CD28-SP600125-PSICD3/CD28+SP600125|>10 and in the same direction as PSICD3/CD28SP600125-PSIunstim

and p< 0.05, paired student t-test across all three donors). GSK3-

sensitive events were calculated in a similar manner.

RASL-seq Gene Ontology
Gene ontology (GO) and KEGG pathway analysis was performed using DAVID version
6.7 (http://david.abcc.ncifcrf.gov/). The list of JNK-dependent changes was submitted as
the gene list (Table S3) with the total queried RASL-seq events w/ >10 reads across
conditions (Table S2) submitted as the background list. The same background was used
for the GSK3-sensitive events. We selected significant categories with a p-value < 0.05
and DAVID enrichment score >1.

RASL-seq AVISPA Motif Enrichment
Hg19 coordinates for JNK-dependent splicing events (described above) and JNK
nonresponsive events (|ΔPSI|<3 and p>0.5) were extracted, non-cassette events (e.g.
alternative 5’ splice sites) were filtered out, leaving 89 and ~950 cassette exons,
respectively, and these events were run through AVISPA. AVISPA has been described
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in detail previously (Barash et al. 2013) and has been used to predict known and novel
regulators of alternative splicing (Gazzara et al. 2014). Briefly, given a cassette exon
AVISPA extracts a set of over 1,400 features and utilizes an ensemble of splicing code
models to classify exons as alternative or constitutive, predict their tissue-specific
splicing patterns, and suggest motifs important to splicing outcome in exon-proximal
regions (Barash et al. 2013). A hypergeometric test was performed to identify features
significantly overrepresented in JNK-dependent cassette exons, compared to events not
responsive to JNK inhibition. CELF2 binding sites were defined by AVISPA as UG-rich
and CUG-rich motifs (see Barash et al. 2013 for complete description of feature set).

Human Thymocytes
De-identified human thymus samples were generated as discards from pediatric cardiac
surgery and obtained through the Co- operative Human Tissue Network in accordance
with IRB #811028. Single-cell thymocytes suspensions were incubated with RBC lysis
buffer to deplete for RBCs then stained with anti–CD8-APC (Becton-Dickinson
#555369), anti– CD4-FITC (Becton-Dickinson #555346), and a mixture of antibodies to
deplete non-thymocytes (human T-cell depletion antibody mix, Invitrogen #113.44D) that
were labeled with PE via a secondary antibody (Becton-Dickinson rat anti-mouse PE
#349073). DN and DP cells were isolated by gating for PE− viable cells, then collecting
the most intense APC/FITC double stained (DP) or lowest 2–3% staining (DN) a the
University of Pennsylvania biohazard cell sorting facility.
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Table 7.1 Primers used for RT-PCR analysis
Gene

Forward Primer

Reverse Primer

Tm

SLMAP

GACACAGACTGTACTCTCAGAACTG

GCCAGAGCTTCTCCATGAGAGC

65

GTGGAGTCGCGGAGTAGTCCTCATGG

CAGCATCCCAAAGTCACCAAGATAAACC
CTCC

70

CTGCAGATAGTGAAAAGTCCAACGCTGTG
G

CCCAGGTGGCAGTGTTGAGCTGCTGC

70

CELF2
TRAF3

CACGAAGACACCGACTGTCCCTGC

CGAGCGAGTTGCTCCACTCCTTCAGC

70

GCAAACATCCGAGTCTGGGATCAGTGC

CCTCTTCTGTAACTTCCACCTCTGGAACT
GG

70

GAAGCAGGGTGAAGTCAGTAAGGCA

CACACGCCATTCTCCCATCCAGAAAT

65

GCAGAAGTGGTCCAGGGACAAAGTAGG

GACTCTTGGTTTGGTGCCACTACTACTTC
C

70

SEC16A

GATGGCCTCCTCGCTCTCTCATCCC

GCCAGCTGAGCAGGGTTGTAGAAGG

70

PPP1R12A

CCAAGCACCACATCAACACCAACAG

GCAAGACAATCTAGAAGATCAACACAG

65

GTCTACTAGATGACTGGGCAAGTAAGGG

GAACCTCCTCCATTCTGTTGAGGATAGC
C

70

CCAGGTGAGGTAGGTTATTCAGGCTCTCC

GCTTGGAGTCATACGAATGGGAACTGG

70

CAACCACAGCAGATGACTGCAGTTCAGAG

GTCCCATAGGTAACCCTCATTTCTTCCAG
C

70

CD45-E6

GGCAAGCCCAACACCTTCCCCCACTG

CTGAAACTTTTCAA CCCCTGGTGGCAC

70

H2AFY

GTTGATGTCACTTGGCGATATTCCTG

ACTTCCAAGGGCCCGTTCTTTTTCC

70

TRIM26

GGATTCGCGGCCCGGAGCTCGG

GCCACAGTCAATGGTCACAGGGTCC

70

CGGGGTACCAGTGGTTCCAGTGGCCGGC
G

AGATCTAAGCTTCTCTCCGTCCACACTCT
CAGTGG

65

EHMT2
DDHD1

GAAGCCAGTTGCCTCACCTTCTGCTACC

GGGCAACATCCAAGGATGACCAATAGGC

70

GGGAGATGTCAAACTGGCTGACTTTGGG

GCCAGTTTGAGAAAGTGGTGGAAATTCT
GGGTCC

70

TIR8

GCCGACCTCTTGGTGAACCTGAGCC

GGTCCTTGTCGTCCTGCAGCTGCG

70

LUC7L

CTGCCTGAGAGAAGTCGTCGCG

CCCATGACATCCTGGCTGGGACG

70

CD45-E4

GGCAAGCCCAACACCTTCCCCCACTG

CTGAAACTTTTCAA CCCCTGGTGGCAC

70

PIGQ

GATCCATCTGCTCGTGGACCTCATCAACT
C

GTAGGTGTGCACCACGCGGCTGTAGG

CD45-E5

GGCAAGCCCAACACCTTCCCCCACTG

CTGAAACTTTTCAACCCCTGGTGGCAC

70

MAP2K7

CGACCTCAACCTGGATATCAGCC

GGAGCTCTCTGAGGATGGCGAGC

65

GATACAGTAAAGACATAAATACCACATTTG
ACAAATGG

GATAGTTGACACTCAGGAACAGCACGG

65

CARD8

FAM36A

BRD8
NGLY1

ZC3H14

MACF1
REPS1

AKAP9

MAP4K2
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65

Fyn

GTCTCTGCTGCCGCCTAGTAGTTCCC

CACCACTGCATAGAGCTGGACCAGC

70

ZNF384

CAGAGTCCAAGTCAGACCAGCTGACC

GGAAGAGCTGAGACAATCATGGGAGCC

70

ERP29

CTTCCTGCTCCTCTCCGCTCCGCATG

CGCTGGATGGCTCCAACCTTAACTGC

70

TRIM65

GAAGAGGGGAGCCACCCTGG

GGCCCCGGGACTGACGACAG

65

CKB

CAGCAGCTCATCGACGACCACTTCC

GAGGATGTAGCCCAGGTGAGGGTTCC

70

FAM21C

CCAATCCACTGCCGATATCTTTGGTGACG

GAGCTTGCCAGGCAGCAGAGACGC

70

UGCGL1

CTATCTTGGATTCCCAAGGCAAGACTGCT
GC

CATACAGTAACTGCCGTCCAGAAGGGC

MAP7D1

CATCCAACGGTCAGTGAAGAAGACGTGG

GACTCCGAGCAAGGAAGGAGAGAGTGG

70

GAGGTCGAGCGCCTAGTGTCGGAG

GCGATGATGATGAAGATGATGTTCATGTC
AC

65

CTTTGTAAGACGATCTCTGTGGCAAGGC

GGAACCACAACTATGTTATTTGAGTGCAG
G

65

GTGACTTCACCGAAGACCAGACCGC

GTGACAAGAACATGCCGGATTTCAGCAC
C

70

CCDC14

GCTGAAACTGTACACGGGCTTGATGG

GAGTCTGCACGTGCTCACAGAGGG

70

GALT

CCATGACCCTCTCAACCCTCTGTGTCC

CTGCACCCAAGGGTACTGGGCACC

70

MAP3K7

CTCCCGTGGGAGCAGTGTGGAGAGC

GTTACAGTCAAGTCTTGGATGGATCTACG

70

ATF2

TGTGGAATATGAGTGATGACAAACC

TTCATTCTCAAATGGACTCGCCAAC

65

GCTATTATTCGTGAATTGGGTGGTATTCCA
ATTGTTGC

GGCACGGAGAAGTCCTTCTGTCATGG

70

ARMC10
FAM33A

CCAGAAAGCTGAGTCTGATCTGGATTAC

GTGAAATTTGAATTGCTCTGCCGCAG

70

CATCGTCCAGTAAGACCGTCCCGGACG

GACACTGAAAGGACTCTCCTCAATTTTCC
CAGC

70

CGCGTACTTGCTTTGTAAGTGATCTGAAG
CG

CTGCAAGCAATCTGTGGAGAAATCCTGG
C

70

ACTR10

GACCTGGCTTTATCTACTGGATGAGTTCC
G

CTGATAGACCTGGTCATTCCTCAACAGA
GC

70

CD3D

CTCCATCCGCCACAACCTTTCCCTGC

GGGAGTTCGGTTTTGATGGTCATGTTCC
G

70

CAGATGGTCACCATGTTTAGATATTAGCAG
TCCC

GTCTCATCTTGGCTGGCCAGCAGAC

70

CTCTCAGCCAACCACCTCTGAGAGC

GAGGGGTTGTAGGAGGTCTTTCTAAATC
CAG

70

GCTCTTGCAAAAGAAATGCGAGCAGATGC

CTTTATGACATGGATTTTCAGCATGTTCT
ACAGCC

70

CCGAAGGCTCTCCATCGAAGGCAAC

CTCTCTCATGAGGTCTTCTTGTTTGGTTA
CTTCC

70

GACAAAGGAAGTTGTGTCAATGGGAACAG

GGTCTCGTCTAAGTTTCCACACTCC

65

FIP1L1

LRRC28

MYL6

SFRS8

FoxM1

RNF216

C2orf33

WDR67

DGUOK
ADAT1
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70

G
GAAGCGCAGGCGGCCAATGGAACC

CAGAAGTGGGCTCAGAAGTTGGCTTCAA
GG

70

BAX

CTCTGAGCAGATCATGAAGACAGG

GAAAACATGTCAGCTGCCACTCG

65

CAMTA1

GCGAGGAGGAGGAGGATGTGGC

CTCATTAGTGTTCCAGCGGTGCC

65

CCAR1

CACTGGTCTCCTTCGTTGGATGGACC

GTCTTTGGATCAAGTTTAGACCAATGGGT
AGG

70

CELF2

CTGCAGATAGTGAAAAGTCCAACGCTGTG
G

CCCAGGTGGCAGTGTTGAGCTGCTGC

70

FIP1L1

GAGGTCGAGCGCCTAGTGTCGGAG

GCGATGATGATGAAGATGATGTTCATGTC
AC

65

LEF1

GAGAGAGAAACTACAGGAATCTGCATCAG

CAAGCTTCCATCTCCAGAAGAGGTCC

70

LUC7L

CTG CCT GAG AGA AGT CGT CGC G

CGT CCC AGC CAG GAT GTC ATG GG

65

MKK7

CGACCTCAACCTGGATATCAGCC

GGAGCTCTCTGAGGATGGCGAGC

65

MTF2

AAGATATGAGCATGTTCTGGAGGC

GTATATGGGCCAGGTGGACGACC

65

PRPF3

CTGTTTGAGGCTGTGGAGGAAGGC

GGAGCTTAGTCAGCATGCCAGGG

65

RBM3

GTCAAGGACCGGGAGACTCAGCGG

GCAGACTTGCCTGCATGATCCACACGG

70

RNF34

AGGAGGTCGGCAGTGTGAGGAGC

CTGAATGGACCGGTGGCTCCTGC

70

SMARCA4

CTCGTGGATCATCAAGGACGACG

CGCTTCCGTGATGATTTCTTCTGC

65

TRA2A

TGGTTGCCGACTCTTTCCTCTTCC

CTACGAGATCCTGACCTGCTCTCC

70

ZDHHC20

CTTGGGTGATGGTTGCAGTTTTCC

CTGAGATTCACTGTCCAACAAGCG

65

TNF-α

CACCATGAGCACTGAAAGCATGATCCG

GGCCAGAGGGCTGATTAGAGAGAGG

60

B2M

CTCGCGCTACTCTCTCTTTCTGG

ATGGATGAAACCCAGACACATAGC

60

IL-4

CATGAGAAGGACACTCGCTGCCTGG

TTCCAACGTACTCTGGTTGGCTTCC

70

Actin

CCCTGGCATTGCCGACAGG

GCCGATCCACACGGAGTACT

60

PI4KB
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Table 7.2 Primers used for cloning and in vitro transcription
Gene

Primer 5'-3'

Ta

MKK7I1-2 NdeI-F

GGAATTCCATATGCCTCCTCCTCGTTTATGATTTGATTTC

65

MKK7I1-2 PstI-R

AAAACTGCAGTAACTGGATGGGGAAAAGGAAGAAA

65

MKK7I2-3 PstI-F

AAAACTGCAGCAGGTACCAGCCTTTTTATCATCGC

70

MKK7I2-3 Bglll-R

GGAAGATCTGGACGCCATTCTGCGGCCGGG

70

MKK7I1-2 T7-F

TAATACGACTCACTATAGGCCTCCTCCTCGTTTATGATTTGATTTC

70

MKK7I2-3-R

GGACGCCATTCTGCGGCCGGG

70

Beta-globin T7-F

TAATACGACTCACTATAGGGACCAATAGAAACTGGGCATATGG

65

Beta-globin-R

CTTCTCTGTCTCCACATGCCCAG

65

JNK1a1- BamHI-F

cgcGGATCCagcagaagcaagcgtgacaaca

65

JNK1a1-XbaI-R

ctagtctagaTCACTGCTGCACCTGTGCTAAAG

65

MKK7cDNA-BamHIF
MKK7cDNA-EcoR1-

CGCGGATCCATGGCGGCGTCCTCCCTGGAAC

65

CCGGAATTCCTACCTGAAGAAGGGCAGGTGGGGC

65

R
MKK7-LcDNA-R

GGTCTTCCGGAAGCGCATCTTCC

65

swCTCF EHMT2-F

GGGACAGCATGACTCTCAGCCTCAGGGCAGGAGGG

50

swCTCF EHMT2-R

GAGGCTGAGAGTCATGCTGTCCCTGTCCCGGCAATTGG

50

swARS EHMT2-F

ACCCAGCATGACTCTCAGGCTGGTAATTGCCAATTGC

50

swARS EHMT2-R

CAGCCTGAGAGTCATGCTGGGTCCCCTCGCTGG

50

outside T7-F

CTAATACGACTCACTATAGGGAGC

50

Outside GloIVS3-R

CCTGATTTGGTCAATATGTGTATCG

50

mgNGLY1-F

GGGAATTCCATATGGTTCTGTTTGTGTGTTTCCACTAGC

70

mgNGLY1-R

CAGAAGATCTTATTCTGGTTGGCGATTACATGGG

70

mgBRD8NdeI-F

CGGGAATTCCATATGCTTAGAATGATGGTGGTTTGCACCC

70

mgBRD8RBamHI-R

CGCGAGATCTGACAAGAGAAAAACTATTTGCTGAGTACTGCC

70

mgZC3H14NdeI-F

CGGGAATTCCATATGGCCATGCTTATTGTGCAGTTGGC

70

mgZC3H14BAMH1R
mgMKK7-F

CGGGAATTCCATATGGCCATGCTTATTGTGCAGTTGGC

70

GGAATTCCATATGCTCTCCTGACCTGAGTCAGCGTGG

70

mgMKK7-R

GAAGATCTGGAATGTGCTCCTTGTCCAGTGGG

70

mgMKK7210-F

GGAATTCCATATGCCGAGGAGTCCCCTCCAGGCGTC

70

mgMKK7220-R

AGAAGATCTGTCCAAAGTGGAGCTGGGAGTAAGG

70

mgEHMT2-F

CGGGGTACCAGTGGTTCCAGTGGCCGGCG

70

mgEHMT2-R

AGATCTAAGCTTCTCTCCGTCCACACTCTCAGTGG

70
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Table A1.1. Prediction of Alternative Splicing by RNA-Seq.

JSL1 (-PMA) JSL1 (+PMA)
Gene name Chromosome
SLMAP
PPP1R12A
FAM136A
UGCGL1
FAM36A
BRD8
FIP1L1
LUC7L
ZNF384
GALT
HYOU1
DDHD1
ARHGEF7
SEC16A
TIR8
PLSCR3
BTBD10
RABL5
NGLY1
PUS1
PPA2
FAM21C
AKAP9
BTF3L4
POLQ
H2AFY
EHMT2
ZMIZ2
BPTF
NTAN1
RBM23
BPTF
C11orf57
C2orf33
SENP7
MACF1
MVK
CUGBP2
ZC3H14

3
12
2
2
1
5
4
16
12
9
11
14
13
9
11
17
11
7
3
12
4
10
7
1
3
5
6
7
17
16
14
17
11
2
3
1
12
10
14

Strand
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

A coordinates

57886612'57886701
78723503-78723679
70382158-70382239
128630436-128630459
243071869-243071983
137523143-137523187
53939997-53940041
218333-218402
6658090-6658137
34637489-34637564
118432941-118433035
52588312-52588395
110655637-110655721
138459325-138459384
396843-396993
7237644-7237879
13423147-13423304
100748125-100748214
25748814-25748978
130989671-130989773
106597287-106597351
51529744-51529830
91459408-91459461
52298095-52298161
122661587-122661771
134714412-134714502
31964725-31964826
44766275-44766352
63302134-63302322
15049355-15049457
22447382-22447429
63302134-63302322
111450821-111450850
227925474-227925533
102702604-102702653
39616720-39616782
108501990-108502134
11348567-11348646
88132831-88132905
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%inclusion

%inclusion

dela PSI
(rest-stim)

80.65
68.12
12.12
62.16
90.91
70.79
71.43
48.48
46.67
53.85
57.52
54.84
61.11
53.33
55.56
50.00
68.89
65.08
94.34
66.67
94.39
78.38
72.41
92.00
59.26
83.13
56.32
24.24
82.46
80.39
100.00
75.34
68.18
80.95
58.33
41.33
93.75
92.31
55.29

6.67
9.28
64.71
15.56
48.39
28.74
30.77
88.57
86.67
93.10
18.31
15.79
100.00
17.33
91.49
85.71
33.33
100.00
59.42
100.00
61.24
46.43
40.54
60.87
28.21
52.33
87.10
54.93
52.00
50.00
70.00
45.45
38.46
51.52
87.65
12.08
64.71
63.33
84.21

74
59
53
47
43
42
41
40
40
39
39
39
39
36
36
36
36
35
35
33
33
32
32
31
31
31
31
31
30
30
30
30
30
29
29
29
29
29
29

WDR67
MED15
FAM33A
RPL41
LRRC40
TRPM2
PIGQ
COL4A3BP
FAM122B
ZNF346
PSD4
RPS2
PTPRC-E6
CCDC88A
TNRC6C
SFRS12
MAP3K7
WASF1
LRMP
CARD8
C10orf84
VPS11
PLEKHM2
ARPP-21
TMEM69
NRM
ERP29
AP1GBP1
MAP4K2
PARP6
DPP8
PTPRC-E4
C1orf85
PTPRC-E5
ABCD3
EDEM2
UBE2V1
MTRR
HISPPD1
RFXANK
TMC6
MYEF2
LTBP4

8
22
17
12
1
21
16
5
23
5
2
16
1
2
17
5
6
6
12
19
10
11
1
3
1
6
12
17
11
15
15
1
1
1
1
20
20
5
5
19
17
15
19

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

124215535-124215627
19259400-19259519
54551462-54551638
54797240-54797262
70427363-70427544
44671321-44671422
572249-572310
74730891-74730968
133751276-133751332
176403996-176404140
113672788-113672932
1954278-1954367
196938139-196938282
55383709-55383792
73605421-73605537
65490393-65490516
91310992-91311072
110588531-110588628
25110566-25110713
53433452-53433601
120091229-120091429
118447516-118447763
15920411-15920470
35704235-35704379
45929233-45929369
30765032-30765208
110941943-110942081
33011591-33011824
64324948-64325079
70330240-70330349
63533654-63533806
196932464-196932661
154531174-154531431
196935316-196935456
94696751-94696787
33189344-33189469
48134073-48134198
7939728-7939816
102540467-102540510
19168995-19169060
73632565-73632661
46230589-46230660
45814635-45814766
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93.75
25.42
90.48
66.67
72.00
72.22
66.67
33.33
55.29
65.71
64.63
58.70
79.87
65.31
68.12
61.70
34.55
45.00
97.50
84.62
77.14
100.00
59.14
100.00
88.24
84.76
49.34
45.83
64.71
61.22
69.23
33.18
52.63
94.02
75.00
75.00
75.00
95.35
34.69
46.15
60.98
48.39
11.11

64.86
54.29
61.64
95.35
100.00
100.00
94.44
5.66
27.66
93.33
92.20
86.21
52.42
92.45
95.12
34.78
7.69
18.18
70.73
58.14
51.02
73.91
33.33
74.19
62.50
59.09
74.76
20.43
90.00
86.44
94.44
7.97
77.78
68.87
100.00
100.00
100.00
70.37
9.76
71.05
85.59
23.81
35.48

29
29
29
29
28
28
28
28
28
28
28
28
27
27
27
27
27
27
27
26
26
26
26
26
26
26
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
24

MAPK11
BAT2D1
NFYA
TBC1D13
HDAC10
ZNF289
C19orf2
MAN1B1
FYN
DLG1
UNC84B
BAT5
DMPK
ARHGAP17
PPP1R12A
TOR2A
VAPB
SRRM1
ATF2
MFN2
ZDHHC20
TRIM65
SGSM3
HDAC10
HDAC10
C22orf13
RBCK1
TPCN2
NOL8
ICMT
PMS2
DPY19L4
HISPPD1
FAM122B
MAP2K7
C11orf79
C1orf103
NCOR2
STX16
KIAA1191
AP1G2
RHOT1
RUNX3

22
1
6
9
22
11
19
9
6
3
22
6
19
16
12
9
20
1
2
1
13
17
22
22
22
22
20
11
9
1
7
8
5
23
19
11
1
12
20
5
14
17
1

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-

49048125-49048183
169825131-169825367
41156528-41156614
130592835-130592875
49028248-49028332
47150837-47150878
35153940-35153974
139117829-139117951
112128000-112128164
198372908-198373006
37480593-37480657
31777830-31777886
50965481-50965738
24858186-24858419
78724077-78724244
129534664-129534791
56443064-56443167
24846157-24846286
175694488-175694514
11964614-11964758
20893200-20893303
71399489-71399554
39127543-39127625
49029659-49029724
49029387-49029415
23280917-23281104
349524-349675
68578765-68578841
94113249-94113362
6216121-6216290
5995957-5996112
95816034-95816158
102549920-102550039
133733839-133733979
7876693-7876740
60962052-60962161
111295433-111296960
123507605-123507661
56677753-56677915
175719420-175719527
23105611-23105735
27562248-27562370
25106337-25106495
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68.42
4.55
17.46
69.23
94.12
24.14
46.09
67.57
100.00
32.14
62.50
53.33
76.47
35.00
68.00
63.33
76.67
40.54
44.44
100.00
100.00
76.81
90.77
71.43
70.59
40.74
43.80
77.14
77.14
88.64
69.49
84.21
53.49
55.00
61.29
60.00
28.77
73.33
48.42
38.89
59.29
39.13
72.41

92.77
28.89
41.79
93.55
69.81
0.00
70.21
91.67
76.00
8.20
86.36
77.14
100.00
11.54
91.40
86.67
100.00
17.24
67.74
76.74
76.74
100.00
67.74
94.44
93.55
17.81
66.67
100.00
100.00
65.79
46.67
61.54
30.86
32.56
38.89
82.35
51.11
95.65
70.68
61.11
81.48
16.98
94.52

24
24
24
24
24
24
24
24
24
24
24
24
24
23
23
23
23
23
23
23
23
23
23
23
23
23
23
23
23
23
23
23
23
22
22
22
22
22
22
22
22
22
22

ZNF496
COX4NB
LOC647696
FBXW8
WSB1
PCMTD1
VPS29
IVNS1ABP
ATXN2
COQ5
RBM23
EIF4A2
TSR1
CD97
B3GALNT2
RLTPR
DSCR3
MGC4172
P2RX4
ARHGEF12
KIAA0746
LYPLA2
PPP2R5C
IWS1
PPP5C
ODF2
CDK5RAP2
MBD1
MYCBP2
SLAIN2
CMAH
ZNF33B
ARMC10
C18orf19
CKB
DUSP22
ARFGAP3
LRRC28
GOLGA4
NT5C2
SIP1
TOR1B
LARP4

1
16
17
12
17
8
12
1
12
12
14
3
17
19
1
16
21
17
12
11
4
1
14
2
19
9
9
18
13
4
6
10
7
18
14
6
22
15
3
10
14
9
12

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

245552623-245552730
84371486-84371580
42602282-42602407
115871806-115871894
22658897-22659072
52914560-52914751
109421645-109421734
183542240-183542380
110438341-110438550
119444400-119444549
22450377-22450452
187985445-187985584
2186081-2186184
14368889-14369035
233719096-233719196
66236944-66237035
37534667-37534810
32030213-32030305
120139320-120139467
119785313-119785369
25458014-25458584
23992085-23992116
101453921-101454037
127997787-127997837
51578508-51578573
130259298-130259537
122209111-122209347
46054554-46054721
76705292-76705399
48091350-48091427
25214566-25214701
42447749-42447893
102520160-102520336
13661861-13661972
103056559-103056682
280114-280163
41637971-41638107
97634304-97634344
37290031-37290096
104889153-104889226
38672616-38672674
131611005-131611132
49092455-49092503
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1.82
90.21
68.75
93.22
61.67
29.41
53.33
36.62
100.00
65.71
100.00
62.57
73.47
42.03
71.22
70.27
69.70
60.61
93.94
44.00
78.95
100.00
19.35
74.36
75.90
37.50
73.33
60.00
76.47
51.81
95.00
79.49
88.89
79.59
65.71
75.86
82.76
73.53
74.07
75.38
100.00
80.00
30.43

23.81
68.25
90.70
71.43
83.45
7.69
75.00
14.95
78.38
87.23
78.57
83.89
94.74
63.27
92.45
91.49
90.91
81.82
72.73
22.86
100.00
78.95
40.35
95.35
96.77
16.67
52.54
80.65
55.84
31.20
74.47
100.00
68.42
100.00
86.11
55.56
62.50
93.75
94.29
95.45
80.00
100.00
10.53

22
22
22
22
22
22
22
22
22
22
21
21
21
21
21
21
21
21
21
21
21
21
21
21
21
21
21
21
21
21
21
21
20
20
20
20
20
20
20
20
20
20
20

SEC22C
TRIM26
TRAF3
KIAA0182
CCDC14
ALKBH3
SEC16A
MYL6
REPS1
MAP7D1

3
6
14
16
3
11
9
12
6
1

+
+
+
+
+

42580261-42580384
30280412-30280521
102425650-102425724
84225021-84225239
125157380-125157502
43870167-43870255
138459918-138459992
54839674-54839781
139289231-139289311
36413086-36413196

28.57
77.27
97.85
62.58
94.74
74.58
71.43
73.14
94.55
64.71

8.70
97.14
78.05
82.35
75.00
94.29
91.11
92.71
75.00
84.21

20
20
20
20
20
20
20
20
20
20

Table A1.1. Prediction of Alternative Splicing by RNA-Seq. Complete data from the RNA-Seq
alternative splicing analysis pipeline, comprising all ~ 11,000 exons for which greater than 10 exonjunction reads were obtained. Gene names highlighted in bold indicate those AS events which have
been validated by RT-PCR. Gene names highlighted in grey indicate those AS events which were
analyzed by RT-PCR and found to be inconsistent with the RNA-Seq prediction.
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Table A1.2: Non-Signal-Responsive Exons in JSL1 Cells Predicted by RNA-Seq
Gene
PMS1
WDR67
FoxM1
SFRS8
ACTR10
DGUOK
PI4KB
RNF216
MAX
C2orf33
ADAT1
CD3D

% Inc - PMA
RT-PCR
86
75
67
55
98
9
6
0
55
14
14
19

StDv % inc +PMA
RT-PCR
2
85
3
73
1
79
3
52
1
99
2
9
1
4
0
0
4
57
3
14
1
18
3
16

StDv
2
6
3
1
0
1
1
0
3
1
2
1

RT-PCR
Differential
-1
-2
12
-3
1
0
-2
0
2
0
4
-3

% Inc - PMA
Solexa
100
80
71
86
62
66
23
54
43
73
77
78

% Inc + PMA
Solexa
100
80
71
87
63
67
24
53
41
76
80
74

Solexa
Differential
0
0
0
1
1
1
1
-1
-2
3
3
-4

Table A1.2. RT-PCR analysis of exons predicted NOT to change in inclusion value between
resting and stimulated JSL1 cells. (n> 3 for all data)
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Table A1.3. Ingenuity Pathway Analysis results. Complete genes and statistics above
threshold of p>0.03 for (A) Functional analysis.
Category

p-value

Molecules

Nervous System
1.16E-03-4.69E-02 RUNX3,WASF1,NTAN1,FYN,ATF2,SIGIRR
Development and Function
Organ Morphology
1.16E-03-3.42E-02 WASF1,FYN,FBXW8,ATF2,TRPM2
Cell Cycle

3.41E-03-3.42E-02 NCOR2,IVNS1ABP,PPP5C,MFN2,AKAP9,FYN,TOR2A,MAP2K7,ATF2

Cell-To-Cell Signaling and
Interaction
Connective Tissue
Development and Function
Hematological System
Development and Function
Hematopoiesis

3.41E-03-4.37E-02 NCOR2,CMAH,PTPRC,FYN,TRAF3,HYOU1,ATF2,DLG1,MAP3K7

Immune Cell Trafficking

3.41E-03-4.37E-02 NCOR2,RUNX3,CMAH,PTPRC,FYN,TRAF3,HYOU1,DLG1,MAP3K7

Inflammatory Response

3.41E-03-4.37E-02 NCOR2,RUNX3,CMAH,PTPRC,FYN,TRAF3,HYOU1,DLG1,MAP3K7

Cancer

6.67E-03-4.37E-02 NCOR2,RUNX3,CCDC88A,FYN,TRAF3,MAP2K7,HYOU1,ATF2,ARMC1

Cellular Growth and
Proliferation
Hematological Disease

6.67E-03-3.42E-02 RUNX3,PTPRC,FYN,MAP2K7,ATF2,ARMC10

Immunological Disease

6.67E-03-3.42E-02 LYPLA2,TRAF3,MAP2K7,RFXANK

Skeletal and Muscular
System Development and
Function
Tissue Development

6.67E-03-4.69E-02 ICMT,LUC7L,MFN2,SLMAP,TOR2A,MAP2K7,DLG1,ARHGEF7,MAP3K7,
MYL6,P2RX4,COL4A3BP

Cellular Development
Gene Expression

Post-Translational
Modification
Protein Folding
Cell Signaling

3.41E-03-3.42E-02 IVNS1ABP,PPP5C,LTBP4,FYN,TOR2A,MAP2K7,ARHGEF7,MAP3K7
3.41E-03-4.37E-02 NCOR2,RUNX3,CMAH,NFYA,PTPRC,FYN,TRAF3,HYOU1,DLG1,MAP3
K7
3.41E-03-3.42E-02 RUNX3,NFYA,PTPRC,FYN,MAP3K7

6.67E-03-3.42E-02 LYPLA2,TRAF3,MAP2K7,ATF2

6.67E-03-4.69E-02 ICMT,LUC7L,RUNX3,CMAH,PTPRC,FYN,MAP2K7,DLG1,ARHGEF7,MY
L6,MAP3K7
8.17E-03-3.42E-02 RUNX3,NFYA,PTPRC,FYN,ATF2,ARMC10,MAP3K7
1.09E-02-4.22E-02 IVNS1ABP,C1orf85,ZMIZ2,MAPK11,HDAC10,ARHGEF7,PPP2R5C,BPTF
,ARHGEF12,RUNX3,BRD8,ATF2,MAP3K7,EHMT2,NFYA,FYN,PUS1,MB
D1,MAP2K7,ZNF496,DUSP22,MYCBP2,ZNF384,NCOR2,PPP5C,C19orf
2,MACF1,RFXANK,MED15
1.21E-02-3.42E-02 EDEM2,ERP29,LTBP4,UGGT1,FYN,MAN1B1
1.21E-02-1.21E-02 EDEM2,ERP29,LTBP4,UGGT1,MAN1B1

Tissue Morphology

1.29E-02-3.61E-02 ICMT,MFN2,UBE2V1,CARD8,PTPRC,RBCK1,FYN,MAP4K2,MAPK11,PP
P5C,NT5C2,RFXANK,MAP3K7
1.42E-02-3.42E-02 LTBP4,RUNX3,SLMAP,PTPRC,FYN,ATF2,MYL6,P2RX4,COL4A3BP

Cell Death

1.58E-02-3.42E-02 RUNX3,PTPRC,TRAF3,MAP3K7

Cellular Assembly and
Organization
Cellular Function and
Maintenance
Behavior

1.59E-02-3.42E-02 ABCD3,CCDC88A,CKB,LRMP,WASF1,FYN,MAP4K2,ARHGEF7,DLG1,A
P1G2,MAP3K7
1.8E-02-3.42E-02 MFN2,CCDC88A,CKB,WASF1,FYN,DLG1,ARHGEF7,SIGIRR,MAP3K7

Carbohydrate Metabolism

2.18E-02-3.42E-02 CMAH,GALT,B3GALNT2,LYPLA2,MAN1B1,MTRR

Reproductive System
Disease
Cell-mediated Immune
Response
Molecular Transport

2.18E-02-2.18E-02 EHMT2,FBXW8

RNA Trafficking

2.18E-02-4.69E-02 NTAN1,FYN,SIGIRR

2.84E-02-3.42E-02 FYN,DLG1
2.84E-02-4.69E-02 ABCD3,SRRM1,NT5C2,ATXN2,GALT,LYPLA2,DMPK,FYN,TRAF3,DLG1,
P2RX4
2.84E-02-2.84E-02 SRRM1,ATXN2

© 2000-2011 Ingenuity Systems, Inc. All rights reserved.
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Table A1.3. Ingenuity Pathway Analysis results. Complete genes and statistics above
threshold of p>0.03 for (B) Canonical Signaling analysis.
Ingenuity Canonical
Pathways

-log(p-value)

Molecules

Phospholipase C Signaling 2.22E00

PPP1R12A,ARHGEF12,RHOT1,FYN,ATF2,HDAC10,ARHGEF7,MYL6

Cardiomyocyte
Differentiation via BMP
Receptors

ATF2,MAP3K7

2.18E00

Production of Nitric Oxide 1.87E00
and Reactive Oxygen
Species in Macrophages

PPP1R12A,RHOT1,MAPK11,MAP2K7,PPP2R5C,MAP3K7

Regulation of Actin-based 1.8E00
Motility by Rho

PPP1R12A,WASF1,RHOT1,MYL6

CD40 Signaling

1.74E00

MAPK11,TRAF3,MAP2K7,MAP3K7

April Mediated Signaling

1.73E00

MAPK11,TRAF3,MAP2K7

B Cell Activating Factor
Signaling

1.66E00

MAPK11,TRAF3,MAP2K7

NF-κB Signaling

1.64E00

UBE2V1,TRAF3,MAP2K7,SIGIRR,MAP3K7

SAPK/JNK Signaling

1.56E00

MAP4K2,ATF2,MAP2K7,MAP3K7

Role of PKR in Interferon
Induction and Antiviral
Response

1.54E00

TRAF3,ATF2,MAP3K7

Role of MAPK Signaling in 1.54E00
the Pathogenesis of
Influenza

MAPK11,ATF2,MAP2K7

RhoA Signaling

PPP1R12A,ARHGEF12,WASF1,MYL6

1.52E00

© 2000-2011 Ingenuity Systems, Inc. All rights reserved.
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Table A1.4 Ingenuity Pathway Analysis: Functional Categories.
Transcripts Up-regulated upon Stimulation
Functional Categories

p-value

Molecules

Inflammatory Response

1.18E-21-3.65E-03

Cellular Movement

5.7E-14-2.8E-03

Immune Cell Trafficking

5.7E-14-3.65E-03

Hematological System
Development and
Function

1.65E-13-3.65E-03

SELL,CD40LG,MBP,CTSW,LTB,TGFBR2,CD28,IFITM2,CD226,KRT1,
CD84,GZMA,STAT5A,IL4R,PTPRE,HSH2D,SAMSN1,ITGA6,IER3,LGA
LS9B,APOBEC3G,IL18BP,SELP,PNP,RARRES3,ITGA1,GPR68,RXRA,
TFPI,ADCYAP1 (includes
EG:11516),LCP2,TMEM173,TNFSF10,TNFAIP3,LGALS9,ARRB1,TIMP
1,GBP2 (includes
EG:14469),SEMA4A,HPGDS,SLA2,EPAS1,FLT1,RELB,EGR1,CD69,A
LOX5AP,CD58,SLIT2,IL16,CCR4,RETN,GATA3,LGALS1
CD40LG,SELL,TNFAIP3,LTB,TNFSF10,LGALS9,TGFBR2,CD28,ARR
B1,TIMP1,CD226,STAT5A,PIK3C2B,TP53INP1,IL4R,EPAS1,FGFR1,P
OU4F1,EGR1,RELB,CD69,FLT1,SH2D3C,ITGA6,CD58,ALOX5AP,TRP
C6,IER3,SLIT2,IL18BP,IL16,RETN,SELP,CCR4,TGFA,ITGA1,CD82,HH
EX,ADCYAP1 (includes
EG:11516),TFPI,RXRA,GATA3,LCP2,LGALS1,ETV5
CD40LG,SELL,MBP,TNFSF10,LTB,TNFAIP3,LGALS9,TGFBR2,CD28,
ARRB1,TIMP1,CD226,SEMA4A,CD84,SLA2,GZMA,STAT5A,PTPRE,IL
4R,HSH2D,EPAS1,SAMSN1,RELB,EGR1,FLT1,CD69,SH2D3C,ITGA6,
ALOX5AP,CD58,IER3,SLIT2,IL16,IL18BP,CCR4,RETN,SELP,ITGA1,G
ATA3,ADCYAP1 (includes EG:11516),RXRA,LCP2,LGALS1
CD40LG,SELL,MBP,ZFP36L1,LTB,HES1 (includes
EG:15205),TGFBR2,CD28,CD226,CD84,GZMA,STAT5A,PTPRE,IL4R,
TP53INP1,HSH2D,SAMSN1,SH2D3C,ITGA6,IER3,LGALS9B,IL18BP,L
ST1,SELP,PNP,ITGA1,HHEX,TFPI,RXRA,ADCYAP1 (includes
EG:11516),LCP2,TNFSF10,TNFAIP3,LGALS9,CD52,ARRB1,TIMP1,LY
L1,SEMA4A,HPGDS,SLA2,EPAS1,FLT1,CD69,EGR1,RELB,CD58,AL
OX5AP,SLIT2,IL16,ZFPM2,CCR4,RETN,HLA-E,CD82,GATA3,LGALS1

Cardiovascular System
Development and
Function

7.36E-12-3.29E-03

Organismal Development 7.36E-12-2.8E-03

Cell-To-Cell Signaling and 7.64E-12-3.65E-03
Interaction

Cellular Growth and
Proliferation

6.01E-11-3.65E-03

CD40LG,SELL,MB,ZFP36L1,TNFSF10,TNFAIP3,SPRY4,TGFBR2,CD
28,TIMP1,CASP10,STAT5A,TUBB3,IL4R,EPAS1,ADAMTS1,SPRY1,F
GFR1,FLT1,TUBA4A,TRPC6,SLIT2,PLXND1,IL18BP,ZFPM2,SELP,TG
FA,ITGA1,HHEX,TFPI,GATA3,LGALS1
MB,ZFP36L1,TNFAIP3,TNFSF10,LTB,HES1 (includes
EG:15205),SPRY4,TGFBR2,CD28,TIMP1,FOXB1,KRT1,STAT5A,IL4R,
EPAS1,ADAMTS1,SPRY1,POU4F1,RELB,FLT1,FGFR1,EGR1,ITGA6,
SLIT2,PLXND1,IL18BP,ZFPM2,SELP,TGFA,ITGA1,HHEX,TFPI,GATA3
,ADCYAP1 (includes EG:11516),RXRA,LCP2,LGALS1
CD40LG,SELL,MBP,LTB,HES1 (includes
EG:15205),TGFBR2,CD28,CD226,CD84,CASP10,GZMA,STAT5A,IL4R
,PTPRE,HSH2D,SAMSN1,FGFR1,ITGA6,SELP,PNP,RARRES3,ITGA1
,RXRA,ADCYAP1 (includes
EG:11516),TFPI,PARVG,LCP2,TNFAIP3,TNFSF10,LGALS9,CD52,TIM
P1,FOXB1,SEMA4A,SLA2,SPRY1,CD69,RELB,FLT1,EGR1,CD58,SLI
T2,PLXND1,IL16,RETN,CCR4,TGFA,CD82,GATA3,SIGLEC6,LGALS1
CD40LG,SGK1,MBP,ZFP36L1,LTB,HES1 (includes
EG:15205),TGFBR2,CD28,CD84,STAT5A,TUBB3,IL4R,TP53INP1,PTP
RE,HSH2D,ADAMTS1,SAMSN1,POU4F1,FGFR1,SH2D3C,ITGA6,TR
PC6,IER3,LST1,SELP,PNP,RARRES3,NEIL1,ITGA1,HHEX,ADCYAP1
(includes
EG:11516),RXRA,TFPI,LCP2,ETV5,DUSP6,TNFSF10,TNFAIP3,LGAL
S9,CD52,COL6A1,TIMP1,HPGD,GBP2 (includes
EG:14469),HPGDS,EPAS1,SPRY1,EGR1,CD69,RELB,FLT1,CD58,SLI
T2,IL16,RETN,HLA-E,TGFA,CD82,GATA3,LGALS1
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Table A1.4 Ingenuity Pathway Analysis: Functional Categories.
Transcripts Up-regulated upon Stimulation
Tissue Morphology

7.91E-11-3.31E-03

Cellular Development

1.46E-09-3.35E-03

Dermatological Diseases 2.06E-09-3.4E-03
and Conditions

Inflammatory Disease

2.06E-09-3.4E-03

Hematopoiesis

1.21E-08-2.59E-03

Renal and Urological
Disease

1.87E-08-3.4E-03

Cardiovascular Disease

2.53E-08-9.39E-04

Immunological Disease

2.72E-08-3.4E-03

Cancer

2.73E-08-3.58E-03

Cell-mediated Immune
Response

5.47E-08-2.59E-03

SELL,CD40LG,SGK1,TNFAIP3,TNFSF10,LTB,HES1 (includes
EG:15205),TGFBR2,CD28,TIMP1,HPGDS,STAT5A,TUBB3,IL4R,EPAS
1,ADAMTS1,SAMSN1,POU4F1,FLT1,CD69,EGR1,RELB,FGFR1,SH2
D3C,ITGA6,LGALS9B,IL18BP,SELP,CCR4,PNP,TGFA,RARRES3,ITG
A1,GATA3,ADCYAP1 (includes EG:11516),RXRA,LCP2
CD40LG,MBP,LTB,HES1 (includes
EG:15205),SPRY4,TGFBR2,CD28,IFITM2,STAT5A,TP53INP1,IL4R,TU
BB3,ADAMTS1,FGFR1,POU4F1,ITGA6,TRPC6,IER3,SELP,PNP,RAR
RES3,ITGA1,HHEX,TFPI,ADCYAP1 (includes
EG:11516),RXRA,LCP2,ETV5,MB,NID2,TNFSF10,TNFAIP3,LGALS9,C
D52,TIMP1,LYL1,HPGD,SEMA4A,EPAS1,SPRY1,FLT1,CD69,EGR1,R
ELB,SLIT2,ZFPM2,RETN,TGFA,CD82,GATA3,LGALS1
SELL,LAPTM5,SGK1,MBP,LTB,TNFAIP3,TNFSF10,TMC6,CLEC2B,TG
FBR2,CD28,CD52,TIMP1,IFITM2,FAR2,GBP2 (includes
EG:14469),KRT1,TMC8,TUBB3,IL4R,IER2,RELB,FGFR1,FLT1,EGR1,
TUBA4A,ITGA6,ALOX5AP,PLXND1,IL16,SELP,CCR4,HLAE,TGFA,ITGA1,GATA3,RXRA,LCP2,LGALS1
SELL,CD40LG,SCML1,SGK1,MBP,LTB,TGFBR2,CD28,IFITM2,CD226,
KRT1,FAM101B,CASP10,GZMA,TP53INP1,AMPD3,IL4R,TUBB3,ADA
MTS1,POU4F1,FGFR1,ITGA6,IL18BP,LST1,SELP,ITGA1,RXRA,LCP2,
LAPTM5,TMEM173,TNFAIP3,TNFSF10,CLEC2B,CD52,COL6A1,SLFN
5,ARRB1,TIMP1,HPGD,GBP2 (includes
EG:14469),SEMA4A,EPAS1,RELB,CD69,FLT1,EGR1,TUBA4A,ALOX5
AP,CD58,NMT2,SLIT2,PLXND1,IL16,RETN,CCR4,HLAE,TGFA,GATA3,LGALS1
CD40LG,MBP,TNFAIP3,TNFSF10,LTB,HES1 (includes
EG:15205),TGFBR2,CD28,CD52,TIMP1,LYL1,SEMA4A,STAT5A,IL4R,
TP53INP1,EPAS1,FLT1,RELB,EGR1,CD69,ZFPM2,SELP,PNP,RARRE
S3,ITGA1,HHEX,RXRA,ADCYAP1 (includes
EG:11516),GATA3,LCP2,LGALS1
TUBB3,CD40LG,EPAS1,SGK1,SAMSN1,FLT1,FGFR1,TUBA4A,ITGA6
,TNFSF10,TNFAIP3,TRPC6,IL16,CD28,COL6A1,SELP,TIMP1,TGFA,IT
GA1,CPXM1
CD40LG,KIAA1462,TNFSF10,TNFAIP3,TGFBR2,CD28,CD52,TIMP1,T
OX2,DPF3,STAT5A,PTPRE,TUBB3,EPAS1,MAST4,FLT1,EGR1,TUBA
4A,ALOX5AP,HIVEP3,RCBTB2,ZFPM2,SELP,TGFA,RXRA,TFPI,GATA
3
CD40LG,SELL,SCML1,MBP,LTB,TGFBR2,CD28,IFITM2,CD226,KRT1,
FAM101B,CASP10,GZMA,TUBB3,AMPD3,IL4R,HSH2D,MAST4,FGFR
1,ITGA6,PREX2,IL18BP,LST1,SELP,PNP,ITGA1,RXRA,LCP2,ETV5,LA
PTM5,TMEM173,TNFAIP3,TNFSF10,PLCH1,CLEC2B,CD52,SLFN5,A
RRB1,TIMP1,SEMA4A,GBP2 (includes
EG:14469),HPGDS,DPF3,EPAS1,CD69,TUBA4A,NMT2,SLIT2,PLXND
1,IL16,TMEM2,CCR4,HLA-E,TGFA,GATA3,LGALS1
SELL,CD40LG,SGK1,MBP,LTB,HES1 (includes
EG:15205),TGFBR2,CD28,IFITM2,KRT1,CASP10,GZMA,STAT5A,IL4
R,PTPRE,TP53INP1,TUBB3,ADAMTS1,SAMSN1,IER2,FGFR1,ITGA6,
TRPC6,IER3,APOBEC3G,IL18BP,SELP,PNP,ITGA1,RXRA,TFPI,ETV5,
DUSP6,TNFSF10,TNFAIP3,PLCH1,CD52,COL6A1,ARRB1,TIMP1,HP
GD,ANTXR2,HPGDS,GBP2 (includes
EG:14469),EPAS1,RELB,FLT1,CD69,EGR1,TUBA4A,CD58,SLIT2,KLH
L6,IL16,ZFPM2,LPCAT2,RETN,CCR4,HLAE,TGFA,LIMD2,CD82,GATA3,LGALS1
CD40LG,SELL,MBP,TNFSF10,LTB,TNFAIP3,TGFBR2,CD28,CD52,CD
226,SEMA4A,STAT5A,IL4R,CD69,RELB,EGR1,FLT1,ITGA6,IL18BP,IL
16,CCR4,SELP,PNP,GATA3,ADCYAP1 (includes
EG:11516),LCP2,LGALS1
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Table A1.4 Ingenuity Pathway Analysis: Functional Categories.
Transcripts Up-regulated upon Stimulation
Cellular Function and
Maintenance

5.47E-08-2.59E-03

Lymphoid Tissue
Structure and
Development

5.47E-08-2.59E-03

Neurological Disease

8.72E-08-2.72E-03

Hematological Disease

9.44E-08-3.51E-03

Connective Tissue
Disorders

1.11E-07-2.32E-03

Skeletal and Muscular
Disorders

1.11E-07-2.32E-03

SCML1,CD40LG,TMEM173,TNFSF10,LTB,TNFAIP3,CLEC2B,CD28,C
OL6A1,SLFN5,TIMP1,IFITM2,CD226,GBP2 (includes
EG:14469),FAM101B,CASP10,GZMA,IL4R,AMPD3,TUBB3,EPAS1,AD
AMTS1,POU4F1,CD69,FLT1,FGFR1,TUBA4A,ALOX5AP,NMT2,SLIT2,
PLXND1,IL16,IL18BP,LST1,CCR4,SELP,RETN,HLA-E,RXRA,LGALS1

Cell Death

2.06E-07-3.4E-03

Tissue Development

2.66E-07-3.6E-03

CD40LG,SGK1,MBP,LTB,HES1 (includes
EG:15205),TGFBR2,CD28,MICAL1,UBA7,CD226,CASP10,GZMA,STA
T5A,IL4R,TP53INP1,TUBB3,PTPRE,HSH2D,POU4F1,FGFR1,ITGA6,I
ER3,PNP,RARRES3,ITGA1,HHEX,ADCYAP1 (includes
EG:11516),RXRA,MB,DUSP6,TMEM173,TNFSF10,TNFAIP3,LGALS9,
ARRB1,TIMP1,ANTXR2,FOXB1,HPGDS,HCST,EPAS1,CD69,EGR1,FL
T1,RELB,SLIT2,PPP1R16B,HLAE,TGFA,CD82,GATA3,LGALS1,FAIM3
SELL,CD40LG,SGK1,MBP,ZFP36L1,LTB,HES1 (includes
EG:15205),TGFBR2,CD28,CD226,KRT1,STAT5A,IL4R,PTPRE,ADAM
TS1,FGFR1,POU4F1,ITGA6,TRPC6,IER3,IL18BP,LST1,SELP,ITGA1,
HHEX,PARVG,RXRA,ADCYAP1 (includes
EG:11516),TFPI,LCP2,MB,CHST7,NID2,TNFSF10,LGALS9,TIMP1,AN
TXR2,FOXB1,SHANK3,EPAS1,SPRY1,FLT1,RELB,EGR1,CD69,HIVE
P3,CD58,SLIT2,PLXND1,ZFPM2,CCR4,TGFA,CD82,GATA3,LGALS1

Genetic Disorder

3.34E-07-1.51E-03

Antigen Presentation

9.91E-07-3.4E-03

Gastrointestinal Disease

1.71E-06-3.58E-03

Hepatic System Disease 1.71E-06-1.57E-03

CD40LG,SGK1,MBP,LTB,TNFAIP3,TNFSF10,HES1 (includes
EG:15205),TGFBR2,CD28,CD52,SEMA4A,GZMA,SLA2,STAT5A,PIK3
C2B,IL4R,RELB,EGR1,CD69,FLT1,TRPC6,RETN,CCR4,PNP,ADCYAP
1 (includes EG:11516),GATA3,LCP2,LGALS1
CD40LG,MBP,LTB,TNFAIP3,TNFSF10,HES1 (includes
EG:15205),TGFBR2,CD28,CD52,TIMP1,SEMA4A,STAT5A,IL4R,FLT1,
EGR1,RELB,CD69,SH2D3C,KLHL6,SELP,PNP,ITGA1,TFPI,ADCYAP1
(includes EG:11516),GATA3,LCP2,LGALS1
SELL,CD40LG,MBP,EGR1,CD58,TNFSF10,IL18BP,CD28,CD52,ARRB
1,TIMP1,SEMA4A,LCP2,LGALS1
SELL,CD40LG,SGK1,LTB,TNFAIP3,TNFSF10,TGFBR2,CD28,CD52,H
PGDS,CASP10,STAT5A,TUBB3,CD69,FLT1,FGFR1,EGR1,TUBA4A,IT
GA6,CD58,IER3,KLHL6,IL16,PNP,ITGA1,RXRA
SCML1,CD40LG,TMEM173,TNFSF10,LTB,TNFAIP3,CLEC2B,CD28,C
OL6A1,SLFN5,TIMP1,CD226,GBP2 (includes
EG:14469),FAM101B,CASP10,GZMA,IL4R,AMPD3,TUBB3,EPAS1,AD
AMTS1,POU4F1,CD69,FLT1,FGFR1,TUBA4A,ALOX5AP,NMT2,SLIT2,
PLXND1,IL16,IL18BP,LST1,CCR4,SELP,RETN,HLA-E,RXRA,LGALS1

CD40LG,SGK1,DUSP6,MBP,TNFSF10,TNFAIP3,HES1 (includes
EG:15205),TMC6,CLEC2B,TGFBR2,CD28,CD52,COL6A1,TIMP1,ANT
XR2,FAR2,HPGD,GBP2 (includes
EG:14469),KRT1,TMC8,CASP10,GZMA,TP53INP1,TUBB3,IL4R,EPAS
1,ADAMTS1,IER2,RELB,FGFR1,FLT1,EGR1,ITGA6,TUBA4A,ALOX5A
P,IER3,SLIT2,IL16,CCR4,SELP,TGFA,CD82,ITGA1,GATA3,RXRA,LCP
2,ETV5,LGALS1
CD40LG,SELL,LTB,TNFAIP3,TNFSF10,CD28,ARRB1,TIMP1,CD226,K
RT1,GZMA,IL4R,PTPRE,EPAS1,RELB,CD69,FLT1,ITGA6,CD58,SLIT2
,IL16,RETN,ITGA1,LCP2,LGALS1
CD40LG,SGK1,DUSP6,LTB,TNFSF10,LGALS9,TGFBR2,COL6A1,TIM
P1,IFITM2,HPGD,CASP10,STAT5A,TP53INP1,TUBB3,IL4R,EPAS1,A
DAMTS1,RELB,EGR1,CD69,FGFR1,FLT1,TUBA4A,ITGA6,CD58,SLIT
2,LPCAT2,RETN,HLAE,TGFA,ITGA1,CD82,TFPI,RXRA,PCBP3,LGALS1,ETV5
CD40LG,TUBB3,IL4R,EPAS1,EGR1,FGFR1,FLT1,TUBA4A,ITGA6,LTB
,TNFSF10,LGALS9,TGFBR2,TIMP1,TGFA,RXRA,PCBP3
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Table A1.4 Ingenuity Pathway Analysis: Functional Categories.
Transcripts Up-regulated upon Stimulation
Lipid Metabolism

3.42E-06-3.4E-03

Small Molecule
Biochemistry

3.42E-06-3.4E-03

Humoral Immune
Response

3.82E-06-2.96E-03

Molecular Transport

7.55E-06-3.04E-03

Skeletal and Muscular
1.09E-05-2.22E-03
System Development and
Function
Respiratory Disease
1.23E-05-6.66E-04

Organismal Injury and
Abnormalities
Reproductive System
Disease

1.86E-05-1.81E-03

Reproductive System
Development and
Function
Gene Expression

4.16E-05-1.41E-03

Drug Metabolism
Infectious Disease

1.4E-04-3.8E-04
1.85E-04-2.32E-03

3.5E-05-3.4E-03

9.82E-05-3.65E-03

Embryonic Development 2.1E-04-2.22E-03

Organ Development

2.1E-04-2.59E-03

Cell Signaling

2.19E-04-3.35E-03

Vitamin and Mineral
2.19E-04-1.12E-03
Metabolism
Carbohydrate Metabolism 2.42E-04-2.8E-03
Cell Cycle

3.8E-04-3.65E-03

CD40LG,SGK1,HCAR1,MBP,TNFSF10,GBP5,CD28,TIMP1,HPGD,FA
R2,HPGDS,STAT5A,PIK3C2B,IL4R,EGR1,FLT1,ITGA6,ALOX5AP,SLC
O2A1,IL16,IL18BP,LPCAT2,RETN,TGFA,CD82,ADCYAP1 (includes
EG:11516),RXRA,TFPI,LGALS1
CD40LG,MB,SGK1,HCAR1,MBP,TNFSF10,TNFAIP3,GBP5,CD28,ARR
B1,TIMP1,HPGD,FAR2,HPGDS,PIK3C2B,STAT5A,IL4R,FLT1,EGR1,IT
GA6,ALOX5AP,SLCO2A1,IL16,IL18BP,LPCAT2,RETN,TGFA,CD82,TF
PI,RXRA,ADCYAP1 (includes EG:11516),GPR68,LGALS1
STAT5A,CD40LG,TP53INP1,IL4R,HSH2D,SAMSN1,RELB,FLT1,CD69,
EGR1,SH2D3C,LTB,KLHL6,TGFBR2,CD28,LYL1,PNP,HHEX,KRT1,LG
ALS1
SELL,CD40LG,SGK1,HCAR1,MBP,TNFSF10,GBP5,CD28,ARRB1,TIM
P1,HPGD,HPGDS,SLA2,PIK3C2B,IL4R,EGR1,ALOX5AP,TRPC6,IL16,
IL18BP,RETN,SELP,CCR4,TGFA,GPR68,ADCYAP1 (includes
EG:11516),RXRA,TFPI,LCP2,LGALS1
TGFBR2,RETN,TIMP1,FLT1,FGFR1,ITGA6,TNFSF10,TNFAIP3,TRPC
6,RXRA,TFPI
SELL,TUBB3,EPAS1,EGR1,DUSP6,FLT1,FGFR1,TUBA4A,HES1
(includes
EG:15205),SLIT2,TGFBR2,IL16,SELP,TIMP1,TGFA,HPGD,ITGA1,RX
RA,CASP10
SELL,IL4R,CD40LG,EPAS1,MB,FLT1,FGFR1,EGR1,TNFAIP3,LTB,TN
FSF10,TGFBR2,SELP,TIMP1,TGFA,LCP2
CD40LG,SELL,SGK1,MBP,TGFBR2,CD52,COL6A1,TIMP1,IFITM2,AN
TXR2,GBP2 (includes
EG:14469),KRT1,CASP10,GZMA,TP53INP1,TUBB3,PTPRE,IER2,FGF
R1,FLT1,RELB,EGR1,CD69,ITGA6,TUBA4A,IER3,SLIT2,APOBEC3G,
ZFPM2,LPCAT2,CCR4,TGFA,ITGA1,CD82,RXRA,GATA3,ETV5
TGFBR2,STAT5A,TIMP1,FLT1,EGR1,HPGD,TGFA,FOXB1,HES1
(includes EG:15205),ADCYAP1 (includes EG:11516)
CD40LG,IL4R,EPAS1,RELB,EGR1,TNFAIP3,IER3,CD28,TGFA,GBP2
(includes EG:14469),ADCYAP1 (includes
EG:11516),RXRA,GATA3,LCP2,LGALS1
IL18BP,CD40LG,TGFA,HPGD,TNFSF10,SLCO2A1,HPGDS
CD40LG,SGK1,CTSW,TNFSF10,TNFAIP3,TMC6,CLEC2B,CD28,UBA
7,IFITM2,HPGD,ANTXR2,TMC8,GZMA,EPAS1,FGFR1,RELB,CD58,B
ZRAP1,ALOX5AP,APOBEC3G,IL16,RETN,RARRES3,RXRA
MB,LTB,HES1 (includes
EG:15205),TGFBR2,TIMP1,FOXB1,KRT1,STAT5A,EPAS1,ADAMTS1,
SPRY1,POU4F1,RELB,FLT1,FGFR1,EGR1,ITGA6,SLIT2,IL18BP,ZFP
M2,SELP,TGFA,ITGA1,HHEX,GATA3,ADCYAP1 (includes
EG:11516),RXRA,LCP2
MB,LTB,HES1 (includes
EG:15205),TGFBR2,TIMP1,FOXB1,SEMA4A,KRT1,STAT5A,EPAS1,A
DAMTS1,SPRY1,RELB,FLT1,FGFR1,EGR1,ITGA6,SLIT2,IL18BP,ZFP
M2,SELP,TGFA,ITGA1,HHEX,GATA3,ADCYAP1 (includes
EG:11516),RXRA,LCP2
SLA2,PIK3C2B,CD40LG,SELL,MB,SAMSN1,FGFR1,MBP,ITGA6,TNF
SF10,TNFAIP3,TRPC6,IL16,CD28,SELP,CCR4,TGFA,ADCYAP1
(includes EG:11516),LCP2,LGALS1
SLA2,PIK3C2B,SELL,MBP,TRPC6,IL16,CD28,SELP,CCR4,TGFA,ADC
YAP1 (includes EG:11516),LCP2,LGALS1
CD28,CD40LG,ARRB1,LPCAT2,FLT1,TGFA,GPR68,ADCYAP1
(includes EG:11516),LGALS1
STAT5A,CD28,CD40LG,IL4R,TNFSF10,LGALS1
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Table A1.4 Ingenuity Pathway Analysis: Functional Categories.
Transcripts Up-regulated upon Stimulation
Cell Morphology

3.8E-04-3.29E-03

Energy Production
Hair and Skin
Development and
Function
Nervous System
Development and
Function
Tumor Morphology

3.8E-04-3.8E-04
3.8E-04-2.8E-03

3.8E-04-3.31E-03

PTPRE,CD40LG,FLT1,EGR1,ITGA6,TNFSF10,TGFBR2,CD28,TGFA,
RARRES3,CD82,RXRA,GATA3,LCP2
HPGD,SLCO2A1
TGFBR2,PIK3C2B,SELL,MB,TIMP1,SH2D3C,TGFA,ITGA1,SEMA4A

Hepatic System
Development and
Function
Developmental Disorder
Endocrine System
Development and
Function
Hypersensitivity
Response
Organismal Survival

9.67E-04-2.22E-03

PTPRE,MBP,POU4F1,FGFR1,EGR1,ITGA6,SLIT2,HES1 (includes
EG:15205),ARRB1,CCR4,TGFA,FOXB1,ADCYAP1 (includes
EG:11516),GATA3
SELL,FLT1,FGFR1,ITGA6,SLIT2,TGFBR2,IL18BP,TIMP1,TGFA,ITGA1
,ADCYAP1 (includes EG:11516),TFPI,LGALS1
CD28,SELL,CD40LG,SLIT2,TFPI,ADCYAP1 (includes EG:11516)
GZMA,CD28,CD40LG,CD52,EPAS1,SELP,TGFA,ITGA1,ADCYAP1
(includes EG:11516),LCP2
TGFBR2,TIMP1,FLT1,TGFA,LTB,HHEX,LGALS1

1.12E-03-1.12E-03
1.12E-03-1.12E-03

TGFA,KRT1
EGR1,HES1 (includes EG:15205)

1.12E-03-2.28E-03

IL16,PTPRE,SELL,SELP,CD226,LCP2

1.63E-03-1.63E-03

Renal and Urological
System Development and
Function
Cellular Assembly and
Organization
Digestive System
Development and
Function
Organ Morphology
Protein Synthesis
Post-Translational
Modification
Metabolic Disease

1.81E-03-2.03E-03

STAT5A,IL4R,CD40LG,FLT1,POU4F1,PNP,ANTXR2,TNFSF10,ITGA1,
ADCYAP1 (includes EG:11516),TFPI,LGALS1
CD28,ADAMTS1,TIMP1,SPRY1,FGFR1,SLIT2,GATA3,PLXND1

2.22E-03-2.22E-03

PTPRE,MBP

2.22E-03-2.22E-03

FGFR1,ITGA6

2.22E-03-2.55E-03
2.22E-03-2.22E-03
3.35E-03-3.35E-03

TGFBR2,TIMP1,FGFR1,ITGA6,PNP,TGFA,ALOX5AP
CD28,CD40LG
CD28,SELL,SAMSN1,FGFR1,ITGA6,LGALS1

3.37E-03-3.37E-03

SELL,CD40LG,TNFSF10,HES1 (includes
EG:15205),CLEC2B,PLCH1,TGFBR2,CD28,CD52,TIMP1,GBP2
(includes
EG:14469),HPGDS,CASP10,DPF3,PTPRE,TUBB3,EPAS1,HSH2D,MA
ST4,SAMSN1,CD69,FGFR1,TUBA4A,BZRAP1,HIVEP3,PREX2,NMT2,
LST1,TMEM2,SELP,RETN,TGFA,ADCYAP1 (includes
EG:11516),PCBP3

4.39E-04-2.8E-03

Cellular Compromise
5.64E-04-2.8E-03
Free Radical Scavenging 6.83E-04-2.28E-03
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Table A1.4. Ingenuity Pathway Analysis results for targets of regulated gene expression.
Complete list of genes and statistics above threshold of p<0.03 for (A) Functional analysis of genes
up-regulated. (B) Functional analysis of genes down-regulated. (C) Canonical Signaling pathway
analysis of genes up-regulated. (D) Canonical Signaling pathway analysis of genes downregulated.
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Table A1.4B: Ingenuity Pathway Analysis: Functional Categories.
Transcripts Down-regulated upon Stimulation

Functional
Categories

p-value

Molecules

Nervous System
Development and
Function

6.74E-07-1.09E-02

Cellular Development

1.72E-06-1.09E-02

Inflammatory Response

2.18E-06-1.09E-02

Cellular Movement

4.94E-06-1.09E-02

Tissue Development

7.87E-06-1.09E-02

Cardiovascular Disease

1.18E-05-1.09E-02

Hematopoiesis
Organismal Injury and
Abnormalities
Cell Death

1.2E-05-1.09E-02
1.2E-05-1.09E-02

Cell-mediated Immune
Response
Cellular Function and
Maintenance

4.22E-05-1.09E-02

GAB2,SLIT1,SLC6A9 (includes
EG:116509),EPHB2,ATF5,POU3F2,SH3GL2,IRX5,PDGFC,EIF4EBP1,
VEGFA,MYC,SLC23A1,GFRA1,MAL,PHGDH,NOTCH3,CXCR4,HERP
UD1,S1PR3,ARHGEF10,CBS,GNAO1,RAG1,ARPP21,SYNGR1
TEAD4,GAB2,DDIT3,SLIT1,EPHB2,ATF5,POU3F2,IRX5,PDGFC,EIF4
EBP1,CD1D,VEGFA,MYC,GFRA1,RAG2,MAL,LONP1,RIPK4,NOTCH
3,CXCR4,TRIB3,S1PR3,GNAO1,TSHR,RAG1,ARPP21
GAB2,CXCR4,ASS1,EPHX2,CD1B,ULBP1,DNTT,CD1E,PDGFC,TUB,
EIF4EBP1,CD1D,VEGFA,S1PR3,MYC,CBS,RAG2,GNAO1,ANXA3,TS
HR,RAG1,CST7
GAB2,SLIT1,EPHB2,CXCR4,POU3F2,HSPA5,CD1D,VEGFA,MYC,S1
PR3,LGMN,PTPRU,GFRA1,ANXA3,GNAO1,TSHR,RAG1
GAS2 (includes
EG:14453),TEAD4,GAB2,SLIT1,EPHB2,POU3F2,IRX5,PDGFC,CD1D,
EIF4EBP1,MYC,VEGFA,SLC23A1,GFRA1,MAL,RAG2,PHGDH,RIPK4,
NOTCH3,CXCR4,TRIB3,S1PR3,ARHGEF10,CBS,KHDRBS3,TSHR,R
AG1,AARS
GAB2,RASL10B,DDIT3,CXCR4,EPHX2,SNTB1,SH3GL2,PDGFC,TUB,
EIF4EBP1,MYC,VEGFA,PTPRU,MGAT4A,LGMN,CBS,GFRA1,GNAO1
,RAG2,PHGDH,RAG1,KIAA0226L,PMEPA1
MYC,VEGFA,GAB2,CXCR4,RAG2,TSHR,RAG1,LONP1,CD1D
MYC,VEGFA,SLC7A11,SLC23A1,DDIT3,CBS,EPHX2,RAG2,MAL,GNA
O1,TSHR,RAG1
GAS2 (includes
EG:14453),GAB2,SLC7A11,DDIT3,EPHB2,ATF5,SH3GL2,HSPA5,CD1
D,EIF4EBP1,MYC,VEGFA,LGMN,GFRA1,MAL,RAG2,EEF1E1,CXCR4
,ULBP1,HERPUD1,TRIB3,TUB,S1PR3,MZB1,GNAO1,RAG1,AARS,P
MEPA1
CXCR4,RAG2,RAG1,LONP1,CD1D

2.63E-05-1.09E-02

4.22E-05-1.09E-02

Hematological System
4.22E-05-1.09E-02
Development and
Function
Lymphoid Tissue
4.22E-05-1.09E-02
Structure and
Development
Embryonic Development 6.15E-05-1.09E-02

Organ Development

6.15E-05-1.09E-02

Organismal Development 6.15E-05-1.09E-02

Hair and Skin
Development and
Function
Cardiovascular System
Development and
Function

8.11E-05-1.09E-02

9.98E-05-1.09E-02

GAB2,NOTCH3,DDIT3,EPHB2,CXCR4,HERPUD1,TRIB3,HSPA5,TUB,
CD1D,GLRB,VEGFA,S1PR3,MYC,ANXA3,RAG2,RAG1,AARS,LONP1
GAB2,NOTCH3,DDIT3,CXCR4,ULBP1,HSPA5,PDGFC,CD1D,S1PR3,
VEGFA,MYC,CBS,GNAO1,RAG2,TSHR,RAG1,LONP1
MYC,VEGFA,GAB2,EPHB2,CXCR4,RAG2,RAG1,LONP1

RIPK4,NOTCH3,SLIT1,EPHB2,CXCR4,POU3F2,IRX5,PDGFC,MYC,S
1PR3,VEGFA,SLC23A1,CBS,GFRA1,RAG2,KHDRBS3,PHGDH,RAG1
,AARS
RIPK4,NOTCH3,SLIT1,EPHB2,CXCR4,POU3F2,IRX5,PDGFC,MYC,S
1PR3,VEGFA,SLC23A1,CBS,GFRA1,RAG2,KHDRBS3,PHGDH,RAG1
,AARS
TEAD4,RIPK4,NOTCH3,SLIT1,CXCR4,EPHB2,EPHX2,POU3F2,IRX5,
PDGFC,VEGFA,S1PR3,MYC,LGMN,SLC23A1,CBS,GFRA1,KHDRBS
3,ANXA3,RAG2,TSHR,PHGDH,RAG1,AARS
RIPK4,VEGFA,MYC,SLC7A11,GFRA1,POU3F2,AARS

TEAD4,MYC,S1PR3,VEGFA,NOTCH3,CBS,SLIT1,EPHB2,CXCR4,EP
HX2,ANXA3,PDGFC
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Table A1.4B: Ingenuity Pathway Analysis: Functional Categories.
Transcripts Down-regulated upon Stimulation
Cell Morphology

9.98E-05-1.09E-02

Cellular Growth and
Proliferation

1.17E-04-1.09E-02

Connective Tissue
Disorders
DNA Replication,
Recombination, and
Repair
Genetic Disorder

1.17E-04-1.09E-02

GAB2,SLIT1,DDIT3,SLC6A9 (includes
EG:116509),CXCR4,EPHB2,TRIB3,EIF4EBP1,VEGFA,S1PR3,MYC,C
BS,GFRA1,MAL
TEAD4,GAB2,SLC7A11,DDIT3,EPHB2,EPHX2,POU3F2,HSPA5,IRX5,
PDGFC,EIF4EBP1,CD1D,MYC,VEGFA,LGMN,STC2,GFRA1,RAG2,E
EF1E1,NOTCH3,CXCR4,ULBP1,S1PR3,PTPRU,GNAO1,RNF187,TS
HR,RAG1
VEGFA,GAB2,RAG2,RAG1

1.17E-04-1.09E-02

MYC,RAG2,RAG1

1.17E-04-1.09E-02

GAB2,SLC7A11,DDIT3,EPHB2,ASS1,EPHX2,HSPA5,EIF4EBP1,GLRB
,VEGFA,MYC,LGMN,GFRA1,MAL,RAG2,PHGDH,PSAT1,NOTCH3,CX
CR4,HERPUD1,DAAM2,GPT2 (includes
EG:108682),TUB,ARHGEF10,GNAO1,TSHR,RAG1,ARPP21,SYNGR1

Hematological Disease
Immunological Disease

1.17E-04-1.09E-02
1.17E-04-1.09E-02

Infectious Disease
Inflammatory Disease
Skeletal and Muscular
Disorders

1.17E-04-1.09E-02
1.17E-04-1.09E-02
1.17E-04-1.09E-02

MYC,VEGFA,CXCR4,ANXA3,RAG2,RAG1,HSPA5
VEGFA,MYC,GAB2,LGMN,CXCR4,ANXA3,RAG2,PHGDH,RAG1,HSP
A5,CD1D
VEGFA,CXCR4,RAG2,RAG1,CD1D,EIF4EBP1
VEGFA,LGMN,CXCR4,RAG2,PHGDH,RAG1,CD1D
PSAT1,GAB2,DDIT3,EPHB2,EPHX2,DAAM2,HERPUD1,SH3GL2,CD1
E,C16orf74,HSPA5,S1PR3,GLRB,VEGFA,ARHGEF10,RAG2,GNAO1,
RAG1,ARPP21
MYC,TEAD4,VEGFA,GAB2,LGMN,CBS,CXCR4,TSHR,TRIB3,PDGFC

Skeletal and Muscular
1.17E-04-1.09E-02
System Development and
Function
Tissue Morphology
1.39E-04-1.09E-02

GAB2,NOTCH3,DDIT3,EPHB2,CXCR4,EPHX2,PDGFC,CD1D,EIF4EB
P1,MYC,VEGFA,S1PR3,LGMN,CBS,GFRA1,RAG2,GNAO1,MTHFD2,
RAG1
SLC7A11,CBS,SLC6A9 (includes
EG:116509),ASS1,PHGDH,MTHFD2,PYCR1
SLC7A11,SLC6A9 (includes
EG:116509),CXCR4,ASS1,EPHX2,CD1B,TRIB3,CD1D,MYC,S1PR3,V
EGFA,CBS,RAG2,MZB1,TSHR,MTHFD2,PHGDH,PYCR1
S1PR3,VEGFA,MYC,CXCR4,RAG2,TSHR,RAG1

Amino Acid Metabolism

2.19E-04-1.09E-02

Small Molecule
Biochemistry

2.19E-04-1.09E-02

Humoral Immune
Response
Cancer

2.5E-04-1.09E-02
2.55E-04-1.09E-02

TEAD4,MYO7B,SLC7A11,DDIT3,ATF5,EPHB2,ASS1,HSPA5,PDGFC,
EIF4EBP1,CD1D,MYC,VEGFA,NEIL3,GFRA1,RAG2,MAL,MTHFD2,P
HGDH,EEF1E1,TFDP2,LONP1,PSAT1,NOTCH3,CXCR4,MFAP4,SDF
2L1,ANXA3,RNF187,KHDRBS3,TSHR,RAG1,CST7,CEP70,SYNGR1

Cell Signaling

5.15E-04-1.05E-02

Connective Tissue
Development and
Function
Immune Cell Trafficking

6E-04-1.09E-02

GAB2,EPHB2,CXCR4,ASS1,HERPUD1,HSPA5,VEGFA,S1PR3,MYC,
GFRA1,GNAO1,MZB1,RAG2,TSHR
MYC,VEGFA,TEAD4,GAB2,LGMN,CBS,CXCR4,TSHR,TRIB3,PDGFC

6.29E-04-1.09E-02

MYC,VEGFA,S1PR3,GAB2,CBS,CXCR4,GNAO1,ULBP1,TSHR,CD1D

Cell Cycle
Cellular Assembly and
Organization
Lipid Metabolism

6.93E-04-1.09E-02
6.93E-04-1.09E-02

VEGFA,MYC,DDIT3,ATF5
MYC,VEGFA,SLIT1,CXCR4,EPHB2,GFRA1,GNAO1,POU3F2,SYNGR
1,HSPA5,EIF4EBP1
MYC,S1PR3,VEGFA,CBS,EPHX2,CD1B,TRIB3,CD1D

6.93E-04-1.09E-02
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Table A1.4B: Ingenuity Pathway Analysis: Functional Categories.
Transcripts Down-regulated upon Stimulation
Neurological Disease

6.93E-04-1.09E-02

1.15E-03-1.09E-02

GAB2,SLC7A11,DDIT3,EPHB2,EPHX2,SH3GL2,CD1E,HSPA5,PDGF
C,EIF4EBP1,CD1D,MYC,VEGFA,GLRB,GFRA1,RAG2,MAL,PHGDH,P
SAT1,CXCR4,HERPUD1,DAAM2,C16orf74,S1PR3,OGN,ARHGEF10,
CBS,KHDRBS3,GNAO1,RAG1,ARPP21,SYNGR1
MYC,VEGFA,CXCR4,GFRA1,ANXA3,POU3F2,EIF4EBP1
VEGFA,MYC,DDIT3,HSPA5,EIF4EBP1
GAB2,SLC7A11,DDIT3,SLC6A9 (includes
EG:116509),EPHB2,CXCR4,HERPUD1,HSPA5,VEGFA,S1PR3,MYC,C
BS,GNAO1,TSHR
MYC,S1PR3,VEGFA,GAB2,CXCR4,EPHB2,GNAO1,TSHR,HERPUD1,
HSPA5
MYC,VEGFA,CBS,MTHFD2

Tumor Morphology
Cellular Compromise
Molecular Transport

6.93E-04-1.09E-02
9.03E-04-1.09E-02
1.04E-03-1.09E-02

Vitamin and Mineral
Metabolism
Hepatic System
Development and
Function
Visual System
Development and
Function
Organismal Survival

1.04E-03-8.44E-03

1.15E-03-1.09E-02

VEGFA,PDGFC

1.62E-03-1.62E-03

Nucleic Acid Metabolism
Antigen Presentation
Respiratory Disease
Post-Translational
Modification
Dermatological Diseases
and Conditions
Developmental Disorder
Reproductive System
Disease
Nutritional Disease
Endocrine System
Disorders
Metabolic Disease

2.06E-03-1.09E-02
2.38E-03-1.09E-02
2.41E-03-1.09E-02
3.02E-03-1.09E-02

SLC6A9 (includes
EG:116509),EPHB2,CXCR4,PDGFC,MYC,VEGFA,S1PR3,CBS,MAL,R
AG2,TSHR,PHGDH,MTHFD2,EEF1E1,RAG1
GAS2 (includes
EG:14453),MYC,VEGFA,GAB2,CXCR4,GFRA1,ULBP1,TSHR,PDGFC,
CD1D
CBS,CXCR4,MZB1,TSHR
VEGFA,CBS,ULBP1,TSHR,CD1D
VEGFA,CXCR4,CD1D
MYC,VEGFA,DDIT3,HERPUD1

3.15E-03-1.09E-02

MYC,VEGFA,LGMN,CXCR4,PHGDH,RAG1,CD1D,EIF4EBP1

3.15E-03-1.09E-02
3.15E-03-1.09E-02

VEGFA,GFRA1,ASS1,PHGDH,TSHR,EIF4EBP1
VEGFA,LGMN,NOTCH3,MTHFD2,PMEPA1

3.17E-03-3.17E-03
4.09E-03-1.09E-02

MYC,VEGFA,GPT2 (includes EG:108682),TUB,EIF4EBP1
MYC,DDIT3,TSHR,TRIB3

4.09E-03-1.09E-02

Organ Morphology
Gene Expression
Protein Synthesis
Gastrointestinal Disease

4.49E-03-1.09E-02
6.05E-03-6.05E-03
6.24E-03-6.24E-03
6.46E-03-1.09E-02

Hepatic System Disease
Psychological Disorders
Endocrine System
Development and
Function
Behavior
Antimicrobial Response
Auditory and Vestibular
System Development and
Function
Carbohydrate Metabolism

6.46E-03-1.09E-02
8.06E-03-8.06E-03
8.46E-03-1.09E-02

RIPK4,SLC7A11,DDIT3,EPHB2,ASS1,SNTB1,TRIB3,SH3TC1,SH3GL
2,PDGFC,TUB,CD1D,EIF4EBP1,MYC,VEGFA,LGMN,MZB1,RAG2,KH
DRBS3,TSHR,PHGDH,KIAA0226L
VEGFA,MYC,NOTCH3,GFRA1,MZB1,GNAO1,RAG1,IRX5
DDIT3,TRIB3
MYC,VEGFA,CBS,CXCR4,RAG2,HSPA5,EIF4EBP1
TEAD4,MYO7B,SLC7A11,ATF5,EPHB2,CXCR4,HSPA5,PDGFC,VEGF
A,MYC,SDF2L1,NEIL3,GFRA1,MAL,PHGDH,RAG1,TFDP2
MYC,VEGFA,NEIL3,ATF5,PHGDH,RAG1,HSPA5,PDGFC
GLRB,SLC7A11,ARHGEF10,GFRA1,MAL,DAAM2,SYNGR1
MYC,CXCR4,POU3F2

1.06E-02-1.09E-02
1.09E-02-1.09E-02
1.09E-02-1.09E-02

GLRB,VEGFA,EPHB2,GFRA1,GNAO1,RAG1
CD1D
VEGFA,EPHB2

1.09E-02-1.09E-02

CD1D

Cell-To-Cell Signaling and 1.71E-03-1.09E-02
Interaction
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Table A1.4B: Ingenuity Pathway Analysis: Functional Categories.
Transcripts Down-regulated upon Stimulation
Digestive System
Development and
Function
Drug Metabolism
Ophthalmic Disease
Organismal Functions
Protein Folding
Protein Trafficking
Renal and Urological
Disease
Reproductive System
Development and
Function
Respiratory System
Development and
Function

1.09E-02-1.09E-02

MYC,GFRA1

1.09E-02-1.09E-02
1.09E-02-1.09E-02
1.09E-02-1.09E-02
1.09E-02-1.09E-02
1.09E-02-1.09E-02
1.09E-02-1.09E-02

CBS
VEGFA
MYC,VEGFA
VEGFA
DDIT3
MYC,VEGFA

1.09E-02-1.09E-02

MYC,TSHR,POU3F2

1.09E-02-1.09E-02

VEGFA,NOTCH3
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Table A1.4. Ingenuity Pathway Analysis results for targets of regulated gene expression.
Complete list of genes and statistics above threshold of p<0.03 for (A) Functional analysis of genes
up-regulated. (B) Functional analysis of genes down-regulated. (C) Canonical Signaling pathway
analysis of genes up-regulated. (D) Canonical Signaling pathway analysis of genes downregulated.

155

Table A1.4C: Ingenuity Pathway Analysis: Canonical Signaling Pathways
Transcripts Up-regulated upon Stimulation
Ingenuity Canonical
Pathways
Crosstalk between
Dendritic Cells and Natural
Killer Cells
Hepatic Fibrosis / Hepatic
Stellate Cell Activation
T Helper Cell
Differentiation
Altered T Cell and B Cell
Signaling in Rheumatoid
Arthritis
NF-κB Signaling
Allograft Rejection
Signaling
Autoimmune Thyroid
Disease Signaling
Communication between
Innate and Adaptive
Immune Cells
Dendritic Cell Maturation
Role of Tissue Factor in
Cancer
G-Protein Coupled
Receptor Signaling
Graft-versus-Host Disease
Signaling
Extrinsic Prothrombin
Activation Pathway
Eicosanoid Signaling
Role of JAK1 and JAK3 in
γc Cytokine Signaling

-log(p-value)

Molecules

5.99E+00

CD28,CD40LG,HLA-E,CD69,CD226,LTB,TNFSF10

5.31E+00

TGFBR2,CD40LG,IL4R,TIMP1,FLT1,FGFR1,TGFA

4.86E+00

TGFBR2,CD28,CD40LG,IL4R,GATA3

4.06E+00

CD28,CD40LG,RELB,LTB

3.52E+00
2.85E+00

TGFBR2,PIK3C2B,CD40LG,FLT1,FGFR1,RELB,TGFA,TNFAIP3
CD28,CD40LG,HLA-E

2.85E+00

CD28,CD40LG,HLA-E

2.85E+00

CD28,CD40LG,HLA-E

2.21E+00
2.15E+00

PIK3C2B,CD40LG,RELB,LTB,CD58
PIK3C2B,STAT5A,ARRB1,EGR1,ITGA6

1.87E+00

PIK3C2B,LPAR6,CCR4,GPR84,HCAR1,DUSP6,GPR68

1.81E+00

CD28,HLA-E
TFPI

1.71E+00
1.66E+00

ALOX5AP,HPGDS
PIK3C2B,STAT5A,IL4R

1.66E+00
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Table A1.4D: Ingenuity Pathway Analysis: Canonical Signaling Pathways
Transcripts Down-regulated upon Stimulation
Ingenuity Canonical
Pathways
B Cell Development
Alanine and Aspartate
Metabolism
Bladder Cancer Signaling
Ephrin Receptor Signaling

-log(p-value)

Molecules

4.61E+00
2.78E+00

RAG2,DNTT,RAG1
ASS1,AARS,GPT2 (includes EG:108682)

2.67E+00
2.44E+00

VEGFA,MYC,PDGFC
VEGFA,EPHB2,CXCR4,GNAO1,PDGFC

Glycine, Serine and
2.20E+00
Threonine Metabolism
Lipid Antigen Presentation 2.01E+00
by CD1
Axonal Guidance Signaling 1.93E+00

PSAT1,CBS,PHGDH

Atherosclerosis Signaling
Clathrin-mediated
Endocytosis Signaling
Urea Cycle and
Metabolism of Amino
Groups
Primary Immunodeficiency
Signaling

1.80E+00
1.72E+00

CXCR4,PDGFC
VEGFA,EPHB2,SH3GL2,PDGFC

1.71E+00

ASS1,PYCR1

1.67E+00

RAG2,RAG1

CD1B,CD1D
VEGFA,SLIT1,EPHB2,CXCR4,GNAO1,PDGFC
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Table&A2.1&Proteins&bound&to&MKK7&introns&identified&by&RNA&purification&followed&by&mass&spec
Peptide&Count& Peptide&Count&
Total&Peptide&
Unstimulated&
Stimulated Fold&Stim/Unstim
Counts
Tested&binding
Gene&ID
Molecular&Weight
+
sp|O95319*3|CELF2_HUMAN;sp|O95319|CELF2_HUMAN;sp|O95319*5|CELF2_HUMAN;sp|O95319*4|CELF2_HUMAN
55754;54285;52054;54365
3
18
6.00
21
–
sp|Q14980*2|NUMA1_HUMAN;sp|Q14980|NUMA1_HUMAN
236513;238257
3
16
5.33
19
–
sp|P08670|VIME_HUMAN53652
14
39
2.79
53
sp|Q92922|SMRC1_HUMAN;tr|Q58EY4|Q58EY4_HUMAN;tr|Q05CR1|Q05CR1_HUMAN
122867;122911;91756
4
8
2.00
12
–
sp|P43243|MATR3_HUMAN
94623
14
26
1.86
40
sp|P55265*2|DSRAD_HUMAN;tr|E7ENU4|E7ENU4_HUMAN;sp|P55265*4|DSRAD_HUMAN;sp|P55265*3|DSRAD_HUMAN
133274;140828;140838;13117010
18
1.80
28
–
sp|P31483*2|TIA1_HUMAN;tr|C9JTN7|C9JTN7_HUMAN
41801;31625
4
7
1.75
11
–
sp|Q01085*2|TIAR_HUMAN;sp|Q01085|TIAR_HUMAN
43449;41591
6
9
1.50
15
–
sp|P52272*2|HNRPM_HUMAN;sp|P52272|HNRPM_HUMAN
73621;77516
13
19
1.46
32
–
sp|Q8WXF1|PSPC1_HUMAN
58744
5
7
1.40
12
–
sp|P14866|HNRPL_HUMAN
64133
15
20
1.33
35
sp|P23246|SFPQ_HUMAN76150
20
25
1.25
45
–
sp|Q96I24|FUBP3_HUMAN
61640
15
18
1.20
33
sp|Q92841*2|DDX17_HUMAN;tr|Q59F66|Q59F66_HUMAN;tr|C9JMU5|C9JMU5_HUMAN;sp|Q92841*3|DDX17_HUMAN
72542;81068;72576;72557
10
12
1.20
22
tr|Q53GL6|Q53GL6_HUMAN
32550
16
19
1.19
35
sp|Q15365|PCBP1_HUMAN
37498
17
20
1.18
37
–
sp|Q15233|NONO_HUMAN
54232
19
22
1.16
41
sp|Q9NXV6|CARF_HUMAN
61125
13
15
1.15
28
sp|P51991|ROA3_HUMAN39595
20
22
1.10
42
P00761
24409
314
337
1.07
651
Streptavidin
16622
586
622
1.06
1208
sp|P09651*2|ROA1_HUMAN;tr|F8W6I7|F8W6I7_HUMAN;sp|P09651*3|ROA1_HUMAN
34196;33155;29386
41
41
1.00
82
sp|O75533|SF3B1_HUMAN
145830
17
17
1.00
34
sp|Q15393|SF3B3_HUMAN
135577
12
12
1.00
24
sp|P17844|DDX5_HUMAN;tr|B5BUE6|B5BUE6_HUMAN
69148;69121
12
12
1.00
24
sp|Q15459|SF3A1_HUMAN
88886
8
8
1.00
16
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–
–
+

–
+

–
+

sp|P38159*2|RBMX_HUMAN;tr|H3BT71|H3BT71_HUMAN;tr|H0Y6E7|H0Y6E7_HUMAN
40846;32197;31859
8
8
1.00
16
sp|Q9UHX1*2|PUF60_HUMAN;sp|Q9UHX1|PUF60_HUMAN;sp|Q9UHX1*6|PUF60_HUMAN;sp|Q9UHX1*5|PUF60_HUMAN
58172;59876;55400;57103
6
6
1.00
12
sp|P62805|H4_HUMAN 11367
5
5
1.00
10
sp|Q96PK6|RBM14_HUMAN
69492
5
5
1.00
10
sp|P35579|MYH9_HUMAN
226530
5
5
1.00
10
sp|P84103|SRSF3_HUMAN;tr|B4E241|B4E241_HUMAN
19330;14203
5
5
1.00
10
sp|Q9Y230|RUVB2_HUMAN;tr|B3KNL2|B3KNL2_HUMAN
51157;47404
5
5
1.00
10
sp|Q08554*2|DSC1_HUMAN;sp|Q08554|DSC1_HUMAN
93835;99987
5
5
1.00
10
sp|P22626|ROA2_HUMAN37430
37
36
0.97
73
sp|P26599*2|PTBP1_HUMAN;sp|P26599|PTBP1_HUMAN;sp|P26599*3|PTBP1_HUMAN
59037;57221;59633
42
40
0.95
82
sp|Q15717|ELAV1_HUMAN
36092
33
31
0.94
64
sp|Q99729*3|ROAA_HUMAN
30588
12
11
0.92
23
sp|O00148|DX39A_HUMAN
49130
12
11
0.92
23
sp|P68871|HBB_HUMAN;tr|C8C504|C8C504_HUMAN
15998;15997
11
10
0.91
21
sp|Q13838*2|DX39B_HUMAN;tr|F8VQ10|F8VQ10_HUMAN
50679;50745
14
12
0.86
26
sp|Q14103*3|HNRPD_HUMAN;sp|Q14103|HNRPD_HUMAN
32835;38434
24
20
0.83
44
sp|P38919|IF4A3_HUMAN46871
6
5
0.83
11
sp|P09661|RU2A_HUMAN;tr|Q53G61|Q53G61_HUMAN;tr|H0YMA0|H0YMA0_HUMAN
28416;28402;15839
6
5
0.83
11
sp|Q9Y265|RUVB1_HUMAN;tr|B5BUB1|B5BUB1_HUMAN
50228;50216
6
5
0.83
11
sp|Q15366*2|PCBP2_HUMAN;sp|Q15366|PCBP2_HUMAN;sp|Q15366*6|PCBP2_HUMAN;sp|Q15366*3|PCBP2_HUMAN
38651;38580;38151;38222
29
24
0.83
53
sp|P61978*2|HNRPK_HUMAN;sp|P61978|HNRPK_HUMAN
51028;50976
40
33
0.83
73
sp|P07910*2|HNRPC_HUMAN;sp|P07910|HNRPC_HUMAN
32338;33670
47
38
0.81
85
sp|Q9H0D6|XRN2_HUMAN
108583
10
8
0.80
18
sp|P21333*2|FLNA_HUMAN;tr|Q5HY54|Q5HY54_HUMAN
280016;276548
49
39
0.80
88
ENSEMBL:ENSBTAP00000016242;sp|P68363|TBA1B_HUMAN
50180;50152
32
25
0.78
57
sp|P09874|PARP1_HUMAN
113084
13
10
0.77
23
sp|P31943|HNRH1_HUMAN;tr|G8JLB6|G8JLB6_HUMAN
49229;51230
13
10
0.77
23
tr|B4DTA2|B4DTA2_HUMAN
30214
12
9
0.75
21
sp|P01857|IGHG1_HUMAN;tr|Q6PYX1|Q6PYX1_HUMAN;tr|Q6GMX6|Q6GMX6_HUMAN
36106;38162;51083
8
6
0.75
14
sp|P63104|1433Z_HUMAN
27745
11
8
0.73
19
sp|P25311|ZA2G_HUMAN34259
7
5
0.71
12
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–

–

sp|P02774|VTDB_HUMAN52964
7
5
0.71
12
sp|Q92499|DDX1_HUMAN82432
7
5
0.71
12
sp|P26368*2|U2AF2_HUMAN;tr|B5BU25|B5BU25_HUMAN;sp|P26368|U2AF2_HUMAN
53121;53137;53501
7
5
0.71
12
sp|P01011|AACT_HUMAN47651
35
24
0.69
59
sp|Q92945|FUBP2_HUMAN
73115
66
44
0.67
110
sp|Q00839*2|HNRPU_HUMAN;sp|Q00839|HNRPU_HUMAN
88980;90585
9
6
0.67
15
sp|Q09028*2|RBBP4_HUMAN;sp|Q09028|RBBP4_HUMAN;sp|Q09028*3|RBBP4_HUMAN
47585;47656;46158
6
4
0.67
10
sp|P61088|UBE2N_HUMAN
17138
8
5
0.63
13
sp|P52597|HNRPF_HUMAN
45672
7
4
0.57
11
sp|Q13263*2|TIF1B_HUMAN;sp|Q13263|TIF1B_HUMAN
79474;88550
9
5
0.56
14
sp|P01008|ANT3_HUMAN52602
35
19
0.54
54
sp|Q96AE4|FUBP1_HUMAN
67560
39
21
0.54
60
sp|P51610*4|HCFC1_HUMAN;tr|A6NEM2|A6NEM2_HUMAN;sp|P51610|HCFC1_HUMAN
213403;213474;208730
13
7
0.54
20
sp|P07437|TBB5_HUMAN49671
35
18
0.51
53
sp|P68371|TBB4B_HUMAN;tr|Q8N6N5|Q8N6N5_HUMAN;tr|Q8IWP6|Q8IWP6_HUMAN
49831;49808;49753
28
14
0.50
42
sp|P67809|YBOX1_HUMAN
35924
12
6
0.50
18
sp|P68104|EF1A1_HUMAN;tr|Q6IPT9|Q6IPT9_HUMAN;tr|Q53HR5|Q53HR5_HUMAN;sp|Q5VTE0|EF1A3_HUMAN
50141;50185;50125;50185
27
13
0.48
40
sp|P11021|GRP78_HUMAN
72333
13
6
0.46
19
sp|P07737|PROF1_HUMAN
15054
9
4
0.44
13
sp|O43143|DHX15_HUMAN
90933
7
3
0.43
10
sp|Q14141*4|SEPT6_HUMAN;tr|Q8NFH9|Q8NFH9_HUMAN;tr|Q6NT82|Q6NT82_HUMAN;tr|Q6B514|Q6B514_HUMAN;tr|F5H1J5|F5H1J5
49167;63143;48847;50204;52250;49303
7
3
0.43
10
sp|P07900|HS90A_HUMAN;tr|Q2VPJ6|Q2VPJ6_HUMAN
84660;68372
15
6
0.40
21
tr|D3DUZ3|D3DUZ3_HUMAN
82423
18
7
0.39
25
sp|Q13085*2|ACACA_HUMAN;sp|Q13085|ACACA_HUMAN
259684;265551
21
8
0.38
29
sp|P13796|PLSL_HUMAN 70289
22
8
0.36
30
sp|P31946|1433B_HUMAN
28082
14
5
0.36
19
sp|P27348|1433T_HUMAN
27764
12
4
0.33
16
sp|P31146|COR1A_HUMAN
51026
12
4
0.33
16
sp|Q9UKA9*2|PTBP2_HUMAN;sp|Q9UKA9|PTBP2_HUMAN
57647;57491
12
4
0.33
16
sp|Q04917|1433F_HUMAN
28219
9
3
0.33
12
sp|P42166|LAP2A_HUMAN
75492
9
3
0.33
12
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sp|P14625|ENPL_HUMAN;tr|Q5CAQ5|Q5CAQ5_HUMAN
92469;92340
9
3
0.33
tr|B4DMA2|B4DMA2_HUMAN
79195
22
7
0.32
sp|P62258|1433E_HUMAN;tr|G9K389|G9K389_HUMAN;tr|G9K388|G9K388_HUMAN
29174;41286;41224
16
5
0.31
sp|P61981|1433G_HUMAN
28303
10
3
0.30
sp|P62826|RAN_HUMAN;tr|J3KQE5|J3KQE5_HUMAN
24423;26816
10
3
0.30
sp|P04406|G3P_HUMAN 36053
41
11
0.27
sp|P13639|EF2_HUMAN 95338
12
3
0.25
sp|P60842|IF4A1_HUMAN46154
8
2
0.25
sp|Q9P258|RCC2_HUMAN56085
9
2
0.22
sp|P07237|PDIA1_HUMAN
57116
9
2
0.22
sp|Q16181*2|SEPT7_HUMAN;tr|Q3LIE9|Q3LIE9_HUMAN;tr|E7ES33|E7ES33_HUMAN
50581;48774;50609
9
2
0.22
sp|P26641|EF1G_HUMAN50119
15
3
0.20
sp|P10809|CH60_HUMAN;tr|B3GQS7|B3GQS7_HUMAN
61055;60680
33
6
0.18
sp|P07195|LDHB_HUMAN36639
11
2
0.18
sp|P00558|PGK1_HUMAN44615
17
3
0.18
sp|P62937|PPIA_HUMAN;tr|A8K486|A8K486_HUMAN
18012;18013
20
3
0.15
sp|P13489|RINI_HUMAN 49974
16
2
0.13
sp|P11142|HSP7C_HUMAN
70898
28
3
0.11
sp|P09429|HMGB1_HUMAN;tr|Q5T7C6|Q5T7C6_HUMAN;tr|Q59GW1|Q59GW1_HUMAN
24894;18808;20164
11
1
0.09
sp|P30101|PDIA3_HUMAN;tr|G5EA52|G5EA52_HUMAN
56782;54964
13
1
0.08
sp|P29401*2|TKT_HUMAN;tr|Q53EM5|Q53EM5_HUMAN;sp|P29401|TKT_HUMAN
68814;67906;67878
13
1
0.08
sp|P06733|ENOA_HUMAN47169
14
1
0.07
sp|P15311|EZRI_HUMAN 69413
15
1
0.07
sp|P26038|MOES_HUMAN
67820
17
1
0.06
sp|P50395|GDIB_HUMAN50663
11
0
0.00
sp|P27797|CALR_HUMAN;tr|Q53G71|Q53G71_HUMAN
48142;46919
10
0
0.00
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12
29
21
13
13
52
15
10
11
11
11
18
39
13
20
23
18
31
12
14
14
15
16
18
11
10

Table A2.2: Delta PSI values for significant anti-CD3/CD28 responsive splicing events in primary
human CD4+ cells. (detailed description at end of table)

Event ID and Gene
Name
2173TRA2A
532FBXO38
2948SFRS3
1080LEF1
2565LUC7L
2063SFRS7
288PPIL5
3549RBM3
2934NT5C3
5599FIP1L1
1849IPO9
1634ZDHHC20
25EZH2
1213BAX
1483LRRFIP2
2830TIMM8B
1451EYA3
6116CXorf45
6384RAD51C
2349MTF2
2577BPTF
5202LETMD1
196ZNF207
5681SWAP70
1034SNX14
5419TFAM
772FHL1
6460TROVE2
1095PRPF3
2385DNM1L
5759AK311167
2183KIAA0515
5411OGDH
684CD74
3462RPGR
2972CCNL2
901SMARCA4
120SHC1
3251TMEM183A
3464RNF167
6587PRUNE
687MRE11A

antiCD3/CD28
GSK3i effect JNKi
-50.90
-47.30
-49.80
-59.20
-85.50
-45.30
-51.80
-29.70
-23.5
-41.20
-13.80
-15.2
-27.50
-28.70
-46.10
-21.4
-42.00
-29.90
-46.30
-55.2
-27.70
-46.50
-23.70
-30.00
-31.20
-30.00
-24.20
-18.8
-21.80
-18.50
-19.20
-27.80
-47.20
-45.0
-25.70
-22.10
-35.60
-28.2
-20.90
-29.7
-25.20
-19.80
-15.20
-28.10
-13.30
-16.20
-14.10
-16.00
-19.70
-10.50
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effect
-79.2
-77.9
-76.2
-74.3
-72.8
-64.5
-63.6
-54.6
-47.3
-44.9
-44.3
-43.9
-42.7
-42.7
-42.0
-41.4
-40.1
-37.7
-34.9
-34.2
-33.5
-33.2
-32.6
-31.9
-30.0
-29.5
-28.0
-25.8
-24.5
-24.3
-23.9
-22.8
-22.4
-21.4
-20.0
-19.8
-19.3
-16.8
-14.8
-14.7
-14.3
-14.1

1835ERC1
6609PRMT2
3612MAZ
293HNRNPK
6631MTHFD2L
6605ERCC2
1154MADD
2403FNBP1
3026RIF1
5364ZNF271
5485CREM
3397IMAA
1699ACTL6A
1220NUP98
1225STK4
6393PCNP
5457PPP6R3
5868C20orf72
5664STARD3NL
1567NCOR1
3223GIT1
975BCLAF1
3598CAMTA1
5517PPP2R2D
1788GTF2I
5964SGK3
6482SNHG3-RCC1
80DTNB
433FLJ00353
377ECT2
6550CCDC7
6851KTN1
6578C10orf28
5865CDKN2AIP
33TBRG4
5659RNF34
3668CUGBP2
902PTS
767RP5-1022P6.2
6023DDR1
473FOXRED1
886C2orf4
915CSNK1D
5989EIF3EIP
569KIF21B
1065EIF4A2
2456EIF4A2
699EXOC7
1678FUBP3

-13.00
-17.60
-33.80
-10.10
-29.90
-12.50
-13.40
13.00
10.00
25.80
22.60
15.10
12.80
37.20
13.70
11.00
10.20
15.40
16.50
24.30
16.70
14.00
20.70
14.50
22.80
15.00
15.60
23.80
20.30
10.80
40.50
21.00
31.80
23.00
14.10
14.70
36.60
37.40
15.00
30.00
33.40
12.90
12.10
31.30
36.40
42.30
42.30
36.90
41.50

-34.8
-26.8

28.4
35.0
9.8

14.3
12.2

35.0
18.8

23.8

10.3
10.0
18.9
18.9
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-13.8
-13.6
-11.1
-10.8
-10.5
-10.1
-9.8
9.5
11.5
11.6
12.1
12.2
12.7
13.2
14.1
14.4
14.7
14.7
16.2
16.3
16.8
17.7
18.0
18.6
19.3
19.5
21.1
21.1
22.7
24.1
24.8
25.6
26.4
26.5
27.3
28.6
29.0
30.7
32.8
36.1
36.6
37
37.1
37.3
37.7
38.4
38.4
39.7
40.2

59PPP5C
2263FUS
876EIF4H
5214WHSC1L1
736FGFR1OP2
6316CCAR1
1767CD97
1314DAZAP1
785CHTF8
2793CHTF8
2758HDC
5526KIAA1219
1690POMT1
2640CAMKK2
3665SNRNP70
1905ABLIM1
2084ASCC2
6132THAP9
187BPTF
5585OFD1
6659PILRB
369BRE
472EP400
3551HRAS
959C12orf30
592ACIN1
6475IRAK4
1260USP15
1740TXNRD1
6186GEMIN7
2704ZDHHC13
3015C2orf33
2107MAPKAP1
2TPP2
6877MRRF
480EIF4G1
1613SYNCRIP
1348PAN3
3705OS9
64ZMIZ1
5133PILRB
5746DKFZp667H0616
6590PIP5K1A
184L3MBTL3
1783BANP
6781C20orf199
2998ANXA7
2467SF1
3374MBNL1

44.80
16.00
39.70
23.20
33.30
47.60
29.30
20.00
-57.30
-57.30
-43.20
-43.30
-27.80
-45.20
-76.40
-35.90
-45.30
-41.60
-30.90
-44.00
-17.70
-48.30
-23.20
-37.30
-34.30
-33.70
-46.90
-29.10
-28.00
-33.70
-41.10
-25.10
-27.40
-33.30
-25.50
-13.10
-25.20
-32.10
-25.50
-17.70
-24.50
-30.70
-29.70
-21.90
-27.20
-20.40
-20.20
-25.10
-22.80

23.8

-54.2
-54.2
-51.4
-48.1
-46.4
-44.5
-44.2
-44.2
-42.6
-42.2
-41.8
-40.5
-39.8
-39.7
-37.4
-35.5
-35.2
-34.4
-32.4
-32.1
-31.6
-31.4
-30.9
-30.7
-30.5
-30.0
-29.0
-28.9
-28.7
-28.5
-28.5
-28.1
-27.6
-27.5
-27.4
-25.0
-24.9
-24.1
-23.9
-23.8
-23.7
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40.6
40.9
41.5
43.3
43.3
44.5
49.9
59.8

1242UBTF
1645MFN2
2585OSBPL9
2671RBMS1
2795SMAD2
6883ANKHD1-EIF4EBP3
2713PCBP2
357EHMT1
860DKFZp434I0612
3329DIAPH1
5558M-RIP
833CD47
3083PXN
6798PSMD13
6462AKT2
6855SMARCD1
278HISPPD2A
2526PDK1
5714ESNA1
6641GNPAT
3603SENP6
2379RICTOR
2402FAM135A
2753bim-alpha1
1425PAPOLA
6326CSNK1G2
6568ZNF146
708CDC16
2687C1orf9
6693RABGAP1L
1060PI4KB
6134NGFRAP1
6820TMEM106C
6745ZFYVE27
1200MBD1
3095MADD
2055GTPBP10
779DKFZp762G052
1600KIAA0494
2436FIP1L1
492PACSIN2
3326BIN1
6674SS18L1
597COL4A3BP
700RAPGEF1
5853BC037884
6873LTBP4
296IFNAR2
3218SFRS15

-28.50
-26.10
-16.20
-11.10
-20.90
-17.50
-22.70
-35.40
-18.90
-23.20
-24.60
-18.10
-16.40
-23.40
-19.90
-31.10
-14.70
-14.90
-11.40
-25.50
-26.90
-14.20
-22.50
-19.10
-12.90
-11.80
-22.10
-30.20
-22.20
-13.50
-12.60
-11.20
-18.30
-17.10
13.00
10.70
14.50
16.70
11.80
11.40
24.80
11.60
18.40
24.30
10.00
10.50
15.80
11.90
14.80

-23.2
-23.2
-22.5
-22.1
-21.8
-21.3
-21.2
-20.9
-20.8
-19.6
-19.3
-18.2
-18.0
-16.9
-16.9
-16.7
-16.4
-15.3
-15.3
-15.0
-14.1
-14.1
-13.6
-12.8
-12.8
-12.1
-11.8
-11.5
-11.5
-11.3
-11.3
-10.9
-10.7
-10.6
9.7
9.9
10.2
10.5
10.7
11.3
11.9
12.0
12.0
12.0
12.3
12.6
12.8
13.0
13.2

166

6476KIAA0391
521CDCA7L
3575RBM4
1438OSBPL9
6582NEDD1
2868ATRX
1755STAG2
2319CCNL1
86CARD16
2620FLJ00246
6035DKFZp434N2030
1010SLMAP
3513ARID5B
2164AKAP9
6280SMA4
6727dJ1198O21.1
1032CNBP
934PTPN4
5906LYRM1
5392XPR1
5843SCLY
2227AP1GBP1
5726TACC1
1705HMGN3
3584KIAA1565
483FIS1
6096ZNF789
5683INF2
5153LOC221442
5341FBXO38
6325NUP214
3041UCHL5
2009BBX
1947SLMAP
5278VAP-B
2886mccb
6541AKR1A1
5579BRPF1
6066UGCGL1
2473CAMKK2
6572TFE3
825NAE1
3268MFF
122CBFB
2434CLSTN1
1375KCTD13
1435SKP2
5290LYRM1
1623AK125149

12.90
10.10
18.20
14.90
18.90
27.20
19.70
14.30
15.40
15.50
27.10
18.70
18.40
17.10
23.50
29.70
17.90
15.70
24.60
25.00
13.80
29.10
20.10
25.20
18.20
17.80
30.00
27.30
31.60
14.60
32.30
29.20
33.00
34.90
33.00
32.40
25.60
36.60
44.40
21.50
25.00
35.70
42.50
35.30
32.10
35.60
29.50
48.60
49.00

13.5
14.4
14.9
15.4
15.7
15.7
16.3
17.0
17.0
17.1
17.5
18.2
18.6
18.9
19.7
19.9
20.0
20.8
20.9
21.0
21.6
21.8
23.4
23.4
24.0
25.0
25.6
27.9
28.1
28.2
29.8
31.2
31.2
32.7
32.8
33.4
33.8
33.9
34.6
35.1
35.2
35.4
35.7
35.9
37.5
38.3
39.7
42.1
47.6
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247PCM1
93CEP57
1872MFF
1890ST7
6184LYPLAL1
5991DKFZp566I1024
827PLAUR
175ABCC1
594ABCC1
1181DNAJC7
2683GOLGA2
5952DENND3
54FAM120A
2759FAM120A
2781CDK5RAP2
506TRPC1
5871ARHGEF10
5151NUB1
6185DBF4B
1135KIAA1782
1317GGCT
1268RAD51L3
5931TNFRSF14
6263SRRM2
778CAMTA1
2649ZFAND3
758DEDD2
5940TBC1D22A
6231PCM1
922TRAF3
5813DAP3
125OSBPL8
5179PIGT
972WBP1
5398AFG3L1
6555HN1L
3515TLK2
3005ZNF195
855ORMDL2
367CHURC1
5371EHMT1
1515PXMP3
3370BCL11A
2896KIAA0723
1205MAP4K1
5490AACS
385ZDHHC16
6729MATR3
3719MAP3K7

50.20
22.70
53.40
-16.10
-18.40
-12.50
-61.80
-54.70
-54.70
-52.20
-51.00
-48.10
-46.20
-46.20
-44.80
-44.10
-42.30
-39.20
-37.70
-36.60
-36.50
-36.00
-35.70
-35.30
-35.00
-33.10
-33.10
-31.90
-31.50
-31.50
-31.00
-28.40
-28.20
-28.10
-27.30
-26.30
-25.60
-23.90
-23.70
-23.40
-23.00
-22.30
-22.30
-21.60
-21.40
-21.10
-21.10
-20.50
-20.30

47.7
49.1
61.5
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896S100PBP
2802CAMK2D
2666IVNS1ABP
6738UPF3
605SFRS10
5751RNF216L
2935KIF23
1959RBM27
6650RAB3IP
3724RAD51L3
2437GPR137
5918FAM120B
382C11orf80
1367C11orf80
2669MTMR3
1180SRPK2
1234FAM48A
968RABEP1
3688BTRC
5995PMS1
1537E2F6
6376IKBKB
3350EIF5
1257MPHOSPH9
2938CBWD2
2315SFRS12
921RBBP6
5668MAST2
3624POLDIP3
1707MBNL2
248MTA1
6675EEFSEC
2866BCLAF1
6385PAN3
2381RPAIN
2924PRNPIP
1599SFRS10
6166METT5D1
5738GPBP1
1903C2orf33
6901RWDD3
6055NDUFB5
1254BAT2D1
961MAP3K3
5675C1orf124
2908TPM2
6866LIN52
3389USF2
2923ARMC8

-19.90
-19.80
-19.60
-19.40
-19.00
-18.10
-17.80
-17.60
-17.20
-17.10
-16.90
-16.40
-16.30
-16.30
-16.10
-16.00
-15.90
-15.20
-15.20
-14.50
-14.40
-14.30
-14.20
-14.10
-13.80
-13.80
-13.40
-13.20
-13.00
-12.90
-12.80
-12.50
-12.20
-12.20
-12.00
-11.90
-11.80
-11.80
-11.60
-11.50
-11.50
-11.40
-11.30
-11.30
-11.30
-11.20
-10.90
-10.70
-10.20
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728TCERG1
595GPBP1
5731THRA
1958TCF12
2297UTX
2386TRIP12
6089LRRC28
5706ARFIP1
5900ARFIP1
2643FBXO25
2114LSM5
2074ATP11C
1138IL15
6554UPF3
662MTMR10
5648SDHC
6417hMLH1
691ANK3
6183RNF13
6146TLK2
3531ZMYND11
471EXOSC1
843EHBP1
1606NASP
3271HIPK2
2159C13orf23
3213NUMB
1876MYO9A
2857ARHGAP17
5602XPA
828FMNL3
2242C2orf37
6340ZNF257
1415SR140
1655MINK1
6392C14orf159
2646PBX3
2484MAPKAP1
5346LYRM1
2169TMPO
31LSR
1551SETD5
2564MARK2
2869DLST
1753RNF115
72APP
2555KIAA0920
1145PKM2
2465SMARCA2

10.10
10.20
10.20
10.40
10.40
10.40
10.50
10.70
10.70
11.40
11.50
11.60
11.60
11.60
11.70
11.90
12.00
12.00
12.00
12.10
12.30
12.40
12.50
12.90
13.10
13.30
13.30
13.60
13.60
13.70
14.10
14.30
14.50
15.10
15.40
15.50
16.50
17.40
17.80
17.90
18.00
18.10
18.50
18.70
18.80
18.90
19.00
19.80
19.90
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1464XPO6
677CLIP1
3494CCM2
2049TTLL5
1747NDUFV3
6774ZNF673
2757ARHGEF1
3028NAT15
943ATXN2
1487RBM5
6003CRKRS
1586TCF7L2
6757SNED1
227PPHLN1
2054SH3KBP1
6315IL9R
1969CAMK2G
3591ATF2
1687ZNF529
3650ZC3H18
5325C14orf135
172MTRR
1373MTRR
1392PATZ1
5755DKFZp666E123
2813NAPB
6898SC4MOL
5513USP3
5147DKFZp762G094
438IKZF1
6426NR4A3
1526RAPH1
1251MBNL2
2461COL6A3
6625NRF1

20.30
20.50
20.90
21.00
22.10
22.70
22.90
23.10
23.30
23.60
23.90
24.10
24.40
24.80
25.20
25.70
25.80
26.50
26.60
27.00
27.60
28.60
28.60
29.80
30.20
31.10
32.00
32.60
33.70
34.50
34.60
52.50
53.80
64.60
69.20

Table A2.2: DeltaPSI for anti-CD3/CD28 calculated as PSI(anti-CD3/CD28)-PSI(unstimulated).
DeltaPSI for GSK3i effect calculated as PSI(GSK3i)-PSI(unstimulated) since SB216763 inhibitor
mimics CD3/CD28-inhibition of GSK3. DeltaPSI for JNKi effect calculated as PSI(anti-CD3/CD28)PSI(anti-CD3/CD28+JNKi pretreatment) as SP600125 blocks CD3/CD28-activation of JNK. All
values shown are the average of at least 3 donors with p<0.05, paired student t-test. Color scale as
shown in Fig 4B.
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Table A2.3: Specific genes that comprise the enriched GOcategories presented in Fig 5.9D.
RNA binding
GENE NAME
Related Genes Species
CDKN2A interacting protein
RG
Homo sapiens
DAZ associated protein 1
RG
Homo sapiens
DEAD (Asp-Glu-Ala-Asp) box polypeptide 50
RG
Homo sapiens
FIP1 like 1 (S. cerevisiae)
RG
Homo sapiens
RNA binding motif (RNP1, RRM) protein 3 RG
Homo sapiens
eukaryotic translation initiation factor 4H
RG
Homo sapiens
far upstream element (FUSE) binding protein
RG
3
Homo sapiens
heterogeneous nuclear ribonucleoprotein K;RG
similar to heterogeneous
Homo sapiens
nuclear ribonucleoprotein K
similar to eukaryotic translation initiation factor
RG4A2; eukaryotic
Homo
translation
sapiens initiation factor 4A, isoform 2
splicing factor, arginine/serine-rich 3
RG
Homo sapiens
splicing factor, arginine/serine-rich 7, 35kDaRG
Homo sapiens
transformer 2 alpha homolog (Drosophila) RG
Homo sapiens

Organelle
GENE NAME
Related Genes Species
CDKN2A interacting protein
RG
Homo sapiens
DAZ associated protein 1
RG
Homo sapiens
DEAD (Asp-Glu-Ala-Asp) box polypeptide 50
RG
Homo sapiens
MRE11 meiotic recombination 11 homolog ARG
(S. cerevisiae) Homo sapiens
PRP3 pre-mRNA processing factor 3 homolog
RG(S. cerevisiae)
Homo sapiens
RPA interacting protein
RG
Homo sapiens
Wolf-Hirschhorn syndrome candidate 1-like RG
1
Homo sapiens
actin-like 6A
RG
Homo sapiens
cAMP responsive element modulator
RG
Homo sapiens
cyclin L2; chemokine (C-C motif) receptor 6RG
Homo sapiens
heterogeneous nuclear ribonucleoprotein K;RG
similar to heterogeneous
Homo sapiens
nuclear ribonucleoprotein K
lymphoid enhancer-binding factor 1
RG
Homo sapiens
nuclear receptor co-repressor 1
RG
Homo sapiens
oxoglutarate (alpha-ketoglutarate) dehydrogenase
RG
(lipoamide)
Homo sapiens
ring finger protein 34
RG
Homo sapiens
similar to translocase of inner mitochondrialRG
membrane 8 homolog
Homo sapiens
B; translocase of inner mitochondrial m
transcription factor A, mitochondrial
RG
Homo sapiens
zinc finger protein 207
RG
Homo sapiens
Chromatin
GENE NAME

Related Genes Species
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MRE11 meiotic recombination 11 homolog ARG
(S. cerevisiae) Homo sapiens
RAD51 homolog C (S. cerevisiae)
RG
Homo sapiens
SWI/SNF related, matrix associated, actin dependent
RG
regulator
Homo
of chromatin,
sapiens subfamily a, member 4
Wolf-Hirschhorn syndrome candidate 1-like RG
1
Homo sapiens
actin-like 6A
RG
Homo sapiens
bromodomain PHD finger transcription factor
RG
Homo sapiens
nuclear autoantigenic sperm protein (histone-binding)
RG
Homo sapiens
nuclear receptor co-repressor 1
RG
Homo sapiens

Metal ion binding
GENE NAME
Related Genes Species
5'-nucleotidase, cytosolic III
RG
Homo sapiens
6-pyruvoyltetrahydropterin synthase
RG
Homo sapiens
CD97 molecule
RG
Homo sapiens
G protein-coupled receptor kinase interacting
RG
ArfGAP 1
Homo sapiens
LUC7-like (S. cerevisiae)
RG
Homo sapiens
MRE11 meiotic recombination 11 homolog ARG
(S. cerevisiae) Homo sapiens
RPA interacting protein
RG
Homo sapiens
Wolf-Hirschhorn syndrome candidate 1-like RG
1
Homo sapiens
additional sex combs like 1 (Drosophila)
RG
Homo sapiens
bromodomain PHD finger transcription factor
RG
Homo sapiens
dystrobrevin, beta
RG
Homo sapiens
four and a half LIM domains 1
RG
Homo sapiens
metal response element binding transcription
RG
factor 2
Homo sapiens
methylenetetrahydrofolate dehydrogenase (NADP+
RG
dependent)
Homo
2-like
sapiens
prune homolog (Drosophila)
RG
Homo sapiens
ring finger protein 167
RG
Homo sapiens
ring finger protein 34
RG
Homo sapiens
serine/threonine kinase 4
RG
Homo sapiens
similar to translocase of inner mitochondrialRG
membrane 8 homolog
Homo sapiens
B; translocase of inner mitochondrial m
splicing factor, arginine/serine-rich 7, 35kDaRG
Homo sapiens
zinc finger protein 207
RG
Homo sapiens
zinc finger, DHHC-type containing 20
RG
Homo sapiens
Protein localization
GENE NAME
Related Genes Species
BCL2-associated X protein
RG
Homo sapiens
CD74 molecule, major histocompatibility complex,
RG
class II invariant
Homo sapiens
chain
ELKS/RAB6-interacting/CAST family member
RG1
Homo sapiens
RPA interacting protein
RG
Homo sapiens
exocyst complex component 7
RG
Homo sapiens
importin 9
RG
Homo sapiens
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nuclear autoantigenic sperm protein (histone-binding)
RG
Homo sapiens
retinitis pigmentosa GTPase regulator
RG
Homo sapiens
similar to translocase of inner mitochondrialRG
membrane 8 homolog
Homo sapiens
B; translocase of inner mitochondrial m
sorting nexin 14
RG
Homo sapiens
Transcription
GENE NAME
Related Genes Species
ELKS/RAB6-interacting/CAST family member
RG1
Homo sapiens
SWI/SNF related, matrix associated, actin dependent
RG
regulator
Homo
of chromatin,
sapiens subfamily a, member 4
Wolf-Hirschhorn syndrome candidate 1-like RG
1
Homo sapiens
actin-like 6A
RG
Homo sapiens
additional sex combs like 1 (Drosophila)
RG
Homo sapiens
bromodomain PHD finger transcription factor
RG
Homo sapiens
cAMP responsive element modulator
RG
Homo sapiens
calmodulin binding transcription activator 1 RG
Homo sapiens
cell division cycle and apoptosis regulator 1RG
Homo sapiens
cyclin L2; chemokine (C-C motif) receptor 6RG
Homo sapiens
far upstream element (FUSE) binding protein
RG
3
Homo sapiens
general transcription factor II, i; general transcription
RG
factor II,
Homo
i, pseudogene
sapiens
lymphoid enhancer-binding factor 1
RG
Homo sapiens
nuclear receptor co-repressor 1
RG
Homo sapiens
similar to Bcl-2-associated transcription factor
RG1 (Btf); BCL2-associated
Homo sapiens
transcription factor 1
transcription factor A, mitochondrial
RG
Homo sapiens
zinc finger protein 207
RG
Homo sapiens
Kegg Pathway
Spliceosome
GENE NAME
Related Genes Species
PRP3 pre-mRNA processing factor 3 homolog
RG(S. cerevisiae)
Homo sapiens
heterogeneous nuclear ribonucleoprotein K;RG
similar to heterogeneous
Homo sapiens
nuclear ribonucleoprotein K
splicing factor, arginine/serine-rich 3
RG
Homo sapiens
splicing factor, arginine/serine-rich 7, 35kDaRG
Homo sapiens
transformer 2 alpha homolog (Drosophila) RG
Homo sapiens
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Table A2.4A: DAVID analysis of JNK-dependent genes in primary human CD4+ T Cells
Annotation Cluster 1 Enrichment Score: 3.51

Count P_Value

SP_PIR_KEYWORDS
SP_PIR_KEYWORDS
UP_SEQ_FEATURE
Annotation Cluster 2

ubl conjugation
isopeptide bond
cross-link:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)
Enrichment Score: 2.37

14
8
6
Count

3.20E-06
1.30E-03
7.40E-03
P_Value

KEGG_PATHWAY
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_MF_FAT
SP_PIR_KEYWORDS
GOTERM_BP_FAT
GOTERM_BP_FAT
SP_PIR_KEYWORDS
UP_SEQ_FEATURE
GOTERM_BP_FAT
GOTERM_BP_FAT
SP_PIR_KEYWORDS
INTERPRO
INTERPRO
SMART
Annotation Cluster 3

Spliceosome
5
RNA splicing, via transesterification reactions
6
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile
6
nuclear mRNA splicing, via spliceosome
6
RNA binding
12
rna-binding
11
mRNA processing
7
RNA processing
8
mrna splicing
5
domain:RRM
5
mRNA metabolic process
7
RNA splicing
6
mrna processing
6
RNA recognition motif, RNP-1
6
Nucleotide-binding, alpha-beta plait
6
RRM
6
Enrichment Score: 2.18
Count

4.30E-07
1.90E-04
1.90E-04
1.90E-04
2.80E-03
3.40E-03
1.70E-02
1.80E-02
1.90E-02
1.90E-02
2.40E-02
2.50E-02
3.10E-02
4.70E-02
4.80E-02
7.90E-02
P_Value

GOTERM_CC_FAT
GOTERM_CC_FAT
GOTERM_CC_FAT
GOTERM_CC_FAT
GOTERM_CC_FAT
GOTERM_CC_FAT

membrane-enclosed lumen
intracellular organelle lumen
organelle lumen
nuclear lumen
nucleolus
nucleoplasm

1.40E-04
3.10E-04
3.60E-04
9.30E-04
1.80E-03
6.80E-03

18
17
17
15
8
11
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GOTERM_CC_FAT
GOTERM_CC_FAT
GOTERM_CC_FAT
GOTERM_CC_FAT
GOTERM_CC_FAT
Annotation Cluster 4

nucleoplasm part
nuclear body
nuclear speck
non-membrane-bounded organelle
intracellular non-membrane-bounded organelle
Enrichment Score: 1.51

8
4
3
16
16
Count

3.00E-02
5.30E-02
1.00E-01
1.80E-01
1.80E-01
P_Value

GOTERM_BP_FAT
BIOCARTA
GOTERM_BP_FAT
GOTERM_BP_FAT
SP_PIR_KEYWORDS
GOTERM_BP_FAT
GOTERM_CC_FAT
GOTERM_BP_FAT
Annotation Cluster 5
UP_SEQ_FEATURE
UP_SEQ_FEATURE
INTERPRO
INTERPRO
SMART
Annotation Cluster 6

chromatin remodeling
Control of Gene Expression by Vitamin D Receptor
chromosome organization
chromatin modification
chromatin regulator
chromatin organization
chromatin remodeling complex
covalent chromatin modification
Enrichment Score: 1.28
zinc finger region:PHD-type 2
zinc finger region:PHD-type 1
Zinc finger, PHD-finger
Zinc finger, PHD-type
PHD
Enrichment Score: 1.26

4
3
8
6
5
6
3
3
Count
3
3
3
3
3
Count

3.60E-03
1.40E-02
1.80E-02
2.70E-02
4.10E-02
5.90E-02
7.50E-02
2.10E-01
P_Value
1.80E-02
1.80E-02
9.90E-02
1.00E-01
1.30E-01
P_Value

SP_PIR_KEYWORDS
SP_PIR_KEYWORDS
SP_PIR_KEYWORDS
GOTERM_MF_FAT
GOTERM_MF_FAT
GOTERM_MF_FAT
GOTERM_MF_FAT
GOTERM_MF_FAT
Annotation Cluster 7

zinc-finger
zinc
metal-binding
zinc ion binding
transition metal ion binding
metal ion binding
cation binding
ion binding
Enrichment Score: 1.12

14
16
19
16
18
22
22
22
Count

3.20E-03
2.30E-02
3.60E-02
5.70E-02
7.50E-02
1.80E-01
1.90E-01
2.10E-01
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GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
SP_PIR_KEYWORDS
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
SP_PIR_KEYWORDS
Annotation Cluster 8

protein localization
protein transport
establishment of protein localization
protein transport
cellular protein localization
cellular macromolecule localization
intracellular transport
protein import
intracellular protein transport
protein localization in organelle
protein targeting
transport
Enrichment Score: 1.11

10
9
9
6
6
6
7
3
5
3
3
6
Count

1.90E-02
2.40E-02
2.60E-02
5.10E-02
5.80E-02
6.10E-02
6.40E-02
1.00E-01
1.30E-01
1.40E-01
2.20E-01
7.30E-01
P_Value

GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
Annotation Cluster 9

negative regulation of gene expression
limb morphogenesis
limb development
negative regulation of macromolecule metabolic process
appendage morphogenesis
appendage development
forebrain development
Enrichment Score: 1.06

7
3
3
7
3
3
3
Count

2.70E-02
7.00E-02
7.20E-02
7.80E-02
8.00E-02
8.40E-02
2.40E-01
P_Value

GOTERM_BP_FAT
SP_PIR_KEYWORDS
SP_PIR_KEYWORDS
GOTERM_BP_FAT
SP_PIR_KEYWORDS
GOTERM_MF_FAT
GOTERM_MF_FAT
SP_PIR_KEYWORDS
GOTERM_MF_FAT

transcription
transcription regulation
Transcription
regulation of transcription
dna-binding
DNA binding
transcription regulator activity
activator
transcription activator activity

15
15
15
17
12
15
11
6
4

7.40E-03
1.30E-02
1.60E-02
4.90E-02
7.90E-02
9.20E-02
1.00E-01
1.10E-01
2.30E-01
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Table A2.4B: DAVID analysis of GSK3-sensitive genes in primary human CD4+ T Cells
Annotation Cluster 1

Enrichment Score: 3.62

Count P_Value

KEGG_PATHWAY
KEGG_PATHWAY
KEGG_PATHWAY
KEGG_PATHWAY
Annotation Cluster 2

Neurotrophin signaling pathway
Focal adhesion
Renal cell carcinoma
Insulin signaling pathway
Enrichment Score: 3.55

6
5
3
3
Count

1.00E-06
1.10E-04
3.30E-03
9.20E-03
P_Value

KEGG_PATHWAY
KEGG_PATHWAY
KEGG_PATHWAY
Annotation Cluster 3

Neurotrophin signaling pathway
Fc epsilon RI signaling pathway
T cell receptor signaling pathway
Enrichment Score: 2.88

6
3
3
Count

1.00E-06
2.80E-03
8.00E-03
P_Value

GOTERM_CC_FAT
GOTERM_CC_FAT
GOTERM_CC_FAT
GOTERM_CC_FAT
GOTERM_CC_FAT
GOTERM_CC_FAT
Annotation Cluster 4

nucleolus
membrane-enclosed lumen
intracellular organelle lumen
nuclear lumen
organelle lumen
nucleoplasm
Enrichment Score: 2.8

12
25
24
22
24
14
Count

3.50E-04
5.80E-04
8.10E-04
9.80E-04
9.90E-04
3.50E-02
P_Value

KEGG_PATHWAY
KEGG_PATHWAY
KEGG_PATHWAY
Annotation Cluster 5

Focal adhesion
VEGF signaling pathway
Chemokine signaling pathway
Enrichment Score: 2.19

5
3
3
Count

1.10E-04
3.30E-03
1.10E-02
P_Value

KEGG_PATHWAY
BIOCARTA
BIOCARTA
Annotation Cluster 6

Focal adhesion
Integrin Signaling Pathway
Signaling of Hepatocyte Growth Factor Receptor
Enrichment Score: 2.17

5
3
3
Count

1.10E-04
4.60E-02
5.60E-02
P_Value

SP_PIR_KEYWORDS
GOTERM_BP_FAT
GOTERM_BP_FAT

chromatin regulator
chromatin modification
chromatin organization

10
10
10

2.60E-04
3.50E-03
1.40E-02
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GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
Annotation Cluster 7

histone modification
covalent chromatin modification
chromosome organization
Enrichment Score: 1.88

6
6
11
Count

1.50E-02
1.90E-02
2.50E-02
P_Value

GOTERM_BP_FAT
KEGG_PATHWAY
GOTERM_BP_FAT
GOTERM_BP_FAT
BIOCARTA
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
Annotation Cluster 8

cellular macromolecular complex subunit organization
Regulation of actin cytoskeleton
cellular macromolecular complex assembly
macromolecular complex subunit organization
Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia
macromolecular complex assembly
cellular protein complex assembly
protein complex assembly
protein complex biogenesis
Enrichment Score: 1.75

10
4
8
11
3
10
5
7
7
Count

8.00E-04
1.50E-03
4.80E-03
1.60E-02
2.30E-02
2.40E-02
2.40E-02
1.00E-01
1.00E-01
P_Value

GOTERM_MF_FAT
SP_PIR_KEYWORDS
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
SP_PIR_KEYWORDS
GOTERM_BP_FAT
GOTERM_CC_FAT
SP_PIR_KEYWORDS
GOTERM_BP_FAT
SP_PIR_KEYWORDS
GOTERM_CC_FAT

RNA binding
rna-binding
RNA processing
RNA splicing, via transesterification reactions
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile
nuclear mRNA splicing, via spliceosome
mRNA metabolic process
mRNA processing
RNA splicing
mrna processing
ribonucleoprotein complex assembly
spliceosome
Spliceosome
ribonucleoprotein complex biogenesis
mrna splicing
ribonucleoprotein complex

17
16
14
6
6
6
11
10
8
7
3
4
3
4
4
7

7.30E-04
8.20E-04
1.20E-03
2.80E-03
2.80E-03
2.80E-03
7.10E-03
1.30E-02
3.00E-02
6.40E-02
8.70E-02
9.80E-02
1.50E-01
1.70E-01
2.30E-01
6.20E-01
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Annotation Cluster 9

Enrichment Score: 1.64

Count P_Value

SP_PIR_KEYWORDS
SP_PIR_KEYWORDS
UP_SEQ_FEATURE
Annotation Cluster 10

ubl conjugation
isopeptide bond
cross-link:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)
Enrichment Score: 1.62

12
8
5
Count

5.10E-03
1.70E-02
1.30E-01
P_Value

GOTERM_CC_FAT
GOTERM_CC_FAT
SP_PIR_KEYWORDS
GOTERM_CC_FAT
GOTERM_CC_FAT
GOTERM_CC_FAT
GOTERM_CC_FAT
GOTERM_CC_FAT
Annotation Cluster 11

centrosome
microtubule organizing center
cytoskeleton
pericentriolar material
microtubule cytoskeleton
microtubule organizing center part
cytoskeleton
cytoskeletal part
Enrichment Score: 1.53

8
8
12
3
10
3
15
9
Count

2.70E-03
4.20E-03
4.90E-03
1.10E-02
3.30E-02
7.00E-02
2.10E-01
3.70E-01
P_Value

GOTERM_MF_FAT
GOTERM_MF_FAT
GOTERM_MF_FAT
GOTERM_MF_FAT
GOTERM_MF_FAT
Annotation Cluster 12

GTPase binding
Ras GTPase binding
small GTPase binding
Rho GTPase binding
enzyme binding
Enrichment Score: 1.39

5
4
4
3
7
Count

7.70E-03
2.10E-02
2.70E-02
4.40E-02
1.10E-01
P_Value

GOTERM_CC_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
Annotation Cluster 13

eukaryotic translation initiation factor 4F complex
posttranscriptional regulation of gene expression
regulation of translational initiation
regulation of cellular protein metabolic process
regulation of translation
Enrichment Score: 1.3

3
6
3
6
3
Count

6.50E-03
1.70E-02
1.90E-02
2.30E-01
2.40E-01
P_Value

GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
Annotation Cluster 14

ubiquitin-dependent protein catabolic process
proteasomal ubiquitin-dependent protein catabolic process
proteasomal protein catabolic process
Enrichment Score: 1.28

6
3
3
Count

3.50E-02
5.90E-02
5.90E-02
P_Value
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GOTERM_CC_FAT
GOTERM_CC_FAT
GOTERM_CC_FAT
Annotation Cluster 15

intracellular non-membrane-bounded organelle
non-membrane-bounded organelle
cytoskeleton
Enrichment Score: 1.24

GOTERM_BP_FAT
SP_PIR_KEYWORDS
SP_PIR_KEYWORDS
GOTERM_MF_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_MF_FAT
GOTERM_MF_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_MF_FAT
GOTERM_BP_FAT
GOTERM_MF_FAT
GOTERM_MF_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT

transcription
Transcription
transcription regulation
transcription factor binding
positive regulation of macromolecule metabolic process
regulation of transcription
DNA binding
transcription cofactor activity
positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process
positive regulation of macromolecule biosynthetic process
positive regulation of nitrogen compound metabolic process
positive regulation of cellular biosynthetic process
positive regulation of biosynthetic process
transcription regulator activity
regulation of RNA metabolic process
transcription coactivator activity
transcription activator activity
positive regulation of transcription
positive regulation of gene expression
positive regulation of gene-specific transcription
regulation of transcription from RNA polymerase II promoter
regulation of transcription, DNA-dependent
positive regulation of transcription, DNA-dependent
positive regulation of RNA metabolic process
regulation of gene-specific transcription
positive regulation of transcription from RNA polymerase II promoter
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31
31
15
Count

2.70E-02
2.70E-02
2.10E-01
P_Value

24
23
22
9
15
30
24
6
11
11
11
11
11
16
20
4
6
9
9
3
9
17
7
7
3
5

2.80E-03
4.30E-03
6.90E-03
7.90E-03
1.00E-02
1.00E-02
2.20E-02
3.10E-02
4.60E-02
4.70E-02
5.10E-02
5.40E-02
5.90E-02
6.70E-02
6.90E-02
8.20E-02
1.10E-01
1.10E-01
1.30E-01
1.50E-01
2.00E-01
2.20E-01
2.40E-01
2.40E-01
2.90E-01
4.60E-01

GOTERM_MF_FAT
transcription factor activity
Annotation Cluster 16 Enrichment Score: 1.14

7
6.40E-01
Count P_Value

INTERPRO
SP_PIR_KEYWORDS
SMART
Annotation Cluster 17

Zinc finger, CCHC-type
repressor
ZnF_C2HC
Enrichment Score: 1.01

3
7
3
Count

6.30E-02
6.70E-02
9.00E-02
P_Value

GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_MF_FAT
GOTERM_MF_FAT
GOTERM_MF_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
UP_SEQ_FEATURE
GOTERM_MF_FAT
INTERPRO
GOTERM_MF_FAT
SMART
GOTERM_MF_FAT
SP_PIR_KEYWORDS
Annotation Cluster 18

histone modification
covalent chromatin modification
one-carbon metabolic process
histone methylation
biopolymer methylation
methylation
protein-lysine N-methyltransferase activity
lysine N-methyltransferase activity
histone-lysine N-methyltransferase activity
protein amino acid alkylation
protein amino acid methylation
domain:SET
histone methyltransferase activity
SET
N-methyltransferase activity
SET
protein methyltransferase activity
methyltransferase
Enrichment Score: 1.01

6
6
5
3
4
4
3
3
3
3
3
3
3
3
3
3
3
3
Count

1.50E-02
1.90E-02
5.30E-02
5.70E-02
5.90E-02
7.50E-02
8.90E-02
8.90E-02
8.90E-02
1.20E-01
1.20E-01
1.20E-01
1.30E-01
1.40E-01
1.40E-01
1.90E-01
3.10E-01
7.90E-01
P_Value

GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT

ubiquitin-dependent protein catabolic process
modification-dependent protein catabolic process
modification-dependent macromolecule catabolic process
proteolysis involved in cellular protein catabolic process
cellular protein catabolic process

6
9
9
9
9

3.50E-02
6.80E-02
6.90E-02
8.80E-02
9.00E-02
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APPENDIX 3: ALTERNATIVE SPLICING DURING THYMOCYTE
DEVELOPMENT

Introduction
In addition to widespread alternative splicing in response to mature T-cell activation, our
lab had evidence suggesting that alternative splicing may regulate gene expression as
consequence of pre-TCR signaling during thymocyte development. Early thymic
progenitors are uncommitted cells that must pass through a series of signaling and
transcriptional checkpoints in the thymus (Bell and Bhandoola 2008; Carpenter and
Bosselut 2010). T cell development in the thymus involves a number of differentiation
and proliferation steps. This process is necessary for the generation of mature T cells
that carry out effector functions in immune response. During the DN stage, T cells must
undergo a checkpoint known as β-selection in which thymocytes signal through their preTCR. Although there are no known ligands that mediate this process, it is thought to
involve receptor oligomerization and intracellular molecules similar to those triggered by
TCR signaling in mature T cells (Yamasaki et al. 2006). Although pre-TCR signal is less
understood, there seems to be parallels between pre-TCR and mature TCR signaling.
After β-selection, thymocytes proceed to become double positive (DP) thymocytes,
characterized by the expression of CD4 and CD8 before they ultimately undergo lineage
commitment and become single positives.
The Lynch laboratory demonstrated that at least one gene, the transcription
factor LEF1 is alternatively alternatively spliced in response to both activation of Jurkat T
cells with PMA and during pre-TCR signaling (chapter 1). That change in spliced
isoforms of LEF1 in the DN to DP stage is directly correlated correlated with increased
TCR-α expression, an important LEF1 target gene. Futhermore, Michael Mallory showed
that the expression of CELF2, the splicing factor regulating LEF1 and MKK7 pre-mRNA
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splicing, increases during the transition from DN to DP in thymocytes. Given, that an
increase in CELF2 protein is sufficient to explain the differential splicing of MKK7 (See
chapter 5), we hypothesized that the increase in CELF2 protein during the DN to DP
transition of thymocyte development may regulate the alternative splicing of additional
genes and that alternative splicing may serve as a broad mechanism to control gene
expression during pre-TCR signaling.

Results

Splicing is regulated during thymocyte development
To first identify additional changes in splicing during T cell development, I FACSisolated DN and DP cell populations from single cell suspensions that I generated from
human thymus (Fig A3.1). I extracted RNA from DN and DP thymocytes that and
submitted the RNA to our collaborators in the Fu Lab who performed RASL-Seq
(described in Chapter 5). Given limited thymic material available and inherent donor
variability, the RASL-Seq analysis only identified 14 high confidence exons that display
>10% PSI changes that are statistically significant across the three donors surveyed
(Fig. A3.2B).
Alternative splicing events in thymocytes are enriched for known CELF2 target genes
Despite the minimal information drawn from the RASL-seq we found that 4 of the
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dentified 14 events (29%) are among the 72 CELF2-dependent activation-responsive
exons identified in the Jurkat cells ((Mallory et al. 2015) and Fig. A3.2B) (P < 0.00036,
two-tailed Fisher’s exact test). An additional CELF2-dependent event (CTTN) was also
observed to change dramatically in the DN vs. DP cells, although with a modest P value
(0.09). Matthew Gazzara in the lab validated the dependence of four of these genes on
CELF2 in Jurkat T cells that express the CELF2 shRNA described in chapter 5. He
further confirmed the change in alternative splicing between DN and DP stages for
SRPK2 (Fig. A3.2C,D). Matthew was unable to obtain RT-PCR data on PIP5K5A given
the presence of highly homologous intronless genes. We had minimal amounts of

Figure A3.1 Isolation of double negative (CD4–CD8–, DN) and double positive (CD4+CD8+, DP)
thymocytes from single cell thymocyte suspensions. Representative FACS plots of gating to isolate DP
and DN thymocytes with anti–CD8-APC, anti–CD4-FITC. For isolating the DN population, cells were stained
with anti–CD8-APC, anti–CD4-FITC, and a cocktail of antibodies to deplete non-thymocytes that were labeled
with PE. For isolation of the DP population cells were stained with anti–CD8-APC, anti–CD4-FITC. Cells
were first gated for PE− (Upper Left), then by forward scatter/side scatter for live cells (Lower Left), and finally
6
DN and DP cells were collected based on the gates shown (Bottom Right). Typical yields were ∼ 2 × 10 DP
5
and 5 × 10 DN cells.
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thymocyte RNA from the DN and DP populations and were not able to detect sufficient
amounts of CTTN, OPA1, or MPRL42 for quantification by RT-PCR, depletion of CELF2
in the Jurkat T cells altered the splicing pattern of these genes in the direction opposite
to that observed upon the transition from DN to DP (Fig. A3.2C), supporting that
increased CELF2 expression in DP cells contributes to the observed alternative splicing
of these genes during pre-TCR signaling. For one of the genes SRPK2, which is
expressed at higher levels, Matthew validated the RASL-seq identified change in splicing
from DN to DP stages in thymocytes, as well as the sensitivity to CELF2 knockdown in
Jurkat T cells (Fig A3.2D).

Discussion
We acknowledge that the RASL-seq identified developmentally regulated
changes in alternative splicing of thymocytes is likely an underestimation of the scope of
this mechanism of gene regulation, due to technical reasons such as inherent donor
variability and limited quantity of material from the very minor fraction that the DN
population represents of total human thymus. Nevertheless, the profiling of alternative
splicing during thymocyte development presented in this appendix proposes that
alternative splicing may regulate a larger set of genes than previously appreciated during
the developmental process of pre-TCR signaling in a manner analogous to TCR
signaling during activation of mature T cells.
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Figure A3.2 Differential alternative splicing in DP relative to DN thymocytes. (A) Table of significant
(p-value < 0.05) differences in percent inclusion (PSI) between DN and DP stages of thymocyte
development identified by RASL-seq. (B) Representative RT-PCR gel of the validation of sensitivity to
CELF2 knockdown, of genes overlapping in the thymocytes and CELF2 knockdown (Mallory 2015) RASLseq experiments, in Jurkat T cells that have been depleted of CELF2 with an shRNA as in Fig 5.5D.
Average percent inclusion of at least three independent experiments is shown below. (C) Same as B, but
including also showing percent inclusion values from DN and DP thymocytes. RNA from FACS purified
DN and DP thymocytes. Average percent inclusion for the thymocytes is the average of at least three
independent donors.

We found that a 1/3 of the developmentally regulated splicing events in
thymocytes are also sensitive to CELF2 depletion in Jurkat T cells, suggesting that
CELF2 may regulate a fraction of DN to DP splicing events. Moreover, the increase in
CELF2 expression during the transition from DN to DP is reminiscent of the increase in
CELF2 mRNA and protein observed upon activation of Jurkat T cells. In chapters 4 and
5 I described the mechanism leading to increased CELF2 expression in T cells.
Specifically, we established that an increase in CELF2 mRNA, is driven by a JNK
signaling-induced increase in message stability that results in increased CELF2 protein.
Thus, JNK signaling through driving increased expression of CELF2 is a plausible
mechanism by which alternative splicing is controlled during thymocyte pre-TCR
signaling, underscoring the biological significance of the JNK/CELF2 signaling pathway.
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APPENDIX 4: EXPERIMENTAL PROTOCOLS
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In vitro Transcription of Cold RNA

1. Transcription reaction:
4µL of linearized plasmid DNA (or more from PCR template and adjust water)
10µL

TINOCO buffer

4µL

each NTP (from 100mM stock)

16µL

PEG

60µL

water

2µL

RNasin

4µL

T7 RNA polymerase

2. Incubate reaction at 37 degrees for 3h.
3. Add 5µL of DNase and incubate at 37 degrees for 15 min.
4. PCA extract/EtOH precipitate and freeze for 15 min.
5. Re-suspend in 10µL of formamide and run on 5-10% PAGE.
6. Examine in UV light.
7. Cut-out bands .
8. Crush gel in 500µL TE buffer plus 0.1% SDS.
9. Incubate overnight with rotation at room temperature.
10. Spin down at max speed for 5 min.
11. Take top phase and PCA extract/EtOH precipitate freeze for 15 min.
12. Re-suspend in 11µL water.
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In vitro Transcription of Hot RNA

1. Make 10X ACG mix
Final Conc.
100mM ATP

Volume

8mM

16µL

100mM CTP 8mM

16µL

100mM GTP 8mM

16µL

H 2O

152µL

2. Transcription Reaction
PCR template (~50ng/uL)

6.25µL

10X ACG

5µL

10mM UTP

2.5µL

100mM DTT

0.25µL

P-32 alpha-UTP

5µL

RNasin

1µL

T7 RNA polymerase

2.5µL

3. Incubate at 37 degrees for 1-3h.
4. Add 2µL RQ1 DNase and incubate at 37 degrees for 15 min.
5. Add water to make 200µL .
6. PCA extract/EtOH precipitate and freeze for 15 min.
7. Re-suspend in 8µL of formamide and run on 5-10% PAGE.
8. Expose to film for 1 min with glow in the dark stickers.
13. Align film to gel and cut-out band.
14. Crush gel in 500µL TE buffer plus 0.1% SDS.
15. Elute overnight with rotation at room temperature.
16. Spin down max speed for 5 min.
17. Collect supernatant and PCA extract/EtOH precipitate.
18. Re-suspend in 11µL water.
19. Spot 1µL in whatman paper and soak in 2mL scintillation fluid.
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Biotinylation of in vitro Transcribed RNA

Using Thermo 3’ end biotinylation kit

1. Thaw kit components on ice
Warm PEG (30%) at 37 degrees for 5 min.
2. Adjust heating block to 85 degrees.
3. Transfer 20-50 pmol of RNA in a maximum of 8µL volume or adjust volume with
water to a tube. Heat RNA for 3 min at 85 degrees. Place on ice immediately.
4. Labeling reaction
20-50 pmol RNA
8µL
10X RNA ligation buffer

3µL

RNase inhibitor

1µL

Biotinylated cytidine

1µL

T4 RNA ligase

2µL

30% PEG

15µL

5.
6.
7.
8.

Incubate at 16 degrees overnight (PCR block).
Bring volume to 100µL.
Add 100µL PCA, vortex and spin 3 min max speed.
Take top phase add 300µL of EtOH, 10µL NaCl (5M) and 1µL glycogen. Vortex
and freeze for 1h at 20 degrees.
9. Spin ma speed 15 min at 4 degrees.
10. Wash with 300µL 70% EtOH.
11. Air dry and re-suspend pellet in 20µL nuclease free water.
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RNA Affinity Purification

Part A- Binding Reaction

1. Prepare binding reaction:
25µL
BC400
66.25µL

BC100

25µL

13% PVA

10µL

80mM MgCL2

10µL

25mM ATP

10µL

creatine phosphate

25µL

0.25ug/uL tRNA/BC100

10µL

2.5pmol/uL RNA (or if at other concentration adjust water)

58.8µL

water

10µL

nuclear extract

2. Incubate binding reactions in 30 degree water bath for 30 min.
Part B- Block Beads

1.
2.
3.
4.

Pool 30µL of Streptavidin beads (Pierce) per reaction.
Wash 3X in 1mL of GFB100.
Spin 2,500 x g for 1 min.
Block beads in: (per reaction)
10uL Heparin 50µg/µL
1mL GFB100

5. Incubate with rotation at 4 degrees for 30 min.
6. Wash 1X with GFB100.
Part-C Couple RNA to Beads

192

7. After last wash re-suspend Beads in (per reaction):
5µL
Heparin
10µL

80mM MgCl2

48.5µL

BC400

197µL

water

8. Add 250µL of bead mix from above to each binding reaction.
9. Incubated for 1h at 4 degrees.
10. Washed 4X in GFB100 + 4mM MgCl2.
11. Re-suspended in 20µL SDS sample buffer, boiled for 5 min.
12. Run 10µL in SDS-PAGE for silver stain and save other 10µL for western blot or
mass spec.
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UV Crosslinking Followed by Immunoprecipitation

1. Binding reaction:
4µL
of nuclear extract (or ~20ug)
1µL

BC400

1µL

13% PVA

1µL

tRNA/BSA/BC100 (0.25ug/uL tRNA+0.2ug/uL BSA in BC100)

0.4µL 80mM MgCl2
0.4µL 25mM ATP
0.4µL creatine phosphate
1µL

of H2O

1µL

radiolabeled RNA

2. Make master mix.
3. Incubate at 30 degrees for 20 min.
4. Pipet into 96-well plate (round bottom) on ice.
5. Place UV lamp (254nm) on top of plate without lid.
6. UV crosslink for 20 min.
7. Place reactions in new tubes with 20U RNase T1 + 20µg RNase A.
8. Digest at 37 degrees for 20 min.
9. Add 10µL SDS sample buffer (+BME).
10. Boil 5 min and run on 12.5% SDS-PAGE.
For IP step:

1. Pool binding UV crosslinking reactions for each IP after step 8 (RNase digestion).
2. Add 5-10µL of antibody depending on concentration.
3. Bring volume to 400µL with 1X RIPA buffer (150mM NaCl, 1% NP-40, 0.5%
sodium deoxycholate, 50mM Tris pH 8, 0.1% SDS) plus protease inhibitor
cocktail.
4. Incubate overnight at 4 degrees with rotation.
5. Pre-wash 40µL of protein G Dynabeads (or protein G sepharose) per reaction
with RIPA buffer.
6. Add IP reactions to beads.
7. Incubate with beads for 1h at 4 degrees.
8. Place on magnet and wash 3X with RIPA buffer.
9. Re-suspend beads in 20µL 2X SDS sample buffer (+BME) and boil for 5 min.
10. Run on 12.5% SDS-PAGE gels.
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RT-PCR

1. RT-step
Master mix (per reaction):
1µL 5X Hyb buffer
1µL reverse primer (1ng/uL)

Add 2µL of master mix to each tube of a PCR strip
Then add 2µL of each RNA(50-500ng/µL).
Run RT program on PCR machine.

2. Make master mix (per reaction):
19.5µL 1.25X RT mix (pre-warm at 43 degrees for ~10min)
0.5µL MMLV (add enzyme prior to adding to tubes with cDNA)

Keep RT program running while adding 20µL of master mix to each tube. Pipet to
mix.
Run RT-Pol program on PCR machine.

3. PCR step
Master mix per reaction:
1µL 5ng/µL reverse primer
1µL 2.5ng/µL forward primer
1µL 2.5ng/µL P-32 labeled forward primer
1.5µL RT-PCR buffer
10.3µL water
0.2µL Taq (5U/µL)

Pipet 15 µL of master mix to new PCR tubes and add 5µL of cDNA from RT-step.
Add a drop of mineral oil.
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Run PCR program:
94 degrees for 2 min
loop X cycle #
94 degrees for 1 min
65-70 degrees for 1 min
72 degrees for 1.5 min
final extension 72 degrees for 5-10 min

Add 15µL of formamide buffer. Boil samples.

Run on 5% acrylamide gel.
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Thymocyte Sorting

Part A- Single Cell Suspensions

1. Disinfect everything with bleach and follow precautions for handling human
tissue. Prepare work area in hood with diaper, beaker with bleach, tweezers,
razor, well plates and microscope slides.
2. Cut-up thymus into chunks ½” to 1”.
3. Place in well plates that accommodates thymus and ~10mL PBS.
4. Take 2 microscope slides and use the rough surface to grind thymus to make
single cell suspension. Discard tissue that doesn’t break up.
5. Filter cell suspension through a glass Pasteur pipette that has a piece of cotton
inserted at the top (from sterile plastic pipettes) to remove clumps.
6. Collect flowthrough in 50mL conical tube. Spin at 1,200 rpm for 5 min at 4
degrees.
7. If pellet is red, resuspend in 10mL of red blood cell lysis buffer. Incubate at room
temperature for 10 min. and spin down at 1,200 rpm for 5 min at 4 degrees.
8. Repeat step 7 if pellet is still red.
9. Re-suspend in PBS without Ca2+/Mg2+, 0.1% FBS, 2mM EDTA. Count cells and
adjust concentration for sorting.
Part B- Double Negative Sorting

CD4 Depletion by Magnetic Sorting

1. Started w/ 6x108 total cells
2. Re-suspended in 60mL of Magnetic sort buffer (PBS, 0.1%FBS, 2mM EDTA, w/o
Ca2+ & Mg2+).
3. Split the 60mL of cells into 2 50mL tubes and added 300µL of CD4 Dynabeads to
each, 600µL total (Dynabeads suggests 25uL per 1x107 cells we would need
1.5mL of beads).
4. Rotated for 30 min at 4oC.
5. Placed on magnet 2 min.
6. Counted cells – total after depletion 4.8x108
7. Add another 500µL of beads split into 2 tubes.
8. Rotated for 30 min at 4oC.
9. Placed on magnet 2 min – spun down and re-suspended in 25mL.
10. Placed in magnet again – counted 2.6x108 total cells after second round of
depletion.
Staining for Double Negative Sort
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11. Re-suspended 1x108 in FACS buffer (PBS, 2% FBS w/o Ca2+ & Mg2+).
12. Added 200µL of antibody mix from Untouched Human T-cell kit.
13. Incubated on ice for 15 min.
14. Washed and re-suspended in 10mL.
15. Added 200µL of anti-mouse PE (BD suggests 20µL per 1x106 cells for a total of
2mL).
16. Incubated 10 min on ice.
17. Washed re-suspended in 10mL.
18. Added 200 uL anti-CD4 FITC and 140µL anti-CD8 APC (BD suggests 20 uL per
1x106 cells a total of 2 mL).
19. Washed and re-suspended in 4mL.
Part C- Double Positive Sorting

ABCDE-

Took 5x107 cells and re-suspended in 5mL FACS buffer.
Added 120µL of anti-CD4 FITC (BD suggestion 1 mL).
Added 80µL anti-CD8 APC (BD suggestion 1 mL).
Incubated for 10 min on ice.
Wahed and re-suspended in 2mL of FACS buffer.

Single Stain Controls

1x106 unstained cells in 500µL FACS buffer
1x106 2µL anti-CD4 in 500µL FACS buffer
1x106 2µL anti-CD8 in 500µL FACS buffer
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